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Abstract  
Chronic diseases, such as cardiovascular disease and diabetes, are the leading causes 
of morbidity and mortality worldwide. Recent studies have shown that in addition to 
diabetes mellitus, non-diabetic degrees of fasting and postprandial hyperglycemia are 
also directly linked to accelerated risks of cardiovascular diseases. Thiamin is a water 
soluble vitamin playing a key regulatory role as a co-enzyme in metabolic pathways 
implicated in the glucose metabolism. There is some evidence that diabetic patients 
are prone to thiamin deficiency possibly because of an increased excretion of thiamin 
in the urine. However, there has been no published study to investigate thiamin status 
in individuals with pre-diabetic range of hyperglycemia. Given this gap, we 
undertook a cross-sectional study, evaluating blood thiamin concentration of subjects 
with impaired glucose regulation compared with healthy people.  
 
To examine the main objective of this study, data of 64 subjects (29 men and 35 
women) were analysed. These subjects consisted of 39 normal healthy volunteers 
and 25 hyperglycemics with plasma glucose levels at pre-diabetic ranges (16 IGT, 9 
IFG). The mean intake of thiamin in both groups as assessed by a validated semi-
quantitative food frequency questionnaire was 1.37±0.72 mg/day for normal subjects 
and 1.46±0.51 mg/day for those with hyperglycemia. These values exceeded the 
Australian RDI for thiamin. There was no significant difference in the levels of RBC 
thiamin in hyperglycemic subjects relative to those in the normoglycemic group 
(0.95±0.17 vs. 0.88±0.24 nmol/g Hb, p=0.22). 
 
The two groups were also evaluated for a range of risk factors for CVD, including 
arterial stiffness. Hyperglycemic subjects had higher levels of fasting DVP 
parameters (SI & RI), accompanied with tendencies toward blunted response to 
ingested glucose load relative to normoglycemic group. These results suggest that 
screening of individuals with hyperglycemia by using a Pulse Trace machine may be 
a means of recognising cardiovascular complications at early stages. Further research 
with a larger sample size is recommended to extend these interesting results. 
 
Hyperglycemia is known to induce a variety of biochemical alterations at the cellular 
level, resulting in a range of vascular and tissue damages. The mechanism of action 
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of supplemental thiamin seems to involve the diversion of "excess" metabolic load 
(glycolytic intermediates) away from glycolysis and toward the reductive pentose 
pathway, a secondary pathway for glucose catabolism. Thiamin supplementation was 
also shown to improve cardiovascular risk factors in diabetic rats, suggesting the 
potential effects of thiamin in prevention of diabetic complications.  
 
To date there has been no published study to investigate these effects in individuals 
with pre-diabetic range of hyperglycemia (IGT). Therefore, our objective in the 
second study was to assess the chronic effect of high dose thiamin supplement (300 
mg/d) on glucose tolerance and some cardiovascular risk factors in individuals with 
hyperglycemia at an early stage. In this intervention study with a double blind cross - 
over design, the hyperglycemic subjects (n=12) were randomly allocated into two 
groups to receive either placebo for 6 weeks followed by a 14-week washout period 
and then thiamin for 6 weeks; or thiamin for 6 weeks, a 14-week washout period and 
placebo for 6 weeks.   
 
The results of our intervention study showed that after 6 weeks of supplementation, 
RBC thiamin increased from 0.93 (±0.17) nmol/g Hb to 1.56 (±0.31) nmol/g Hb. In 
subjects receiving placebo, fasting plasma glucose increased significantly from 
baseline after six weeks (6.11±0.70 vs. 5.87±0.63 mmol/L, p=0.003). This significant 
change was accompanied with concomitant increases in fasting plasma insulin (7.67± 
4.39 vs. 6.64± 3.45 μIU/mL, p=0.04), and HOMA score (2.10±1.32 vs. 1.75±1.01, 
p= 0.02). However in the supplement arm, there was no significant change in fasting 
plasma glucose (6.01±0.79 vs. 6.02±0.68 mmol/L, p=0.83), fasting insulin (7.46 
±4.67 vs. 7.36± 4.40 μIU/mL, p> 0.05) or HOMA score (2.05±1.51 vs. 2.00±1.32, 
p=0.75) determined at week 6 compared to baseline (week 0), indicating that 
supplementation with high dose thiamin may have prevented the natural progression 
of hyperglycemia toward diabetes mellitus in individuals with impaired glucose 
metabolism at early stages. We also found that high dose thiamin therapy can 
improve glucose tolerance (week 0: 9.89±2.50 vs. week 6: 8.78±2.20 mmol/L, 
p=0.004), and attenuate diastolic blood pressure (week 0: 71.42 ±7.41 vs. week 6: 
79.2± 5.84 mm Hg, p=0.005) in patients with impaired glucose metabolism. The 
findings of the present study suggest that thiamin therapy may be effective in patients 
with hyperglycemia at early stages. 
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Previous studies examining the potential effects of thiamin under hyperglycemic 
condition have mainly been limited to animals. The current clinical study suggests 
that thiamin supplementation may be beneficial in humans with pre-diabetic ranges 
of hyperglycemia. Further studies are required to confirm these results and 
investigate the impact of thiamin supplementation on insulin secretion.  
 
The findings of this research have the potential to inform food formulations and 
dietary recommendations for people who are at risk of developing diabetes mellitus, 
and may have a role in the prevention of hyperglycemic complications. The findings 
of this study serve as a base for further research investigating the effectiveness of 
different doses of thiamin on cardiovascular risk factors. 
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1.  Introduction  
Chronic diseases, such as heart disease, stroke and diabetes, are known as the major 
cause of morbidity and mortality in the world, with an increasing rate over the recent 
decades (World Health Organization 1998, 2002). There is now a general consensus 
that the dramatic increase in chronic diseases has been mainly due to lifestyle 
changes, which in turn results in increasing rates of obesity and insulin resistance, 
and subsequently hyperglycemia in diabetic or pre-diabetic ranges. The findings of 
recent studies have shown that in addition to diabetes mellitus, even non-diabetic 
degrees of fasting and postprandial hyperglycemia are directly linked to accelerated 
risks of cardiovascular diseases (Levitan et al. 2004). 
 
Thiamin is a water soluble vitamin playing an essential regulatory role as a co-
enzyme in metabolic pathways involved in glucose metabolism. Evidence shows that 
both type 1 and type 2 diabetic patients are prone to thiamin deficiency, resulting 
mainly from an increased urinary excretion (Thornalley et al. 2007), however there 
are no published studies evaluating thiamin status in individuals with pre-diabetic 
range of hyperglycemia.  
 
In addition, studies have demonstrated that thiamin suppresses key pathogenic 
pathways involved in biochemical abnormalities associated with hyperglycemia in 
vitro (Thornalley, Jahan, and Ng 2001) and improves cardiovascular risk factors in 
diabetic rats (Babaei-Jadidi et al. 2003), suggesting the possible benefits of thiamin 
supplementation in the prevention of diabetic complications. Despite these 
preliminary findings, there is limited literature investigating the effects of thiamin 
supplements on metabolic outcomes in humans, particularly among individuals with 
hyperglycemia at early stages.  
 
The present research work was designed in two studies, to assess the status and 
effects of thiamin on cardiovascular risk factors in subjects with abnormal glucose 
metabolism.     
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1.1 Hypotheses 
1. The blood thiamin concentration is decreased in subjects with impaired glucose 
regulation, relative to healthy people.  
 
2. The chronic consumption of high doses of thiamin decreases the risk of 
hyperglycemic complications by reducing fasting plasma glucose, blood pressure and 
serum lipids, and enhances glucose tolerance, insulin sensitivity, renal function and 
energy expenditure relative to control. 
 
1.2 Objectives 
The study hypotheses were addressed through the following studies: 
 
1. The first hypothesis was addressed with a cross-sectional study, evaluating thiamin 
status in subjects with pre-diabetic ranges of hyperglycemia compared to 
normoglycemic group. Subsequently, potential associations between thiamin status 
and different cardiovascular risk factors were investigated.    
 
The variables of interest for this study were anthropometric factors; biochemical 
measurements of fasting and 2-h blood glucose, fasting and 2-h insulin, serum lipids 
and CRP; systolic and diastolic blood pressure; vascular endothelial function indices 
(RI, SI);  renal function measurements (urinary albumin and GFR); and thiamin 
status parameters.  
 
2.   The second hypothesis was tested with a randomised, double blind, cross-over 
design study, investigating the chronic effect of high dose thiamin supplement (300 
mg/d) on cardiovascular risk factors in subjects with early-stage hyperglycemia, 
relative to control.  
 
The endpoints of this intervention study were anthropometric parameters; 
biochemical measurements of fasting and 2-h plasma glucose, fasting and 2-h 
insulin, serum lipids and CRP; systolic and diastolic blood pressure; renal function 
measurements (urinary albumin and GFR); resting and postprandial energy 
expenditure. 
3 
 
2.  Literature review 
2.1     Chronic diseases 
Chronic disease refers to a range of long-lasting disorders with usually slow 
progression. Chronic diseases such as cardiovascular disease and diabetes are known 
as the main causes of morbidity and mortality globally. It is predicted that by 2020, 
chronic diseases will be responsible for approximately 75% of all deaths in the 
world, compared to an approximate rate of 60% in 2001 (World Health Organization 
2002, 1998).  
 
2.2   Cardiovascular diseases 
Cardiovascular disease (CVD) includes a group of diseases which involve the heart 
and blood vessels, consisting of coronary heart disease, heart failure, hypertension, 
cerebrovascular disease and peripheral artery disease. CVD is identified as the 
leading cause of deaths worldwide (World Health Organization 2009). In Australia 
during 2008,  over 48000 deaths were attributable to CVD, representing 34% of all 
registered deaths (Australian Bureau of Statistics 2008). The main underlying cause 
of CVD is atherosclerosis, a progressive disease characterised by the remodelling of 
the arterial system. Moreover, it is now known that there is a link between 
cardiovascular diseases and diabetes mellitus (Ruderman and Haudenschild 1984), 
and hyperglycemia in either diabetic or pre-diabetic ranges (Balkau, Forhan, and 
Eschwege 2002; Balkau et al. 2004; Barzilay et al. 1999; Coutinho et al. 1999; 
DECODE Study Group 2001, 2003; Gabir et al. 2000; Levitan et al. 2004; Meigs et 
al. 2002; Saydah et al. 2001; Stern et al. 2002; Tominaga et al. 1999) is also 
associated with accelerated atherosclerosis.  
 
2.2.1 Pathophysiology of atherosclerosis 
Atherosclerosis is a chronic inflammatory process, in which deposits of lipid are 
accumulated in the inner lining of large and medium-sized arteries, resulting in 
thickening and hardening of the arterial wall. Pathophysiology of atherosclerosis is 
complex and results from reciprocal actions between plasma atherogenic 
lipoproteins, cellular elements (inflammatory cells and arterial endothelial and 
smooth muscles cells) and arterial wall extracellular matrix (Fan and Watanabe 
2003).     
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Figure 1.  Pathophysiology of atherosclerosis: attachment and penetration of 
leucocytes into intima. White blood cells poorly bind to the normal endothelium. 
However, in the presence of atherogenic stimuli, endothelial cells express selective 
adhesion molecules, mediating the attachment of various classes of leukocytes 
(Fruchart 2003 Feb 23) 
 
There are several hypotheses about the pathogenesis of atherosclerosis, which among 
them the theory of "response-to- injury" is now widely accepted (Ross 1993). 
According to this theory, the process of atherosclerosis begins with injury to the 
arterial wall which triggers a series of inflammatory reactions, mediating arterial 
plaque formation. 
 
Various atherogenic stimuli have been shown to contribute to the arterial wall injury, 
including free radicals, high blood pressure, hyperglycemia, homocysteine, 
substances released from fat cells and especially, oxidised low density lipoprotein  
(LDL) (Sherwood 2009). In general, white blood cells poorly attach to the normal 
endothelium. However, pro-inflammatory factors can stimulate the endothelial cells 
to express adhesion molecules, such as vascular cell adhesion molecule -1 (VCAM-
1), which  mediate  the binding of circulating monocytes and lymphocytes (Li et al. 
1993) [Figure 1].  
 
As a consequence of inflammation, endothelial cells begin to lose their integrity and 
allow the attached leucocytes to move into the intima (Woywodt et al. 2002). The 
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increased endothelial permeability resulting from inflammation also enables the 
plasma atherogenic lipoproteins, in particular particles of low density lipoprotein 
(LDL) to penetrate the endothelial layer. The retention in the intima isolates LDL 
particles from plasma anti-oxidants, facilitating their subsequent oxidative 
modification by reactive oxygen species (ROS) and enzymes (Lusis 2000; Packard 
and Libby 2008). Oxidatively modified LDL particles can in turn promote the arterial 
wall cells to secrete chemoattractant factors such as monocyte chemoattractant 
protein-1 (MCP-1), enhancing the migration of adherent leukocytes (Fan and 
Watanabe 2003; Ross 1999; Takeya et al. 1993). In parallel, the monocytes 
infiltrated in the endothelial layer differentiate into macrophages, in response to 
macrophage colony-stimulating factor (M-CSF). Additionally, M-CSF stimulates 
macrophages to express scavenger receptors, permitting them to endocytose the 
oxidised lipoproteins and take on a foamy appearance under a microscope, known as 
"foam cells" (Qiao et al. 1997; Smith et al. 1995).  Accumulation of these lipid-laden 
macrophages (foam cells) in the subendothelial space forms a visible “fatty steak", a 
hallmark of atherosclerosis in its early stage.  
 
The atherosclerosis process continues with the migration of smooth muscle cells 
(SMCs) from the tunica media to the endothelial layer, under the influence of platelet 
derived growth factor released by activated leukocytes and vascular endothelial cells. 
In response to inflammation, arterial wall smooth muscle cells express genes for 
matrix metalloproteinase enzymes, in particular matrix metalloproteinase - 9 (MMP-
9), degrading extracellular matrix and permitting SMCs to pass through the elastic 
laminate and  enter the subendothelial space (Mason et al. 1999).  
 
Within the intima, various fibrogenic mediators, including a number of peptide 
growth factors, promote SMCs to proliferate, and subsequently produce extracellular 
matrix proteins, especially interstitial collagen, overlying the foam cells. This process 
may cause the early lipid-laden lesion to progress into a fibrotic plaque (atheroma), 
characteristic of the more advanced stage of atherosclerosis (Packard and Libby 
2008).  
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As the atherosclerotic plaque 
grows, it progressively bulges 
into the arterial lumen and 
produces a critical vascular 
narrowing. Typically, two kind 
of atherosclerotic plaques can 
be identified: stable plaque 
containing a thick 
fibromuscular layer overlying a 
small lipid core,  and unstable or 
vulnerable plaque which often 
comprises a large lipid core 
covered by a thin layer of smooth 
muscle cells,  extracellular matrix and abundant inflammatory cells , rendering it 
prone to rupture and clot formation (Fan and Watanabe 2003) [Figure 2].  
 
Inflammatory processes have been shown to not only contribute to the initiation and 
progression of atheroma, but also participate in  its destabilization, leading to the 
thrombotic complication of atherosclerosis (Libby 2002). Subsequent to the plaque 
evolution, activated T lymphocytes resident in the atheroma secrete pro-
inflammatory cytokines, such as interferon (IFN)-γ, inhibiting smooth muscle cells in 
the synthesis of new collagen. In parallel, inflammatory mediators released by T 
lymphocytes can stimulate macrophages to produce matrix metalloproteinase 
enzymes, including MMP-1, MMP-8, MMP-13 and in particular MMP-9, breaking 
down interstitial collagen that exists in the fibrous layer of atheroma (Amento et al. 
1991; Galis et al. 1994; Gough et al. 2006; Sukhova et al. 1999). This process causes 
the rupture of enlarged plaque through the weakened fibrous cap and its adjacent 
endothelial lining, permitting blood elements to make contact with the thrombogenic 
substance in the subintimal space at the site of arterial damage. This contact triggers 
the process of thrombus formation which can impede blood flow through the affected 
artery (Sherwood 2009). 
 
 
Figure 2. Stable and unstable plaques. As 
plaque builds up, it can become either 
stable or unstable. Unstable plaque is more 
prone to sudden rupture, a potentially life-
threatening event (Mangge et al.). 
7 
 
2.2.2 Inflammatory biomarkers and atherosclerosis 
Given the central function of inflammation in atherosclerosis, several studies over 
the last decade have focused on investigating the role of inflammatory biomarkers 
for risk stratification. These biomarkers mainly comprise adhesion molecules like 
VCAM-1; cytokines including tumor necrosis factor, interleukin-1, interleukin-12 
and interleukin-18; matrix metalloproteinases such as MMP-9; and acute phase 
reactants such as PAI-1, fibrinogen and in particular C-reactive protein (CRP) 
(Packard and Libby 2008).  
 
Cellular adhesion molecules 
Cellular adhesion molecules (CAMs) including VCAM-1, ICAM-1 and E- selectin 
have been shown to play an essential role in atherosclerosis process (Cybulsky and 
Gimbrone 1991; Kawakami et al. 2006; Li et al. 1993). These adhesion molecules 
can be detected in serum in their soluble forms. Elevated levels of soluble adhesion 
molecules were found in coronary artery atherosclerosis (Blann, Amiral, and 
McCollum 1996; Damnjanovic et al. 2009), carotid sclerosis (Hwang et al. 1997),  
peripheral artery diseases (De Caterina et al. 1997) and in association with metabolic 
syndrome components, including diabetes mellitus (Doupis et al. 2010), hypertension 
(DeSouza et al. 1997), hyperlipidemia (Hackman et al. 1996) and impaired glucose 
tolerance (Ferri et al. 1998). This suggests a possible role for these inflammatory 
biomarkers in further cardiovascular risk assessment, although it is still a matter of 
controversy  (de Lemos, Hennekens, and Ridker 2000).   
 
Cytokines 
Pro-inflammatory cytokines of the interleukin (IL) group and macrophage-associated 
cytokines, including tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ) and 
colony stimulating factors (CSF), are known to be key players in the pathogenesis of 
atherosclerosis (Mallat et al. 2001; McKellar et al. 2009; Tedgui and Mallat 2006). 
However, the level of circulatory cytokines does not necessarily reflect their actual 
activity (Tedgui and Mallat 2006). Several studies suggested IL-18 as a useful maker 
for risk stratification in individuals with or without established cardiovascular 
diseases (Blankenberg et al. 2003; Blankenberg et al. 2002). Other interleukins, such 
as IL-1 and IL-6, cannot be easily measured in clinical laboratories, because of their 
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short half-lives in plasma (Packard and Libby 2008). TNF-α is another cytokine 
considered for predicting cardiovascular events (Skoog et al. 2002). Nevertheless, 
some researchers proposed soluble tumor necrosis factor receptor (sTNFR) as a more 
reliable marker than measuring TNF-α levels itself (Elkind et al. 2002). 
 
MMP-9 
Consistent with the role of matrix metalloproteinases in plaque formation (Gough et 
al. 2006; Mason et al. 1999), studies indicated that the circulatory concentrations of 
MMP-9 were higher among patients with stable coronary artery disease compared to 
control (Noji et al. 2001; Tayebjee et al. 2005). There was also a direct correlation 
between MMP-9 and the concentration of LDL- cholesterol (Noji et al. 2001). There 
is still limited evidence and further investigations are required to determine whether 
MMP-9 measurement provides more prognostic information compared to other 
markers.  
 
Acute phase reactants 
Acute phase reactants including PAI-1, fibrinogen and CRP have been shown to 
participate in the atherosclerosis inflammatory process (Bini and Kudryk 1994; 
Libby and Theroux 2005; Zwaka, Hombach, and Torzewski 2001). 
 
In a prospective nested case-control study involving a population with high 
prevalence of coronary heart disease, elevated plasma PAI-1 concentrations were 
associated with the first myocardial infarction in both men and women (Thogersen et 
al. 1998). Evidence indicates that PAI-1 production can be directly influenced by key 
cardiovascular risk factors, including genetic predisposition (Dawson et al. 1991; 
Festa et al. 2003), obesity, insulin resistance (Juhan-Vague, Alessi, and Morange 
2000) and neurohormonal causes (Brown et al. 1998). These findings have cast some 
doubts on PAI-1 as an independent predictor of cardiovascular risk (Packard and 
Libby 2008). Additionally, a short half- life in the circulation (6 minutes) and also 
meticulous precautions required for blood sampling process limit PAI-1 as a routine 
measurement in the clinical setting (Packard and Libby 2008). 
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Data from several prospective studies indicate that the concentration of fibrinogen at 
baseline was higher among individuals who experienced a subsequent myocardial 
infarction and stroke (Ma et al. 1999; Wilhelmsen et al. 1984). Furthermore, recent 
studies confirmed the association between fibrinogen and traditional and non-
traditional cardiovascular risk factors (Maple-Brown et al. 2010). However, 
fibrinogen seems a less useful cardiovascular risk marker than CRP (Ridker, 
Stampfer, and Rifai 2001), partly due to its diurnal variations, and problems in its 
measurement reproducibility and standardisation (Packard and Libby 2008). 
 
Among various biomarkers, CRP is accepted as the strongest non-lipid predictor of 
cardiovascular events (Ridker, Hennekens, et al. 2000),  including  myocardial 
infarction (Ridker et al. 2002), stroke (Ridker et al. 2002; Ridker 2003),  cardiac 
sudden death (Albert et al. 2002) and peripheral artery diseases  (Ridker et al. 2008), 
particularly in patients with diabetes mellitus (Linnemann et al. 2006; Pfutzner and 
Forst 2006). In addition, it was shown to predict the risk of recurrent adverse events 
in patients with established cardiovascular disease (Haverkate et al. 1997). Elevated 
levels of CRP also correlated with body weight and presence of metabolic syndrome 
(Linnemann et al. 2006; Zuliani et al. 2009).  Interestingly, some non-diabetes drugs 
known to reduce the risk of atherosclerosis were shown to modify CRP 
concentrations (Fisher et al. 2008; Ridker et al. 2008; Ridker et al. 2001).   
 
With regard to laboratory and clinical aspects, CRP circulates with a long half-life 
and minor seasonal and diurnal fluctuations (Packard and Libby 2008; Pearson et al. 
2003). It can be measured simply by standardised high-sensitive immunoassays 
providing accurate and similar results in fresh, stored or frozen samples (Packard and 
Libby 2008; Pearson et al. 2003). 
 
Based on available evidence, CRP measured by a high sensitive method (hsCRP) has 
been identified as an independent inflammatory marker for predicting the risk of 
coronary disease, and the analyte of choice by the Center for Disease Control and 
Prevention and the American Heart Association (Pearson et al. 2003). 
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 According to the issued 
guideline, the cutpoints in 
clinical practice are: hsCRP 
levels < 1mg/L for low risk, 1.0 
to 3.0 mg/L for average risk, and 
>3.0 mg/L for high risk [Table 1]. 
The risk of cardiovascular events 
was predicted to increase about 2 
fold in individuals categorised as 
high risk compared to the low-
risk group (Pearson et al. 2003).  
 
Given these findings, hs-CRP was the inflammatory marker chosen for evaluating 
the relationship between thiamin status and cardiovascular risk factors in this study.    
 
 2.2.3 Risk factors of cardiovascular disease     
 
2.2.3.1 Lipids and lipoproteins 
Atherogenic dyslipidemia commonly presents as the raised levels of triglyceride and 
LDL-cholesterol, and reduced HDL-cholesterol [although isolated low HDL-
cholesterol occur rarely in some individuals] (Grundy 1998). The role of this lipid 
triad in cardiovascular events has been confirmed by a large number of experimental 
and epidemiological studies (Austin, Hokanson, and Edwards 1998; Gordon et al. 
1989).  
 
2.2.3.1 A    Lipoproteins structure, metabolism and atherogenisity 
Lipoproteins are macromolecular structures containing two major parts: lipids 
(triglyceride, cholesterol and phospholipids) and proteins. The function of 
lipoproteins essentially is to transport the hydrophobic triglyceride and cholesteryl 
esters in the circulation (Smith, Pownall, and Gotto 1978). With regard to the 
lipoproteins structure, the amphipathic phospholipids on the surface of lipoprotein 
Table 1.  Cardiovascular risk assessment 
according to hs-CRP concentrations  
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particles enable the hydrophobic core lipids to be soluble in the aqueous blood 
stream (Chahil and Ginsberg 2006).     
 
Lipoproteins can be divided into five main classes, in terms of their densities, 
namely: high density lipoproteins (HDL), low density lipoproteins (LDL), 
intermediate density lipoproteins (IDL), very low density lipoproteins (VLDL) and 
chylomicrons (CM) (Garrett and Grisham 1995) [Table 2].   
 
In addition to the core lipids, these lipoproteins classes are different in their surface 
proteins, named apolipoproteins. Two main subclasses of apolipoproteins are 
apolipoprotein A (apoA) and apolipoprotein B (apoB), which exists in two isoforms, 
apoB48 and apoB100 (Chahil and Ginsberg 2006).  
 
The triglyceride-rich lipoproteins are assembled and secreted exclusively in the 
intestine or the liver through two distinct pathways, exogenous and endogenous.  
 
In the exogenous pathway, the dietary lipids absorbed by intestinal epithelial cells are 
combined with apoB100 to form chylomicrons. These nascent lipoproteins are then 
released into the blood via lymphatic circulation.  In the bloodstream, the nascent 
chylomicrons receive ApoC and ApoE from HDL particles, and develop into the 
mature form which carry triglyceride and, to a lesser extent, cholesterol to non-
hepatic tissues. 
 
 
Table 2. Classification of  lipoproteins based on density (Garrett and Grisham 
1995) 
 
Density 
(g/mL) 
Class Diameter 
(nm) 
%protei
n 
%cholesterol %phospholipids % 
triacylglycerol  
>1.063 HDL 5-15 33 30 29 4 
1.019-1.63 LDL 18-28 25 50 21 8 
1.006-1.019 IDL 25-50 18 29 22 31 
0.95-1.006 VLDL 30-80 10 22 18 50 
<0.95 CM 100-1000 <2 8 7 84 
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In the endogenous pathway, the triglyceride and cholesterol constituents of 
lipoproteins are primarily synthetised in the liver, assembled with ApoB100 into 
VLDL particles.  Like chylomicrons, these nascent VLDLs require ApoC and ApoE 
to mature in the circulation.   Subsequent to maturation, circulating chylomicrons and 
VLDL are catabolised under the influence of the enzymes, lipoprotein lipase (LPL) 
and lecithin cholesterol acyltransferase (LCA) (Smith, Pownall, and Gotto 1978).  
 
In this process initially, LPL catalyses the hydrolysis of triglyceride in these 
triglyceride - rich lipoproteins, which results in a remnant from the chylomicrons and 
an intermediate density lipoprotein (IDL) from the VLDL particles. The products of 
triglyceride hydrolysis (fatty acid and acylglycerol) can be taken up by peripheral 
tissues for utilisation or storage. 
 
The catabolic process continues with the conversion of IDL to LDL, and ultimately 
the uptake and degradation of chylomicrons remnants (CMR) by the liver and LDL 
particles by the liver and other tissues via a receptor- mediating mechanism. 
 
All apoB-lipoproteins except nascent chylomicrons have the potential to penetrate 
into the endothelial layer (Chahil and Ginsberg 2006) and induce the inflammatory 
atherogenic process in an injured artery, as described before (see Section 2.2.1). 
However, HDL particles containing ApoA are known to be antiatherogenic, mainly 
because of their key role in reverse cholesterol transport (RCT). HDL particles are 
thought to be the only lipoproteins able to receive the cholesterol accumulated in 
peripheral cells, including macrophages in atherosclerotic lesions, and return them to 
the liver for subsequent excretion in the bile (Chahil and Ginsberg 2006).  
 
2.2.3.1.B  Prediction of CVD risk using serum lipids and lipoproteins 
To evaluate the risk of further cardiovascular disease, only serum total cholesterol 
was measured initially. Subsequent studies considered serum LDL cholesterol as the 
most evident atherogenic lipoprotein and consequently, the main target for 
cholesterol lowering interventions (National Cholesterol Education Program (NCEP) 
Expert Panel on Detection 2002).  
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The relationship between 
LDL cholesterol and coronary 
heart disease has been shown 
to be log linear (Law, 
Wald, and Thompson 1994; 
Law 1999). 
 
The risk of cardiovascular 
disease appears to be very 
low when serum LDL 
concentration is below the 
optimal level of 100 mg/dl 
(2.59 mmol/L). However, 
LDL cholesterol at higher levels is directly associated with the accelerated risk of 
atherosclerosis (National Cholesterol Education Program (NCEP) Expert Panel on 
Detection 2002). 
  
In contrast with LDL, population based evidence indicates that higher levels of HDL 
cholesterol are associated with a reduced risk of coronary heart disease (Wilson et al. 
1998). This inverse relationship was shown to be continuous, namely any reduction 
in HDL can result in a concomitant increase in coronary heart disease risk (Gordon et 
al. 1989).  
 
Table 4.  Classification of Total, LDL and HDL Cholesterol levels (National 
Cholesterol Education Program (NCEP) Expert Panel on Detection 2002)   
Total Cholesterol (mg/dL) 
[mmol//L]  
LDL Cholesterol   
(mg/dL) [mmol//L] 
HDL Cholesterol  
(mg/dL) [mmol//L] 
 
< 200 [5.17] 
 
200-239 [5.17- 6.19] 
≥ 240 [6.20] 
 
Desirable 
 
Borderline  
High 
< 100 [2.59] 
100-129  [2.59-3.34] 
 
130-159 [3.46- 4.11] 
160-189 [4.13- 4.89] 
≥ 190 [4.91] 
Optimal 
Near optimal  
 
Borderline  
High 
Very High 
 
< 40 [1.03]  
 
 
≥ 60 [1.55]  
 
Low HDL 
cholesterol  
 
High HDL 
cholesterol 
Table 3. Classification of triglyceride 
levels (National Cholesterol Education 
Program (NCEP) Expert Panel on Detection 
2002) 
Serum triglyceride (mg/dL) [mmol/L] 
 
Normal triglyceride  
Borderline - high 
triglyceride  
 
High triglyceride 
 
Very high triglyceride 
 
< 150 [1.7] 
150-199 [1.7- 2.25] 
 
200-249 [2.26- 2.81] 
 ≥ 500 [5.65] 
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Accordingly, serum HDL levels are classified as two categories of "low HDL 
cholesterol" and "high HDL cholesterol" (National Cholesterol Education Program 
(NCEP) Expert Panel on Detection 2002) [Table 4].  
 
Elevated serum triglyceride is another component of the lipid triad, indicated as an 
independent risk factor for coronary heart disease (Austin, Hokanson, and Edwards 
1998). Raised levels of triglyceride were shown to be strongly associated with 
several lipid (high LDL and low HDL particles) and non-lipid risk factors, in 
particular hyperglycemia (Grundy 1998).  
 
While the pathogenesis of hyperlipidemia associated with hyperglycemia is not fully 
understood, an increase in the hexosamine pathway in the liver due to hyperglycemia 
has been elucidated (Rumberger et al. 2003; Veerababu et al. 2000). Given the 
possible effect of thiamin on the hepatic hexosamine pathway (see Section 2.5.9), it 
is proposed that supplementation with thiamin may alter this effect.   
 
2.2.3.2 Hypertension 
Hypertension, chronic elevation of systemic arterial blood pressure, is established as 
another powerful and independent risk factor for atherosclerosis (MacMahon et al. 
1990; Stamler, Stamler, and Neaton 1993). According to the categorical 
classification, hypertension is 
defined as a systolic blood 
pressure ≥ 140 mmHg or diastolic 
blood pressure ≥ 90 mmHg or 
recent use of antihypertensive 
medication (Chobanian et al. 
2003; National Cholesterol 
Education Program (NCEP) 
Expert Panel on Detection 2002; 
The sixth report of the Joint 
National Committee on 
prevention, detection, evaluation, 
     Table 5. Classification of blood pressure  
     for adult (Chobanian et al. 2003) 
Blood Pressure 
Classification  
SBP 
  mm Hg 
DBP 
Mm Hg 
 
Normal 
 
Prehypertension 
 
Stage 1 
Hypertension 
 
Stage 2 
Hypertension 
 
<120 
 
120-139 
 
140- 159 
 
 
≥ 160 
 
and < 80 
 
or  80 - 89 
 
 
or  90- 99 
 
or  ≥ 100 
        SBP, systolic blood pressure; DBP, diastolic blood  
         pressure 
15 
 
and treatment of high blood pressure  1997). Even patients with blood pressure at 
prehypertension level [Table 5] are shown to have a higher risk CHD relative to 
those with normal blood pressure (Vasan et al. 2001).                                      
 
The unequivocal association between hypertension and CVD events was indicated to 
be consistent and continuous (Chobanian et al. 2003). Therefore, any decrease in 
blood pressure is accompanied with a reduced risk for blood pressure-related 
endpoints (Cutler et al. 1995). 
 
The link between hypertension and atherosclerosis can be essentially explained by 
the new understanding of central role of inflammation in CVD events. It is suggested 
that inflammation may participate in the initiation of hypertension through the 
secretion of several mediators, such as TNF-α, IL- 6 and CRP, resulting in an 
impaired capacity of the endothelium to produce vasodilating  factors,  in particular 
nitric oxide (NO),  thus endothelial dysfunction and  ultimately hypertension 
(Bautista 2003).  The raised blood pressure can, in turn, damage the arterial wall 
(Sherwood 2009) and enhance the vascular inflammation (Boos and Lip 2005). 
Furthermore, the inflammatory process was indicated to be influenced by the renin - 
angiotensin system involved in hypertension pathology (Brasier, Recinos, and 
Eledrisi 2002). Angiotensin II, has a vasoconstricting effect, but can also induce the 
expression of arterial SMCs proinflammatory cytokines, including IL-6 and MCP-1, 
and the endothelium - derived VCAM-1 (Hernandez-Presa et al. 1997; Kranzhofer et 
al. 1999; Tummala et al. 1999).  Angiotensin II can also promote the production of 
reactive oxygen species by arterial endothelial and smooth muscle cells (Griendling 
et al. 1997). A direct relationship between inflammatory markers, particularly CRP, 
and blood pressure was reported by several studies (Bautista et al. 2005; King et al. 
2004), confirming the role of inflammation in the development of hypertension and 
subsequent atherosclerosis.  
 
Thiamin supplementation was shown to have beneficial effect on systolic blood 
pressure of individuals with subclinical thiamin deficiency (Wilkinson et al. 1997)  
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2.2.3.3    Overweight/obesity 
The prevalence of overweight and obesity has reached epidemic proportion 
worldwide, with approximately 1.6 billion adults overweight (World Health 
Organization 2006). The National Health Survey in Australia in 2007-2008 found 
67.7% of men and 54.6% of women to be overweight or obese, peaking among those 
aged 65-74 years (78.9%  of men and 71.4% of women) (Australian Bureau of 
Statistics 2009).  Overweight is defined as a body mass index (BMI, weight in kg 
divided by the square of height in meters) of 25-29.9 kg/m
2
 and obesity as BMI≥ 30 
(National Institutes of Health 1998). Overweight and obese people are not only at a 
raised risk of CVD, they have also higher all-cause mortality (Hubert et al. 1983; 
Wilcosky et al. 1990). Obesity is also strongly associated with other CVD risk 
factors, including hyperglycemia (Hartz et al. 1983; Straczkowski et al. 2003), 
hypertension (Berchtold et al. 1981; Blair et al. 1984) and in particular dyslipidemia 
(high LDL, VLDL and triglycerides and low HDL cholesterol) (Denke, Sempos, and 
Grundy 1994, 1993; Garrison et al. 1980; Olefsky, Reaven, and Farquhar 1974). This 
risk is known to be more significant in the presence of abdominal  obesity, which is 
defined as a waist circumference of more than 88 cm in women and 102 cm for men 
(National Institutes of Health 1998).  In people with central obesity, excess free fatty 
acids originating from intra-abdominal fat stimulate the production of VLDL 
particles in the liver, resulting in a high hepatic lipase activity and subsequent 
increase in the concentration of  LDL (Sibley et al. 2003). The elevated VLDL can 
also lead to HDL particle reduction through enhancing exchange from HDL to 
VLDL, mediated by cholesteryl ester transfer protein (Libby 2002). Furthermore, 
adipose tissue was implicated as a major source of cytokines, such as IL-6 (Yudkin et 
al. 1999), suggesting a contribution to the inflammatory atherogenic process 
independent of its effects on lipoprotein metabolism or insulin sensitivity.    
 
2.2.3.4     Arterial stiffness  
Arterial stiffness is a general term used to define the stiffing of the arterial wall, 
resulting in a declined elasticity of the blood vessel. Arterial stiffness is an 
independent risk factor for cardiovascular disease and occurs mainly as a 
pathological consequence of ageing (Benetos et al. 2002; Wilkinson and McEniery 
2004). However, its progress may be accelerated in the presence of other risk factors, 
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including hypertension, dyslipidemia, obesity and hyperglycemia in either diabetic or 
pre-diabetic ranges (Henry et al. 2003; Liu et al. 1989; Safar, Czernichow, and 
Blacher 2006; Salomaa et al. 1995; Schram et al. 2004; van Popele et al. 2006; 
Wilkinson et al. 2002; Xu et al. 2010). Furthermore, arterial stiffness is known as a 
strong predictor of cardiovascular events and all-cause mortality (Adji, O'Rourke, 
and Namasivayam 2011; Vlachopoulos, Aznaouridis, and Stefanadis 2010).   
  
2.2.3.4.A    Pathogenesis of arterial stiffness 
Although the pathogenesis of arterial stiffness is not fully understood, multiple 
mechanisms have been implicated in its aetiology. These mechanisms include  
 
 
 
Figure 3. Summary of the multiple causes and  locations  of arterial stiffness (Zieman, 
Melenovsky, and Kass 2005) 
 
changes in the structure of extracellular matrix, endothelial function and vascular 
smooth muscle tone (Zieman, Melenovsky, and Kass 2005) [Figure 3].  
 
The integrity and elasticity of the vascular wall are respectively dependent on its two 
extracellular proteins, collagen and elastin (Zieman, Melenovsky, and Kass 2005).  
The proportion of these molecules in the arterial wall is balanced by a slow dynamic 
process of formation and degradation. Disturbance in this balance results in an 
increased production of collagen and concomitant reduction in elastin proportion, 
with in turn a decline the vessel elasticity (Johnson et al. 2001). Different factors 
contributing to arterial stiffness mostly affect the degradation of elastin and collagen, 
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which are in turn regulated by matrix metalloproteases (MMPs) (Zieman, 
Melenovsky, and Kass 2005). 
 
The histological examination of stiffened vessel specimens reveal disarranged 
endothelial cells, increased collagen content, broken elastin molecules, infiltration of 
inflammatory cells, hypertrophied vascular smooth muscle layer, and increased 
matrix metalloproteases (Lakatta 2003; Virmani et al. 1991). 
 
The tensile strength of the vessel wall is mainly due to the enzymatic cross - linking 
of collagen and elastin molecules, making them insoluble to hydrolytic enzymes 
(Reiser, McCormick, and Rucker 1992). However, due to the slow rate of hydrolytic 
turnover, these proteins are also prone to non-enzymatic glycation cross-linking, 
forming stable and irreversible cross - linked components of AGEs (Bailey 2001; 
Lee and Cerami 1992).  
 
This process can lead to an increase in the content of collagen fibres which are now 
stiffer, and distributed irregularly (Verzijl et al. 2000). Non-enzymatic glycation 
reaction can also weaken the integrity of elastin bonds and also predispose the 
protein to mineralisation by calcium and phosphate, accelerating the arterial stiffness 
(Cattell, Anderson, and Hasleton 1996; Konova et al. 2004; Spina and Garbin 1976; 
Watanabe et al. 1996; Winlove et al. 1996). Furthermore, the binding of AGEs to 
their specific receptors (RANGE) on the surface of several cell types augments the 
production of oxidants, pro-inflammatory cytokines and other inflammatory 
mediators, increasing arterial stiffness via activation of MMPs (Kuzuya et al. 2001; 
Yan et al. 1994). Receptor-mediated interaction of AGEs with  RAGE on smooth 
muscle cells can increase cellular proliferation mediated by cytokine or growth-
factor (Vlassara, Bucala, and Striker 1994).  
 
In addition to the structure of the extracellular matrix, arterial stiffness is strongly 
influenced by the endothelial cell function and vascular smooth muscle tone. 
Vascular tone is determined by a mechanostimulation mechanism activated via cell 
stretch and a calcium signalling system, by circulatory vasoactive mediators (i.e. 
bradykinin and thrombin) and by several vasoactive molecules, such as nitric oxide 
(NO), angiotensin II, endothelin, which are mainly produced by the endothelium, and 
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oxidant stress (Dzau 1986; Gurtner and Burke-Wolin 1991; Yanagisawa et al. 1988; 
Zieman, Melenovsky, and Kass 2005). Indeed, endothelial cells are able to release a 
wide range of factors, regulating vascular tone, smooth muscle cell proliferation and 
arterial wall inflammation (Deanfield, Halcox, and Rabelink 2007). 
 
The endothelium refers to a single layer of cells that line all the vessels in the body, 
including conduit vessels, resistance vessels, pre-capillary arterioles and capillaries 
(Vane, Anggard, and Botting 1990). In recent years, the endothelium has been shown 
to be a key protective barrier against the progress of atherosclerosis. Endothelial 
dysfunction, characterised by "inadequate vasodilatation and/or paradoxical 
vasoconstriction in coronary and peripheral arteries", has been generally considered 
as one of the earliest markers of cardiovascular disease (Cersosimo and DeFronzo 
2006). Emerging evidence shows that almost all conventional risk factors for 
atherosclerosis, such as smoking (Celermajer et al. 1996), dyslipidemia (Sorensen et 
al. 1994) and arterial hypertension (Panza 1994) as well as  coronary artery disease 
(Tousoulis, Charakida, and Stefanadis 2008), congestive heart failure (Zelis, Mason, 
and Braunwald 1968) and hyperglycemia (Kawano et al. 1999; Tooke and Goh 1999) 
are associated with an abnormal endothelial vasoactivity. Endothelial dysfunction is 
essentially attributable to a decrease in NO bioavailability, which can be because of a 
reduced production, increased degradation or decreased sensitivity of the 
endothelium to NO (De Caterina 2000). 
 
In normal vascular physiology, NO plays a key role in regulating arterial tone. NO is 
produced in endothelial cells from the oxidation of L-arginine by endothelial NO 
synthase (eNOS) (Forstermann and Munzel 2006). This gas can diffuse throughout 
the arterial smooth muscle cells and stimulate cGMP - mediated vasodilation via 
guanylate cyclase activation (Deanfield, Halcox, and Rabelink 2007). Decreased NO 
bioavailability reduces vascular smooth muscle cell relaxation, resulting in the 
functional stiffness of arteries.   
 
Endothelial dysfunction can be also due to an increased production of ROS, which in 
turn leads to hydrogen peroxide generation. Hydrogen peroxide, similar to NO, 
diffuses to the vascular cells, targets main regulatory proteins and impairs their 
functions (Rhee 2006). Several cardiovascular risk factors such as dyslipidemia, 
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hypertension and hyperglycemia are thought to induce endothelial dysfunction and 
consequently arterial stiffness through the chronic dysregulation of NO and ROS 
production (Celermajer et al. 1994).  There is also convincing evidence indicating 
that resistance to insulin plays a fundamental role in the pathogenesis of endothelial 
dysfunction induced by various risk factors (Caballero 2003; Cohn, Valdes, and 
Capuzzi 2001).  
 
In general, insulin has a vasodilating effect, particularly on skeletal muscle vessels, 
to increase glucose delivery to this insulin-sensitive tissue (Petrie et al. 1996).  
Insulin is suggested to stimulate arterial dilation through the release of NO (Scherrer 
et al. 1994). In the insulin resistant state, insulin-mediated vasodilation may be 
impaired, due to a decrease in NO synthesis or an abnormal response of vascular 
smooth muscle cells to NO (Williams et al. 1996).  Insulin resistance may lead to 
endothelial dysfunction through multiple mechanisms, including: the increased levels 
of asymmetric dimethylarginine (ADMA) which is an endogenous NO synthase 
inhibitor (Stuhlinger et al. 2002), defect in the phosphatidylinositol 3-kinase pathway 
which contribute to insulin-dependent endothelial NO production (Hsueh and 
Quinones 2003; Zeng et al. 2000), activation of mitogen-activated protein kinase 
(MARK) pathway mediating VSMC cell growth as well as migration of endothelial 
cells and monocytes (Pessin and Saltiel 2000), and inflammation (Sriraman and 
Tooke 2004). Resistance to insulin can be also associated with an increased 
production of ROS (Inoguchi et al. 2000) and the activation of the rennin-angiotensin 
system which in turn increases superoxide production (Rajagopalan et al. 1996). 
 
2.2.3.4.B    Measurement of arterial stiffness 
Arterial stiffness can be noninvasively evaluated by a range of devices which are 
essentially designed based on three main methodologies ; 1) estimation of pulse 
wave velocity (PWV), 2) assessment of vessel distensibility by measuring the change 
in arterial diameter in relation to distending pressure, 3) pulse pressure waveform 
analysis. 
 
Assessment of PWV is theoretically derived from Moens-Kortweg equation: 
PWV
2
=E*h/2rρ, where E is Young's Modulus of the arterial wall, h is wall thickness, 
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r is arterial radius at end - diastole, and ρ is the density of blood (Oliver and Webb 
2003). PWV can be practically computed by measuring the time taken for the arterial 
pulse wave to pass the distance between two determined points. Various methods are 
applied to detect the pulse wave, such as Doppler ultrasound or applanation 
tonometry. PWA of large elastic arteries, such as the aorta, has emerged as the gold 
standard marker for regional arterial stiffness (Laurent et al. 2006). Central pulse 
wave velocity determined by measuring carotid-to-femoral transit time, is commonly 
used for evaluating aortic stiffness. However, given a relatively small inter-subject 
variation between subjects with arterial stiffness and healthy individuals, the results 
may not be obvious except in large scale studies (Woodman and Watts 2003). 
Recently, several methods of cardiovascular magnetic resonance (CMR) have been 
used for measuring aortic pulse wave velocity (Ibrahim el et al. 2010).  
 
The change in arterial diameter in relation to distending pressure is a measure of 
local arterial stiffness, and is frequently measured on superficial arteries, such as 
carotid artery. The internal diameter of an artery can be evaluated by the eco-tracking 
technique and applanation tonometry is commonly used for measuring local pulse 
pressure (Benetos et al. 1993). Vessel distensibility can be also evaluated directly by 
magnetic resonance imaging (MRI), measuring the distension of deeper arteries, such 
as the ascending and descending thoracic, and abdominal aorta (Resnick et al. 1997). 
However, this technique is not in common use, because of its expense and also 
limitations regarding accurate and concurrent local arterial pressure measurement 
(Sakuragi and Abhayaratna 2010). 
 
The arterial pressure waveform is composed of a forward pressure wave arising from 
the left cardiac ventricle contraction and a backward travelling wave reflected from 
the periphery, mainly at the branching points of arteries and the sites of increased 
stiffness. In elastic arteries, the backward wave tends to return to the aorta during 
diastole, enhancing diastolic pressure. However, in stiffened vessels, due to an 
increased pulse wave velocity, the reflected wave arrives back earlier in the systolic 
phase of the cardiac cycle, thus augmenting the systolic pressure instead of diastolic 
pressure (Mackenzie, Wilkinson, and Cockcroft 2002). This phenomenon is the basis 
of several methods of measuring arterial stiffness through the analysis of pressure 
pulse waveforms.  
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Pulse wave analysis (PWA) is a non - invasive method of measuring arterial stiffness 
mainly at the central level, such as the ascending aorta (O'Rourke, Pauca, and Jiang 
2001). Aortic pressure waveform can be assessed either from the radial artery 
waveform via a transfer function or the common carotid waveform recorded by 
applanation tonometry. Pulse waves are analysed through three main measurements: 
central pulse pressure, central systolic pressure, and augmentation index, which is 
defined as " the difference between the second and first systolic peak (P2-P1) 
expressed as a percentage of the pulse pressure " (Laurent et al. 2006; London et al. 
1992; Mackenzie, Wilkinson, and Cockcroft 2002; O'Rourke 1971).  
 
Analysis of digital volume pulse (DVP) waveform produced by the Pulse Trace 
system is another technique of evaluating arterial stiffness. The system is based on 
the finger photoplethysmography, and validated in different setting and diseases 
(Chowienczyk et al. 1999; Millasseau et al. 2000; Takazawa et al. 1998).  
 
The device is made of an infra-red sensor (photoplethysmograph), which detects the 
pulse waveforms at the finger. The sensor is connected to an analogue-to-digital 
converter, recording waveforms for 15-30 seconds. DVP consists of two 
components; a forward wave (systolic component) resulting from the transmission of 
pressure along a direct path from the aortic root to the finger, and a backward 
pressure wave (diastolic component), reflected back from the lower body along the 
aorta to the finger.  Accordingly, both the directly transmitted pressure wave and the 
reflected wave can be detected in the upper limb, minimising the contour of DVP.  
Reflection index (RI) and stiffness index (SI) are the two main indices derived from 
the DVP [Figure 4]. 
 
 RI is computed by the % ratio of the heights (amplitude) of reflected wave (diastolic 
component) to the systolic peak, and is a measure of pulse wave reflection and the 
small artery tone. SI can be calculated from the subject's height divided by the time 
between systolic and diastolic peaks, and is a marker of large arterial stiffness 
(Woodman and Watts 2003).  
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Figure 4. Indices derived from DVP; a) RI, a measure of small arterial tone, b) SI, 
a surrogate marker of large arterial stiffness (Micro Medical Ltd 2007) 
 
 
 
 
 
 
 
 
 
SI was shown to be strongly correlated with the augmentation index as well as 
central pulse wave velocity (Woodman et al. 2003).  
 
In comparison with other established methods for arterial stiffness assessment, pulse 
trace system is the simplest technique, and independent of operator skill. Also, its 
reproducibility is consistent with other accepted methods, with a CV of about 15% 
(Woodman and Watts 2003). Given these advantages, in the present study this 
technique was chosen to evaluate arterial stiffness in subjects with abnormal glucose 
regulation compared to normoglycemic volunteers.  
 
2.2.3.5   Hyperglycemia  
It is well known that diabetes mellitus is linked to an increased prevalence of 
cardiovascular diseases (Ruderman and Haudenschild 1984); however evidence from 
more recent studies has shown that pre-diabetic degrees of fasting and postprandial 
hyperglycemia are also associated with accelerated atherosclerosis (Balkau, Forhan, 
and Eschwege 2002; Balkau et al. 2004; Barzilay et al. 1999; Coutinho et al. 1999; 
DECODE Study Group 2001, 2003; Gabir et al. 2000; Levitan et al. 2004; Meigs et 
al. 2002; Saydah et al. 2001; Stern et al. 2002; Tominaga et al. 1999), resulting in the 
inclusion of  hyperglycemia in diabetic or pre-diabetic ranges as a required 
component of metabolic syndrome (Alberti and Zimmet 1998).  
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2.3   Diabetes mellitus and other categories of hyperglycemia  
2.3.1   Diabetes mellitus 
Diabetes mellitus (DM) is a chronic disease with an epidemic prevalence worldwide  
(Colagiuri et al. 2005). According to the estimation of World Health Organization 
(WHO), there are now more than 180 million diabetic patients in the world and it is 
projected to increase more than double by 2030 (World Health Organization 2009). 
In Australia, the prevalence of diabetes mellitus has been based on two main national 
data sources. According to the AusDiab 1999-2000 study which collected blood 
samples, the prevalence of diabetes was estimated to be 7.4% of adults aged 25 or 
over (Dunstan et al. 2001). The second source of information was self-reported data 
collected from the Australian Bureau of Statistics (ABS) series of National Health 
Surveys (NHS). The latest NHS data show that in 2007-2008, 4.4% of Australians 
reported as being diabetic, which was substantially more than the self-reported rate 
of 2.4% in 1995 (Australian Institute of Health and Welfare 2011; Australian Bureau 
of Statistics 2006). Studies indicate that this increase in the prevalence of diabetes is 
associated with an accelerated risk of developing CVD and other major health 
problems (Australian Institute of Health and Welfare 2008). 
 
2.3.1.1   Definition and diagnosis of diabetes mellitus  
Diabetes mellitus refers to a metabolic disorder characterized by chronic 
hyperglycaemia, due to defects in insulin secretion, resistance to insulin or both 
(Alberti and Zimmet 1998). Hyperglycemia may be detected in an asymptomatic 
person with blood glucose just above the diagnostic cut–off values or be found in a 
subject with severe symptoms and blood glucose levels considerably more than 
normal ranges. Additionally, some conditions such as acute infections, trauma or 
surgery may be associated with a transitional hyperglycemia. So, given the lifelong 
consequences of diabetes mellitus, establishing an accurate diagnosis is very 
important and critical. 
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Table 6. Values for diagnosis of diabetes mellitus and other categories of 
hyperglycemia (Alberti and Zimmet 1998)  
 
 
For diagnostic propose, blood glucose may be measured in venous plasma, venous 
whole blood or capillary whole blood [Table 6]. However, fasting plasma glucose 
(FPG) and 2-h OGTT are the tests recommended by WHO and IDF to identify all 
states of hyperglycemia (World Health Organization 2006). Also, for standardisation 
in Australia, venous plasma glucose was chosen as a recommended method of 
diagnosing diabetes and impaired glucose regulation state (IFG, IGT) by the 
Australian Diabetes Society (ADS) (Diabetes Australia Western Australia 2005; 
Welborn 1996). Additionally, according to the guidelines provided by National 
Health and Medical Research Council (NHMRC), venous plasma glucose 
measurements should be performed by an accredited laboratory, and blood glucose 
meters do not have sufficient accuracy required for definitive diagnosis (Diabetes 
Australia Western Australia 2005; National Health and Medical Research Council 
2001; Poirier et al. 1998). 
 
There is now a general consensus (Alberti and Zimmet 1998; Diabetes Australia 
Western Australia 2005; World Health Organization 2006) that for the symptomatic 
person, a single fasting plasma glucose concentration greater than or equal to 7 
mmol/L or a value greater than or equal to 11.1 mmol/L, 2 hours after a 75 g oral 
glucose load is sufficient to establish the diagnosis [Table 6]. However, in 
asymptomatic subjects, at least two diagnostic glucose results in excess of the 
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diagnostic values on different days are essential, either fasting, from a random 
sample, or following oral glucose tolerance tests (OGTT).  
 
2.3.1.2  Classification of diabetes mellitus 
The first classification of diabetes mellitus was offered by the WHO Expert 
Committee in 1980 (World Health Organization 1980). In the 1980 Expert 
Committee report, diabetes mellitus was classified into two major types, “insulin–
dependent diabetes mellitus” (IDDM ) or Type 1 and “non–insulin–dependent 
diabetes mellitus” (NIDDM) or Type 2, as well as other classes of diabetes 
including: other specific types, impaired glucose tolerance (IGT) and gestational 
diabetes mellitus (GDM). In 1985, the WHO Study Group recommended a modified 
form of classification, in which the terms type 1 and type 2 diabetes were eliminated 
and the terms of insulin-dependent and non-insulin dependent diabetes (IDDM and 
NIDDM) retained (World Health Organization 1985). Additionally, a new class of 
malnutrition–related diabetes mellitus (MRDM) was introduced. 
 
The latest classification of diabetes mellitus was established in 1997 to encompass 
both clinical stages and etiological types of hyperglycemia (Kuzuya and Matsuda 
1997). In the new classification, which is universally accepted (Alberti and Zimmet 
1998; Welborn 1996; World Health Organization 2006), the terms “insulin–
dependent diabetes mellitus” (IDDM) and “non–insulin–dependent diabetes 
mellitus” (NIDDM) have been considered as confusing, because insulin treatment 
may be required at some stage of any type of diabetes. Accordingly, in the revised 
classification, these terms are omitted and the terms type 1 and type 2 diabetes 
reintroduced. Other aetiological types, such as diabetes caused by genetic defects or 
infections are classified as "other specific types", and gestational diabetes is the 
fourth class. 
 
2.3.1.3   Risk factors of type 2 diabetes mellitus  
It is believed that a range of genetic, behavioral and biomedical conditions can 
contribute to the onset and development of diabetes. Among them, the following 
factors have been considered as playing a more significant role.  
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 Age. Evidence indicates that the risk of developing diabetes increases with 
age (Australian Bureau of Statistics 2006; Dunstan et al. 2001). Based on 
measured data from the AusDiab 1999–2000 study, among adults aged 35–44 
years the prevalence of diabetes was fewer than 3%. However, this rate 
increased to 23% for people aged 75 years and over (Dunstan et al. 2001). 
 Obesity and low of physical activity. It is believed that individuals with extra 
body fat or/and insufficient physical activity have a greater likelihood of 
developing diabetes mellitus, resulting from the increased risk of resistance to 
insulin and defects in insulin secretion (Chan et al. 1994; Sharma 2006; 
Telford 2007). Based on the National Physical Activity Guidelines for 
Australians, at least 30 minutes of moderate physical activity on at least five 
days of the week, or 150 minutes spread out over five sessions in a week is 
recommended as the sufficient level for prevention of chronic diseases 
(Australian Institute of Health and Welfare 2003; Department of Health and 
Ageing; Australia 1999). 
 Smoking. Longitudinal studies indicate that the incidence of diabetes mellitus 
among smokers was significantly higher than non-smokers. Additionally, in 
was shown that quitting smoking could reduce the increased risk of 
developing diabetes to that of non-smokers after some years (Eyre et al. 
2004). 
 Being from a high-risk racial/ethnic population. Epidemiological studies 
indicate that diabetes mellitus is more common among some certain ethnic 
groups (Harris et al. 1995; Valle, Tuomilehto, and Eriksson 1997; Zimmet 
1992). According to the Australian Bureau of Statistics (ABS) series of 
National Health Surveys (NHS) data, in 2004-2005 the rate of diabetes 
among Aboriginal and Torres Strait Islander peoples was three times more 
than non-indigenous Australians (Australian Bureau of Statistics 2006). In 
addition, it has been shown that Australians who were born in the South 
Pacific Islands, Southern Europe, Middle East, North Africa and Southern 
Asia have higher rates of diabetes compared to Australian-born people 
(Australian Institute of Health and Welfare 2003). 
 Past history of gestational diabetes mellitus (Alberti and Zimmet 1998).  
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 Having a relative with diabetes mellitus (de Courten et al. 1997; Knowler et 
al. 1993; Valle, Tuomilehto, and Eriksson 1997). 
 Being recognized as having impaired glucose regulation [impaired glucose 
tolerance (IGT) or impaired fasting glucose (IFG)] on previous testing. 
According to existing evidence, individuals with impaired glucose regulation 
are 10-15 times as prone to developing diabetes relative to those with normal 
blood glucose levels (Dunstan et al. 2001) and most of them eventually 
(perhaps after many years) develop diabetes (de Vegt et al. 2001; Knowler et 
al. 2002; Larsson et al. 2000; Santaguida et al. 2005; Shaw et al. 1999; 
Tuomilehto et al. 2001; Twigg et al. 2007; Vendrame and Gottlieb 2004). 
Studies investigating the role of impaired glucose regulation as a predictor of 
developing diabetes indicate that the majority of people with diabetes (60%) 
had a history of either IGT or IFG during five years before being diagnosed 
as diabetics (Unwin et al. 2002). 
 
2.3.2   Impaired glucose regulation  
Impaired glucose regulation describes an intermediate stage of abnormal glucose 
regulation between normal glucose state and diabetes (Alberti and Zimmet 1998). 
This disordered carbohydrate metabolism may be represented in the fasting condition 
(IFG) or post– prandial (IGT), with different physiological bases (see Section 
2.3.2.3). In Australia, 16.4% of adults aged 25 and over, participating in the 1999–
2000 AusDiab study, were found to have impaired glucose regulation, with IGT 
being more common than IFG (10.6% and 5.8%, respectively) (Dunstan et al. 2001) 
[Table 7]. 
 
Table 7.  Prevalence of impaired glucose regulation among Australians aged 25 
years and over, 1999–2000 (per cent) (Dunstan et al. 2001) 
 
Measure Males Females Persons 
Impaired glucose tolerance 9.2 11.9 10.6 
Impaired fasting glucose 8.1 3.4 5.8 
Total impaired glucose regulation 17.4 15.4 16.4 
. 
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2.3.2.1   Impaired fasting glycaemia (IFG) 
Impaired fasting glycaemia (IFG) is defined as fasting blood glucose values above 
the normal range, but below those diagnostic of diabetes (Alberti and Zimmet 1998). 
It was estimated that in 1999-2000, 5.8% of Australians aged 25 years and above had 
IFG, being more prevalent among men (Dunstan et al. 2001) [Table 7]. 
 
The diagnostic values for IFG are defined as the fasting plasma glucose 
concentration of 6.1 mmol/L (110 mg/ dl) or greater, but less than 7.0 mmol/L (126 
mg/dl) (Alberti and Zimmet 1998) [Table 6]. Individuals with IFG may be 
reclassified as IGT or diabetic if an OGTT is carried out. Therefore, performing an 
OGTT is recommended for all individuals with IFG to rule out the diagnosis of 
diabetes (Alberti and Zimmet 1998; Diabetes Australia Western Australia 2005). 
 
2.3.2.2   Impaired Glucose Tolerance (IGT)    
Impaired glucose tolerance represents abnormalities of glucose metabolism in the 
post-prandial condition (Alberti and Zimmet 1998). 
 
The worldwide prevalence of IGT was estimated to be 8.2% of the adult population 
(314 million people) in 2003. It is predicted that this rate will increase to 9% (472 
million people) by 2025, with the highest prevalence rate of 13.5% in South-East 
Asia (International Diabetes Federation 2009). 
 
In Australia, according to measured data from 1999-2000 AusDiab study, 9.2% of 
men and 11.2% of women aged 25 and over had IGT [Table 7], peaking among 
Australians aged 75 years and over. This rate was substantially higher than the 
reported prevalence of 3% for both men and women from the 1981 Busselton Study 
(Dunstan et al. 2001).  
 
IGT is diagnosed by means of performing a standard OGTT.  In individuals with 
IGT, blood glucose levels 2 hours after consuming 75 g glucose are greater than 
normal (7.8 mmol/L), but not as high as diagnostic levels for diabetes mellitus (11.1 
mmol/L). Fasting blood glucose levels in people with IGT are normal or moderately 
increased (lower than diabetes levels) [Table 6] (Alberti and Zimmet 1998). Given 
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the considerable day-to-day variability in 2-h plasma glucose level following a 
glucose load, a mean value of two OGTTs is required for diagnosis of IGT by IDF 
(Unwin et al. 2002). Studies indicate that IGT is a major independent risk factor for 
diabetes mellitus (Dunstan et al. 2001). Therefore, it is recommended that in 
individual with IGT, blood glucose measurements should be retested annually 
(Diabetes Australia Western Australia 2005). 
 
It is now established that both IGT and diabetes mellitus are associated with higher 
risks for cardiovascular complications, with diabetes being a stronger risk predictor. 
However, given that the prevalence of IGT is considerably higher than diabetes, it 
has been shown that with some cardiovascular events such as premature deaths, the 
role of IGT was even more significant than diabetes  (DECODE Study Group 1999) 
 
2.3.2.3   Pathogenesis of impaired glucose regulation (IFG & IGT) 
Although IFG and IGT are classified under the same category of impaired glucose 
regulation, the pathophysiologic mechanisms behind these disorders are different 
(Abdul-Ghani et al. 2006; Abdul-Ghani, Tripathy, and DeFronzo 2006; Festa et al. 
2004; Hanefeld et al. 2003). Evidence indicates that IFG and IGT differ mainly based 
on the pattern of insulin secretion and the site of insulin resistance (Abdul-Ghani et 
al. 2006; Abdul-Ghani, Tripathy, and DeFronzo 2006; Hanefeld et al. 2003; Qiao et 
al. 2003).  
 
It is shown that in IFG, hyperglycemia is essentially because of defects in early-
phase insulin secretion as well as hepatic insulin resistance, resulting in the excessive 
fasting hepatic glucose production. Subsequently, during a standard OGTT an 
individual with isolated IFG, the high fasting plasma glucose continues to increase 
throughout the first 30-60 min. Thereafter, due to the normal late-phase insulin 
secretion combined with the appropriate muscle insulin sensitivity, glucose levels 
returns to near fasting values at 120 min [Figure 5]. 
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Figure 5.  Plasma glucose concentration during an OGTT performed in subjects 
with NGT, IGT, IFG or combined IFG/IGT (CGI) (Abdul-Ghani, Tripathy, and 
DeFronzo 2006)  
 
In contrast, people with isolated IGT have a moderate to severe insulin resistance at 
the levels of skeletal muscle rather than hepatic cells.  This resistance to insulin 
combined with deficits in insulin secretion in both early and late phases leads to a 
prolonged hyperglycemia in IGT subjects (Abdul-Ghani et al. 2006; Abdul-Ghani, 
Tripathy, and DeFronzo 2006; Hanefeld et al. 2003; Nathan et al. 2007; Qiao et al. 
2003).  
 
2.3.2.4   Risk factors for impaired glucose regulation (IFG & IGT) 
As with diabetes, the risk of impaired glucose regulation increases with age, 
overweight/obesity, physically inactivity, positive family history of diabetes, 
dyslipidemia or high blood pressure (Amini and Janghorbani 2007; Dunstan et al. 
2001; Harris et al. 1998; International Diabetes Federation 2009; Lim et al. 2000; 
Mohan, Shanthirani, and Deepa 2003). In addition, impaired glucose regulation is 
more prevalent among certain ethnic groups such as Mexican Americans, African 
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Americans and South East Asians (Harris et al. 1998; International Diabetes 
Federation 2009). 
 
2.3.3   Normoglycaemia 
A fasting venous plasma glucose concentration of <6.1 mmol/ l (110 mg/ dl) and a 
2–h plasma glucose of <7.8 mmol/l (140 mg/dl) has been determined as “normal” 
(Alberti and Zimmet 1998; World Health Organization 2006). Values above this are 
related with a progressively higher risk of developing micro and macrovascular 
complications (Alberti 1996; Engelgau et al. 1997). 
 
2.4 Nutrition and hyperglycemia 
The findings of studies have shown that in addition to diabetes mellitus, even non-
diabetic degrees of fasting and postprandial hyperglycemia are directly linked to the 
accelerated risks of cardiovascular diseases (Coutinho et al. 1999; DECODE Study 
Group 2001; Levitan et al. 2004; Meigs et al. 2002). Accordingly, as a part of 
prevention strategies for chronic diseases, studies over the last decade have 
investigated the impact of macro and micronutrients on hyperglycemia in either 
diabetic or pre-diabetic ranges (Anderson 1998; Baliga et al. 2000; Boden et al. 
1996; de Lordes Lima et al. 1998; Greenbaum, Kahn, and Palmer 1996; Paolisso et 
al. 1993; Pittas et al. 2007). For example, Pittas and his colleagues have suggested 
that 3-year supplementation with calcium and vitamin D may modify rises in fasting 
blood glucose and insulin resistance in elderly subjects with IFG,  though there was 
no effect on the markers of inflammation (Pittas et al. 2007).  
 
 The attention of researchers has recently been attracted by thiamin. The 
administration of thiamin has been implicated to have an array of benefits in the 
prevention of hyperglycemia complications (see Sections 2.5.9&2.5.10). 
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2.5   Thiamin 
2.5.1   Chemistry 
Thiamin (also known as vitamin B1 or aneurin) is a water soluble vitamin with 
a chemical formula C12H17N4OS, containing a pyrimidine and a thiazole ring 
connected by a methylene bridge. Thiamin monophosphate (TMP), thiamin 
diphosphate (TDP) [called also thiamin pyrophosphate (TPP)] and thiamin 
triphosphate (TTP) are natural derivatives of thiamin in the blood and tissues. 
Synthetic forms of thiamin include the hydrochloride and mononitrate salts, and non-
water-soluble derivatives (e.g. benfothiamine).  
 
Thiamin is stable at acidic pH and during frozen storage, but becomes increasingly 
unstable at high pH and temperature, and when exposed to ultraviolet light (Brody 
1999; Butterworth 2006; Institute of Medicine 1998; Tanphaichitr 1999).  
 
2.5.2  Dietary sources 
Thiamin is found in a wide range of foods such as yeast, grain products, meat 
products, vegetables, dairy products, legumes, fruits and egg. Of these, bread and 
cereal products are considered the major dietary sources of thiamin, due to their 
staple role in most people's diets. Thiamin is highly concentrated in the pericarp and 
germ of cereals (Butterworth 2006; Institute of Medicine 1998; Tanphaichitr 1999). 
Thus, the thiamin content of whole grains is significantly more than refined grains.  
In some countries, such as Canada, UK and Australia, wheat flour used for making 
bread is fortified with thiamin mononitrate to restore losses during processing. In 
Australia, mandatory fortification of bread-making flour with thiamin was started in 
January 1991 (Harper and Butterworth 1997; The National Health and Medical 
Research Council 1990). According to the Australia New Zealand Food Standards 
Code, bread-making flour must contain at least 6.4 mg/kg of thiamin (Food 
Standards Australia New Zealand 2009). The  National Nutrition Survey 1993 
showed that, as a result of thiamin enrichment program in Australia, only 3% of 
women and 7% of men had a low thiamin intake (Baghurst et al. 1996), while studies 
in the 1980s indicated that thiamin intakes of 10%-20% of Australians were below 
the recommended values (Wood and Breen 1980). 
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2.5.3  Recommended amounts & upper intake level 
The storage of thiamin in the body is limited and it also has a high turnover. 
Therefore, a regular supply is necessary. Because thiamin is involved in energy 
utilisation pathways, requirements are related to energy intake. In most countries, a 
daily requirement of at least 0.4 mg/1000 kcal is recommended for healthy adults 
(Department of Health 1991). In Australia, the recommended dietary intakes (RDI) 
for healthy men and women with moderate activity are set on 1.2 and 1.1 mg/day, 
respectively (National Health and Medical Research Council 2006). 
 
The oral toxicity of the water-soluble forms of thiamin found in foods or dietary 
supplements in humans is very rare and its symptoms are reported mainly at very 
high doses (≥ 7000 mg) (Meador et al. 1993). However, some significant adverse 
effects have been reported following its inappropriate parenteral or intramuscular 
administration (Morinville, Jeannet-Peter, and Hauser 1998; Stephen, Grant, and Yeh 
1992; Wrenn, Murphy, and Slovis 1989). Existing  data from clinical studies are 
insufficient to estimate a tolerable upper intake level (UL) for thiamin (National 
Health and Medical Research Council 2006). 
 
2.5.4   Physiology 
Following ingestion of food or supplements containing thiamin, uptake occurs 
mainly in the proximal part of small intestine (Rindi and Laforenza 2000).  Intestinal 
uptake of thiamin is dose-dependent, through an active, carrier-mediated transport 
system at physiological  concentrations (less than 1 μmol/L) and passive diffusion at 
high concentrations (Rindi and Ferrari 1977). In the intestinal lumen, free thiamin is 
normally taken up across enterocyte membranes using high affinity transporters, 
THR1and THR2 (Thornalley 2005). These thiamin transporters are encoded by two 
members of the SLC (solute carrier) 19A gene family, SLC19A2 and SLC19A3 
(Dutta et al. 1999; Rajgopal et al. 2001). THR1 is the transporter on the basolateral 
surface of gastrointestinal epithelial cells, and in skeletal muscle, placenta, heart, 
liver, kidney and red blood cell plasma membrane (Dutta et al. 1999; Reidling et al. 
2002; Thornalley 2005; Thornalley et al. 2007). The second thiamin transporter, 
THR2, is present on the luminal surface of enterocytes, and in placenta, kidney and 
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liver (Eudy et al. 2000; Said et al. 2004; Thornalley 2005). Another member of the 
SLC19 family (SLC19A1) is known to encode the reduced folate transporter RFC-1, 
transporting folic acid as well as TMP and TDP into cells (Matherly 2001; Zhao, 
Gao, and Goldman 2002). RFC-1 is expressed in various human tissues including: 
erythrocytes and renal brush border membranes, mediating re-absorption of filtered 
TMP and TDP (Thornalley 2005; Thornalley et al. 2007). As a result, these 
metabolites of thiamin are not present in the urine under normal circumstances.  
 
Thiamin absorption is generally enhanced following thiamin deficiency (Laforenza et 
al. 1997), which is suggested to be because of an increased expression of tissue 
THR1 (Laforenza et al. 1997). Thyroid hormones and insulin can influence the 
intestinal tissue and regulate the uptake of thiamin (Patrini et al. 1996). Following 
uptake, thiamin is phosphorylated in the intestinal epithelial cells. However, it is 
released into the blood mainly as its free form. This process is dependent on Na
+
 and 
a transcellular H
+
 gradient (Combs 2008; Rindi and Laforenza 2000).  Thiamin is 
distributed in the blood within both plasma (10%) and cells (90%). In plasma, less 
than 10% of thiamin is phosphorylated, and most of plasma thiamin is bound to 
proteins, mainly albumin (Royer-Morrot et al. 1992). About 80% of total whole 
blood thiamin is present in the erythrocytes, mainly in the form of TDP (Kimura and 
Itokawa 1985; Schrijver et al. 1982). In tissues, thiamin is mainly converted to its 
phosphorylated esters and the highest concentrations are present in the liver, heart, 
kidney, muscles and brain. The thiamin (in its free form) is excreted in the urine and 
thiamin intake in excess of requirements results in an increased urinary excretion 
(Butterworth 2006; Tanphaichitr 1999). 
 
There are a few clinical studies which have investigated the kinetics of thiamin. For 
example, Davis and colleagues reported that after an oral test dose of 10 mg,  the 
mean serum thiamin increased moderately (42%) and then returned to baseline 
within 6 hours (Davis et al. 1984). With higher pharmacological dosages, Royer-
Morrot and colleagues showed that following 11-day administration of thiamin orally 
(250 mg every 12 hours) or intramuscularly (500 mg/once a day) in healthy young 
men, plasma concentrations of thiamin [3.2 ±1.7 μg/L (11±5.7 nmol/L) at baseline] 
reached a steady state after 5.6 [23 μg/L (76 nmol/L)] and 7 days [29 μg/L (96 
nmol/L)], respectively. The mean elimination half-life value of 1.8 days was 
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calculated (Royer-Morrot et al. 1992). In another clinical study (Rabbani et al. 2009) 
conducted in type 2 diabetic patients,  a median (range) plasma thiamin concentration 
of 98.2 (2.6-294.5) nmol/L was found after supplementation with 300 mg/day 
thiamin for 3 months [10.6 (0.8-84.5) nmol/L at baseline].  In these studies, the 
plasma thiamin concentrations were considerably low relative to the administrated 
doses, indicating the very low bioavailability of thiamin and its poor oral absorption,  
its wide distribution in the body and/or its high turnover (Rabbani et al. 2009; Royer-
Morrot et al. 1992; Smithline, Donnino, and Greenblatt 2012; Tallaksen et al. 1993).     
 
2.5.5   Interactions and anti-thiamin factors 
It is known that the uptake and metabolism of thiamin can be impaired following 
alcohol consumption (Hoyumpa 1980). Ethanol was shown to reduce the active 
transport of thiamin into enterocytes via inhibition of Na/K-ATPase (Rindi and 
Ferrari 1977), and alters the phosphorylation of thiamin to TDP (Rindi, Imarisio, and 
Patrini 1986). These effects are the likely explanation for the higher prevalence of 
thiamin deficiency among alcoholics (Butterworth 2006; Wood and Breen 1980).  
 
The availability of thiamin for uptake can be also reduced by anti-thiamin factors 
present naturally in the diet [Table 8] (Prinzo 1999). These include the thiamin-
degrading enzyme (thiaminase) present in raw or fermented fish, shellfish, ferns and 
certain bacteria, and thiamin antagonists found in some foods (e.g. tea, coffee and 
betel nuts) (Butterworth 2006; Prinzo 1999). In vitro, ascorbic acid (vitamin C) has 
been shown to protect the modification of thiamin by tea and other tannin-containing 
products (Kositawattanakul et al. 1977).  
 
The metabolism of thiamin can be also affected by magnesium status. Magnesium 
acts as a cofactor in the transketolase reaction (see Section 2.5.7) (Fattal-Valevski 
2011; Lonsdale, Shamberger, and Obrenovich 2011) and the phosphorylation of 
thiamin to TDP (Voskoboyev and Ostrovsky 1982). It was shown that magnesium 
deficiency may occur in patients with known diabetes (type1&2) (Tosiello 1996). 
However, there has been no indication of hypomagnesemia among those with pre-
diabetes (IGT&IFG) (Simmons, Joshi, and Shaw 2010). 
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Table 8. Types of anti-thiamin factors and their actions (Prinzo 1999) 
 
 
 
2.5.6   Thiamin deficiency 
As mentioned above, thiamin is taken up from gastrointestinal tract, transported 
through the portal blood to the liver, taken up into cells and excess is excreted mainly 
in the urine. So, thiamin deficiency may be caused by an inadequate dietary intake of 
the vitamin, reduced absorption, defective uptake into cells, increased requirements 
and enhanced losses (Butterworth 2006; Institute of Medicine 1998; Tanphaichitr 
1999). 
 
The biological half-life of thiamin is approximately between 9 to 18 days (Ariaey-
Nejad et al. 1970) and given the limited storage of thiamin, a sub-clinical deficiency 
can develop rapidly (Brin 1963). The symptoms in the early stage of deficiency are 
non-specific, including anorexia, weakness, aching, burning sensation in hands and 
feet, indigestion, irritability and depression (Prinzo 1999). Clinical deficiency of 
thiamin can affect the cardiovascular and nervous systems, leading to the major 
diseases of Beriberi and Wernicke-Korsakoff syndrome (Prinzo 1999). 
A genetic defect in the intracellular transport of thiamin can cause the autosomal 
recessive disorder of TRMA syndrome (thiamin-responsive megaloblastic anemia), 
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which is characterised by the triad of megaloblastic anemia with ringed sideroblasts, 
diabetes mellitus, and progressive sensorineural deafness (Neufeld et al. 2001).    
 
Thiamin deficiency has been primarily reported in some parts of South-East Asia, 
where polished rice is the main dietary ingredient, and the diet generally contains 
anti-thiamin factors, such as  tea leaves, herring, shellfish, raw carp, fermented fish 
and betel nuts (Kositawattanakul et al. 1977; Lee 1994; Vimokesant et al. 1982; 
Vimokesant et al. 1975). In Western countries, thiamin deficiency has been mostly 
demonstrated in association with the regular high alcohol intake (Institute of 
Medicine 1998). High alcohol consumption is recognized to alter the uptake and 
metabolism of thiamin (Hoyumpa 1980). Also, studies indicate that patients with 
human immunodeficiency virus-acquired immunodeficiency syndrome (HIV-AIDS) 
(Butterworth et al. 1991), gastrointestinal and liver diseases, persistent vomiting 
(Michel et al. 2010), and appetite disorders as well as those receiving parenteral 
nutrition (Rastenyte et al. 2003) or using certain drugs, such as diuretics, increasing 
excretion of thiamin in the urine (Kwee and Nakada 1983; Suter and Vetter 2000), 
have been recognised as being at high risk for the development of thiamin 
deficiency.  
 
Some recent studies demonstrated that both type 1 and type 2 diabetic patients are 
also at risk of thiamin deficiency (Jermendy 2006; Saito et al. 1987; Thornalley et al. 
2007; Valerio et al. 1999; Vindedzis et al. 2008). The findings of Saito et al (1987) 
indicate that only 23.9 % of 46 diabetic outpatients studied had a total blood thiamin 
concentration more than the normal lower limit. Low levels of plasma thiamin were 
found by Valerio et al. (1999) who compared thiamin status of 10 children with type 
1 diabetes (35.3 ± 3.6 pmol/mL) with that of six age-matched normal subjects (53.2 
± 2.3 pmol/mL, p< 0.05). This was confirmed by Thornalley et al. (2007) who 
showed that thiamin concentration in blood plasma was decreased by 76 per cent in 
type 1 (26 subjects) and by 75 per cent in type 2 diabetic patients (48 subjects). 
However, studies investigating red blood cell thiamin levels in diabetic patients 
reveal opposing results. While, some studies reported low RBC thiamin levels in 
diabetic patients (Vindedzis et al. 2008), it was normal in another study (Thornalley 
et al. 2007). These controversial results could be due to differences in sampling and 
assay techniques, as well as problems in the studies' methodology. For instance, only 
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a few authors (Jermendy 2006; Thornalley et al. 2007) considered excess alcohol 
consumption as an exclusion criteria in their studies, or no data were provided on 
thiamin intake in the study conducted by Thornalley et al. (2007). 
 
The mechanisms responsible for thiamin deficiency in diabetics are not well known. 
In the study conducted by Thornalley et al. (2007) low plasma thiamin was 
associated with an increased excretion of thiamin in the urine. In that study, subjects 
had diabetes of long duration (22.1 ± 13.3 and 13.0 ± 8.9 y for type 1 and type 2, 
respectively). The renal damage resulting from diabetes was clearly evident in 
approximately 1/3 of subjects who had urinary albumin excretion characteristic of 
microalbuminuria and incipient nephropathy. The same group showed that the 
increased fractional excretion of thiamin in diabetics was more significant in patients 
with microalbuminuria and early GFR decline than in individuals with stable renal 
function (Adaikalakoteswari et al. 2008). In addition to an increased renal excretion, 
a decreased intestinal thiamin absorption may also contribute to the low thiamin 
levels observed in diabetic patients (Patrini et al. 1996).  With regard to the role of 
thiamin in glucose metabolism, diabetes-associated thiamin deficiency is expected to 
amplify the cellular damage induced by hyperglycemia.  It is also suggested that the 
consequences of thiamin deficiency described in diabetics could be exaggerated in 
vascular endothelial cells, which are at risk of high intracellular glucose 
concentrations (Kaiser et al. 1993) and subsequent reactive oxygen species (ROS) 
overproduction. Such accumulated ROS could oxidise the limited thiamin available 
in the cells and produce components such as thiochrome and oxydihydrothiochrome, 
which in turn, have inhibitory effects on thiamin-dependent enzymes (Stepuro et al. 
1997; Zimatkina et al. 1991). 
 
2.5.7   Role of thiamin in cell function 
Thiamin plays an essential regulatory role as a co-enzyme in metabolic pathways 
involving sugars, amino acids and fatty acids (Bender 1999; Butterworth 1993; 
Foulon et al. 1999; Gibson and Zhang 2002). It also modulates neural and neuro-
muscular transmission, likely via activation of the chloride ion channel (Bender 
1999).  Following uptake from gastrointestinal tract into the cell, thiamin is rapidly 
phosphorylated to its active form, TDP. TDP is a cofactor for enzymes in glucose 
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and energy metabolism (Bender 1999; Butterworth 1993; Gibson and Zhang 2002), 
including transketolase, pyruvate dehydrogenase complex and α-ketoglutarate 
dehydrogenase (αKGDH) [Figure 6].  
 
Transketolase (TK) is a key enzyme in the pentose phosphate pathway, generating 
pentose sugars which in turn are required for synthesis of nucleic acids and their 
precursors. In fact, this TDP-dependent enzyme catalyses the transfer of two-carbon 
(glycolaldehyde group) fragments from one sugar phosphate to another, leading to 
the lengthening of the carbon chain of the acceptor sugar phosphate at the expense of 
the donor (Bates 2009) [56]: 
 
                        xylulose-5-phosphate(C5) + ribose -5-phosphate(C5)     
                            glyceraldehyde-3-phosphate(C3) + sedoheptulose-7-phosphate (C7) 
and 
                        xylulose-5-phosphate (C5) + erythrose-4-phosphate (C4) 
                           glyceraldehyde- 3-phosphate (C3) + fructose-6-phosphate (C6) 
 
 
Figure 6. Thiamin diphosphate-dependent enzymes. αKGDH, α-ketoglutarate 
dehydrogenase; PDHC,  pyruvate dehydrogenase complex; TK, transketolase 
(Butterworth 2006) . 
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Under hyperglycemic condition, activation of TK can decrease the accumulation of 
triosephosphates, such as glyceraldehyde-3-phosphate, and of fructose-6-phosphate, 
and subsequently increase intracellular concentration of ribose-5-phosphate. A deficit 
in thiamin is known to reduce transketolase activity. The reduced activity of 
transketolase in erythrocytes is commonly used as a marker for thiamin deficiency 
(Nixon et al. 1990; Warnock 1970).  
 
Similarly, pyruvate dehydrogenase and α-ketoglutarate dehydrogenase (αKGDH) 
complex are respectively responsible for the oxidative decarboxylation of pyruvate, 
the end product of glycolysis, and oxidative decarboxylation of a-ketoglutarate into 
the citric acid cycle (Bates 2009). Given the fundamental role of these TDP-
dependent enzymes in cellular glucose metabolism,  thiamin deficiency can lead to 
the accumulation of alanine (Butterworth and Heroux 1989), lactate and pyruvate 
(Hakim 1984; Horwitt and Kreisler 1949) as well as reducing synthesis of high-
energy phosphates and citric acid cycle intermediates (Aikawa et al. 1984).  
 
Thiamin is also a co-enzyme for branched chain keto-acid dehydrogenase, an 
enzyme contributing to the oxidation of the branched-chain amino acids, valine, 
leucine, and isoleucine (Bender 1999), and 2, hydroxyphytanoyl-CoA lyase in fatty 
acid alpha-oxidation  reactions (Foulon et al. 1999).  
 
2.5.8  Assessment of thiamin status 
Thiamin status is generally assessed indirectly by measuring the erythrocyte 
transketolase activity (ETKA) and the thiamin pyrophosphate effect (TPPE), or 
directly by determining thiamin and its phosphorylated esters concentrations in blood 
components or thiamin in the urine. Other less specific and practical methods include 
thiamin concentrations in the cerebrospinal fluid, and the carbohydrate metabolism 
index, which is based on measuring blood pyruvate and lactate levels following a 
glucose load (Bates 2009). A summary of methods which are generally used for 
assessing thiamin status are as follows: 
 
 Erythrocyte transketolase activity: The measurement of erythrocyte transketolase 
activity (ETKA) is considered the best functional test for evaluating the thiamin 
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status in humans (McCormick and Greene 1994). However, it has some 
limitations because factors other than diet affect it, for example alteration in 
binding of apo-enzyme and co-enzyme resulting from the presence of 
transketolase iso-enzymes (Kaczmarek and Nixon 1983), and reduction in the 
synthesis of apoenzyme in patients with liver diseases (Fennelly et al. 1967) and 
diabetes mellitus (Friedrich 1988). ETKA may not also be an accurate assay in 
diabetic patients, because of being affected by changes in the levels of thiamin 
transporter protein (THTR-1, RFC-1) (Thornalley et al. 2007). It is proposed that 
low levels of plasma thiamin found in diabetes may cause increases in expression 
of genes encoding thiamin transporters and their protein levels in erythrocytes, 
which in turn can maintain ETKA in normal ranges (Thornalley et al. 2007). 
Thiamin pyrophosphate effect (TPPE) is an assay for transketolase, revealing the 
saturation status of transketolase with its coenzyme in erythrocytes (Takeuchi et 
al. 1990). This assay is carried out before and after addition of TPP to the 
erythrocytes and reflects the percentage increase in the basal ETKA after 
stimulation with added TPP and is stated as the activity coefficient (Prinzo 1999). 
Low TPPE and high ETKA are diagnostic criteria for thiamin deficiency [Table 
9].  
 
 Urinary thiamin excretion: Determination of urinary thiamin excretion rate has 
been widely used as an index of thiamin status in humans for many years (Mason 
and Williams 1942; Oldham, Sheft, and Porter 1950). The correlations between 
thiamin intake and urinary excretion are mainly significant when the intake is in 
adequate range, however this indicator is less sensitive under thiamin deficiency 
conditions (Bates 2009). Concentration of thiamin in urine increase sharply 
above the thiamin intake threshold of about 0.3-0.4 mg/1000 kcal in adults 
(Interdepartmental Committee on Nutrition for National Defense 1963). The 
measurement of total thiamin in urine or other body fluids and tissues has been 
traditionally quantitated by microbiological methods (Baker et al. 1964) or by 
chemical assay procedure, involving extraction, oxidation of thiamin to 
thiochrome and measurement of its fluorescence (Leveille 1972; Pelletier and 
Madere 1972).  More recently, the development of high performance liquid 
chromatography (HPLC) with pre-column or post-column conversion to 
thiochrome has provided more sensitive, specific and accurate assays of thiamin 
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status, particularly in deficient individuals (Baines 1985; Talwar et al. 2000; 
Warnock 1982). 
 
 Blood thiamin: Thiamin status can be also determined by the direct assay of 
thiamin in plasma or serum (Tallaksen et al. 1991; Weber and Kewitz 1985), 
washed red blood cells or whole blood (Baines 1985; Talwar et al. 2000). The 
measurement of thiamin in plasma/serum is less frequently used to assess tissue 
storage, because, in contrast to erythrocyte thiamin (Brin 1964), the extracellular 
concentration of thiamin is mainly a reflection of the recent intake. Also, 
approximately 10% of total blood thiamin is found in the plasma and 80% is in 
erythrocytes (Talwar et al. 2000). As a result, plasma thiamin concentration is 
difficult to assay precisely without being contaminated by the leakage of thiamin 
from the blood cells during the preparation of samples (Bates 2009). 
Accordingly, some investigators have identified the concentration of TDP in 
erythrocytes determined by the HPLC assay as the most sensitive indicator of 
thiamin status in individuals who are at risk of thiamin deficiency (Baines and 
Davies 1988; Brin 1964; Howard 2000; Talwar et al. 2000).  However, 
Thornalley et al. (2007) suggested using plasma thiamin for evaluating thiamin 
status in diabetic patients, because the measurement of erythrocyte thiamin as 
well as the erythrocyte transketolase activity may be affected by the increased 
thiamin transporter protein levels.  
 
Table 9. Reference values for the primary measures of thiamin status in 
       adults  (Institute of Medicine 1998) 
   
         Indicator                                                Marginal deficiency       Severe deficiency 
         ETKA  (Schrijver 1991)                                 1.20-1.25                           >1.25 
         TPPE % (Brin 1970)                                       15-24                                  ≥25 
         Urinary thiamin (Schrijver 1991)      
              (nmol[μg]/g creatinine)                             90-220 [27-66]                    <27 
                          (nmol[μg]/d)                                  133-333[40-100]                 <40 
         Erythrocyte thiamin  (Schrijver 1991)    
             (nmol/L)                                                        70-90                                 <70 
 
 
44 
 
2.5.8.1  Analytical methods for thiamin measurement 
 Several methods have been described for the determination of thiamin in biological 
fluids and tissues. These techniques can be classified into two categories:  
 
1. Microbiological determinations: Some species of Lactobacilli, such as L. 
viridescents (Hankin and Squires 1960) and L. fermenti (Icke and Nicol 1994), or 
Ochromonas danica (Baker et al. 1964) have been used to measure total thiamin in 
biological materials. These methods are feasible and sensitive to detect 5-50 ng 
amounts of thiamin (Hurst 2008). Icke & Nicol described a microbiological assay of 
thiamin with an inter-batch precision (CV%) ranging from 7.4% to 10%  and  
recovery of thiamin pyrophosphate between 101 - 110 % (Icke and Nicol 1994).  
 
Microbiological methods are not now generally used due to being time consuming 
compared to high performance liquid chromatography (HPLC) methods, and 
methodological complexities.  
 
2. Physicochemical methods:  These methods are used to measure thiamin and its 
phosphate esters in the biological samples using fluorimetry or HPLC.  
 
In fluorimetric assays, following enzymatic hydrolysis of the thiamin phosphate 
esters, a clean-up procedure using ion-exchange chromatography is applied. 
Subsequently, thiamin is oxidised by potassium ferricyanide or other oxidant 
reagents (such as KMnO4 or MnO2) to form thiochrome required for fluorimetric 
detection. Thiochrome derivatives are then extracted into an organic solvent such as 
isobutanol prior to final analysis by a fluorophotometer (Myint and Houser 1965). 
Nowadays, the traditional fluorimetric assays are generally replaced by new HPLC 
techniques.  
 
HPLC methods are now the most common techniques used for the measurement of 
thiamin or its phosphate esters in blood and urine samples. In some methods, thiamin 
is determined directly by HPLC with UV detector (Hilker and Clifford 1982). 
However, methods using HPLC with fluorescence detection (after conversion of 
thiamin to fluorescence thiochrome) are much more sensitive than UV detection 
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(Botticher and Botticher 1986). The thiochrome procedure can be carried out either 
before the chromatographic separation or after the column. Both pre- and post-
column derivatisation techniques are robust, sensitive and precise (Baines 1985; 
Botticher and Botticher 1986; Schrijver et al. 1982; Talwar et al. 2000; Warnock 
1982), however post column methods are less time consuming (analysis time <15 
min) compared to pre-column techniques (Talwar et al. 2000). In contrast, HPLC 
with pre-column derivatisation provide results with sharper peaks and better 
resolution (Zempleni et al. 2007).     
 
The best results can be achieved by reversed phase HPLC (Ake, Soko, and Malan 
2006; Korner et al. 2009; Talwar et al. 2000). A reversed - phase HPLC method with 
post column derivatisation and fluoresence detection was used for determination of 
TDP in whole blood and washed red blood cells by Talwar et al. (2000). The inter- 
run coefficent variation (CV) was reported as <  8%, with recovery of TDP from 
blood samples > 90%  and detection limit of 130 ng on column.  
 
 
2.5.9   The potential effects of thiamin in preventing hyperglycemic 
complications: mechanisms of action 
 
It is well known that hyperglycemia induces a variety of biochemical abnormalities 
at the cellular level (particularly in endothelial cells), resulting in a range of vascular 
and tissue damage. Existing evidence reveals that thiamin may modify specific 
mechanisms involved in hyperglycemic complications (Berrone et al. 2006). These 
mechanisms include: increased flux through the polyol pathway, the hexosamine 
pathway activity, protein kinase C (PKC) activation, advanced glycation end 
products (AGEs) formation, increased oxidative stress formation, and inflammation, 
which occur mainly because of the diversion of excess glycolytic intermediates to 
alternative pathways (Aronson 2008; Aronson and Rayfield 2002; Xu, He, and King 
2005).  
 
 
 
46 
 
The polyol pathway 
The shunting of excess intracellular glucose into the polyol pathway is one of the 
mechanisms suggested to contribute to the pathogenesis of hyperglycemia 
complications (Dagher et al. 2004; Kinoshita 1986) .  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Pathological link between oxidative stress formation and other 
mechanisms involved in hyperglycemia-dependent cell damages. GFAT; 
Glutamine:fructose-6-phosphate amidotransferase, DHAP;   Dihydroxyacetone 
phosphate, DAG;  Diacylglycerol   , PKC;.Protein kinase C, PARP; Poly (ADP-
ribose) polymerase GAPDH; Glyceraldehyde 3-phosphate dehydrogenase, 
AGE; Glycation end products. Reproduced from Brownlee (2001) with 
modification. 
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In fact, glucose flux through the polyol pathway increases considerably when 
intracellular glucose concentrations are high and hexokinase, the enzyme responsible 
for converting glucose into glucose 6-phosphate, becomes saturated [Figure 7, 
pathway 1].  The excess glucose load is then available to aldose reductase, the rate-
limiting enzyme in the polyol pathway, to be catalysed to sorbitol (Beyer and Hutson 
1986; Cárdenas, Cornish-Bowden, and Ureta 1998). 
 
With respect to the slow metabolism of sorbitol and also difficulty in its diffusion 
through cell membranes, accumulation of sorbitol and subsequent imbalance in 
intracellular homeostasis, have been proposed as the likely explanation for 
hyperglycemia-dependent damages in many cell types (e.g. vascular pericytes and 
endothelial cells, corneal epithelial cells,  ganglion and Muller glial cells  and  the 
epithelial cell lining  renal tubules) (Chung and Chung 2003; Crabbe and Goode 
1998; Dvornik 1987, 1987; Kinoshita and Nishimura 1988; Kinoshita 1986; 
Williamson et al. 1993). 
 
Thiamin was demonstrated to be effective in preventing damages induced by 
hyperglycemia via normalisation of the polyol pathway. As mentioned before, the 
increased glucose flux through the polyol pathway is known to be due to the high 
intracellular concentrations of glucose and the subsequent hexokinase saturation 
(Beyer and Hutson 1986; Dagher et al. 2004). High dose thiamin is thought to be 
able to redirect the excess levels of metabolic intermediates, glyceraldehyde-3-
phosphate (G3P) and fructose-6-phosphate, from the glycolytic pathway toward the 
reductive pentose shunt, as an alternative pathway. Consequently, alleviate pressure 
on the polyol pathway [Figure 8] (Hammes et al. 2003). Addition of thiamin (50-500 
µM) to human red blood cells incubated in high glucose condition (50 mM glucose) 
was shown to increase the transketolase activity, increase the concentration of total 
sedoheptulose-7-phosphate and ribose-5-phosphate, and decrease the accumulation 
of triosephosphates pool glycolytic intermediates (Thornalley, Jahan, and Ng 2001). 
The positive effect of thiamin on transketolase activity and a consequent increase in 
the conversion of triosephosphate to ribose-5-phosphate were confirmed by an 
animal study conducted on STZ diabetic rats treated with high dose thiamin (7-70 
mg/kg) for 24 weeks (Babaei-Jadidi et al. 2003).  
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Figure 8. Potential mechanism by which benfotiamine blocks 4 pathways of 
hyperglycemic damage. Hyperglycemia-induced mitochondrial superoxide 
overproduction partially inhibits the glycolytic enzyme GAPDH, thereby diverting 
upstream metabolites from glycolysis into glucose-driven signalling pathways of 
glucose overuse. Thiamin activates the thiamine-dependent pentose phosphate 
pathway enzyme transketolase (TK), which converts excess fructose-6-phosphate and 
glyceraldehyde-3-phosphate to pentose-5-phosphates and erythrose-4-phosphate. P, 
phosphate; GFAT, glutamine; fructose-6-phosphate amidotransferase; DHAP, 
dihydroxyacetone phosphate (Hammes et al. 2003).  
 
Thiamin was also shown to up regulate mRNA level for the thiamin-dependent 
enzyme pyruvate dehydrogenase in vitro, which results in accelerated glycolysis (La 
Selva et al. 1996; Pekovich, Martin, and Singleton 1998). Recently, it was found that 
addition of thiamin to vascular cells cultured in high glucose reduces aldose 
reductase mRNA and activity as well as the intracellular concentrations of glucose 
and sorbitol (Berrone et al. 2006). 
 
The hexosamine pathway 
Glucose metabolism via the hexosamine pathway is another mechanism implicated 
in hyperglycemia complications. In the hexosamine pathway, the glycolytic product 
fructose 6-phosphate, instead of conversion to fructose 1,6 biphosphate, the next 
intermediate of glycolysis pathway, is converted into glucosamine-6-phosphate by 
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the enzyme glutamine:fructose-6-phosphate amidotransferase (GFAT) [Figure 7, 
pathway 2]. Glucosamine-6-phosphate is then converted to UDP-N-
acetylglucosamine (UDP-GlcNAc) which is a substrate for O-linked glycosylation 
(Brownlee 2001; Kolm-Litty et al. 1998) [Figure 9].  
 
In   O-linked   glycosylation a hexosamine, usually N-acetylglucosamine (GlcNAc), 
is added to serine or threonine residues, which otherwise, under normal 
circumstance, are phosphorylated by serine/threonine kinases. Serine/threonine 
prosphorylation is known to play a critical role in the regulation of a number of 
cellular processes, including various enzymes. As a result, involving serine or 
threonine in O-linked glycosylation and producing O-linked GlcNAc may modify 
normal activity of many nuclear and cytoplasmic proteins including some 
transcription factors (Brownlee 2001; Wells, Vosseller, and Hart 2001).   
 
According to cellular studies investigating the pathogenesis of hyperglycemia 
complications, the decrease of endothelial nitric-oxide synthase (eNOS) activity  (Du 
et al. 2001), and an increase in the gene expression levels of TGF-β (Kolm-Litty et 
al. 1998) and PAI-1 (Du et al. 2000), are examples of perturbations mediated by the 
hexosamine pathway products. The hexosamine pathway was also demonstrated to 
be involved in  glucose-mediated de novo lipogenesis in the liver and adipocytes by 
increasing mRNA levels of lipogenic enzymes acetyl-CoA carboxylase (ACC), 
glycerophosphate dehydrogenase (GPDH) and fatty acid synthase (FAS) in vitro 
(adipose cell culture) (Rumberger et al. 2003). The effect of increased hexosamine 
flux in the liver on the hepatic glucose and lipid metabolism was confirmed in 
animals. In the study conducted by Veerababu et al. (2000), overexpression of 
glutamine:fructose-6-phosphate amidotransferase in transgenic mice resulted in 
significant increase in hexosamine end product UDP-N-acetyl glucosamine 
concentration, elevated levels of free fatty acids and triglyceride, and higher content 
of hepatic glycogen relative to their non-transgenic littermates. In the long term (after 
9 months) transgenic mice became also significantly heavier than the age-matched 
controls. This was accompanied with a significant increase in the area under the 
curve with performed intraperitoneal glucose tolerance test. 
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Figure 9. The hexosamine pathway. The glycolytic intermediate fructose-6-
phosphate (Fruc-6-P) is converted to glucosamine-6-phosphate by the enzyme 
glutamine:fructose-6-phosphate amidotransferase (GFAT). Intracellular 
glycosylation by the addition of N-acetylglucosamine (GlcNAc) to serine and 
threonine is catalysed by the enzyme O-GlcNAc transferase (OGT). Increased 
donation of GlcNAc moieties to serine and threonine residues of transcription factors 
such as Sp1, often at phosphorylation sites, increases the production of factors such  
as PAI-1 and TGF-b1. AZA, azaserine; AS-GFAT, antisense to GFAT (Brownlee 
2001). 
 
High dose thiamin has been suggested to divert the excess glycolytic intermediate of 
fructose 6-phosphate away from the hexosamine pathway to the pentose phosphate 
pathway (Thornalley 2005) [Figure 8]. This group (Babaei-Jadidi et al. 2004) proved 
that in STZ diabetic rats, increased TK activity resulting from high dose thiamin 
therapy (70 mg/kg, for 24 weeks) was associated with a decrease in hepatic UDP-N-
acetylglucosamine, an intermediate of the hexosamine pathway, and fatty acid 
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synthase activity. In that study, thiamin therapy with a lower dose of 7mg/kg was 
ineffective.  
   
Protein kinase C (PKC) activation 
One of the mechanisms suggested for the damage induced by hyperglycemia is 
activation of protein kinase C (PKC) through diacylglycerol signalling pathway 
(Feener and King 1997; Ishii et al. 1996; Koya and King 1998). PKC is a family of 
serine/threonine kinases, consisting of at least ten isoforms.  
 
This group of protein kinases can be activated by several  signals such as increases in 
the formation of diacylglycerol  from glycerol-3-phosphate, which is derived initially 
from glycolytic intermediates dihydroxyacetone phosphate and glyceraldehyde-3-
phosphate (Koya and King 1998) [Figure 7, pathway 3]. Activation of PKC enzymes 
can result in a wide range of effects on gene expression, and several signal 
transduction cascades through the phosphorylation of other proteins (Koya et al. 
2000). 
 
It is known that the effects of PCK activation are cell-type specific. For example, in 
vascular smooth muscle cells, activation of PKC modulates growth rate, DNA 
synthesis and growth factor receptor turnover (Koya and King 1998). In adipocytes 
and hepatic cells, PKC activation has been suggested to be involved in 
glycogenolysis and gluconeogenesis pathways (Fitzpatrick, Purves, and Augustine 
2004). PKC activation has been also shown to increase the expression of 
transforming growth factor-β (TGF-β) gene, resulting in thickening of the capillary 
basement membrane (Koya et al. 2000) [Figure 10].  
 
In the same way, PKC activation contributes to glucose-induced endothelial 
dysfunction by increasing oxidative stress and decreasing NO bioavailability 
(Beckman, Creager, and Libby 2002; Brownlee 2001). Activation of the protein 
kinase C was indicated to have an important role in vascular complications of 
hyperglycemia in retinal (Shiba et al. 1993), renal (Craven, Davidson, and 
DeRubertis 1990) and cardiovascular tissues (Inoguchi et al. 1992). 
 
52 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Consequences of hyperglycaemia-induced activation of protein 
kinase C (PKC). Hyperglycaemia increases diacylglycerol (DAG) content, which 
activates PKC, primarily the b- and d-isoforms. Activation of PKC has a number of 
pathogenic consequences by affecting expression of endothelial nitric oxide 
synthetase (eNOS), endothelin-1 (ET-1), vascular endothelial growth factor (VEGF), 
transforming growth factor-b (TGF-b) and plasminogen activator inhibitor-1 (PAI-
1), and by activating NF-kB and NAD(P)H oxidases.(Brownlee 2001).  
 
This is consistent by experimental studies in rats showing that administration of a 
PKC beta inhibitor is able to ameliorate and reverse diabetic vascular dysfunction in 
the renal glomeruli and retina (Ishii et al. 1996; Koya et al. 2000).  
 
Potentially, thiamin can inhibit the PKC activation by shifting the excess 
glyceraldehyde-3-phosphate toward the alternative pentose shunt, and facilitating the 
utilisation of glycolysis products in the Krebs cycle. In support of this effect, Babaei-
Jadidi et al. (2003) verified that high dose thiamin therapy can reverse increased 
glomerular PKC activity in STZ diabetic rats. 
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Advanced glycation end products 
The non-enzymatic modification of proteins by glucose-derived advanced glycation 
end products (AGEs) has been shown to play a major role in the pathogenesis of 
vascular damages induced by hyperglycemia (Horie et al. 1997; Stitt et al. 1997). 
 
The process of AGEs formation is referred as glycation to be distinguished from 
enzymatic glycosylation pathways (Aronson 2008) although not all authors follow 
this practice.  AGEs arise from several parallel glycation pathways initiated by the 
metabolites of glucose in early glycation processes. In these pathways, AGEs are 
mainly produced through the biochemical reactions involving: the autoxidation of 
glucose to glyoxal, the formation of Amadori products, and methylglyoxal arising 
from non-enzymatic fragmentation of glyceraldehyde phosphate and 
dihydroxyacetone phosphate, two intermediates of glycolysis (Degenhardt, Thorpe, 
and Baynes 1998; Thornalley 1990; Wells-Knecht et al. 1995) [Figure 11].  
 
 
Figure 11. Simplified scheme of the complex Maillard reaction and formation 
of some advanced glycation end products (AGEs) in vivo. CEL = 
carboxyethyllysine; MOLD = methylglyoxal lysine dimer; DOLD, 3-
deoxyglucosone lysine dimer; CML, carboxymethyllysine; GOLD, glyoxal lysine 
dimer (Meerwaldt et al. 2008). 
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Reducing sugars such as glucose and  glyceraldehyde can react non-enzymically with 
the amino groups of proteins, which is known as the Maillard or non-enzymatic 
browning reaction (Maillard 1912). The early product of this process (Schiff bases) is 
highly unstable, and a lowered concentration of glucose can reverse this reaction 
within minutes [Figure 12]. Over the course of days, this process continues with the 
rearrangement of unstable Schiff bases to form more stable glycation intermediates, 
termed Amadori products. The same as the Schiff base process, Amadori products 
formation is reversible and dependent on the glucose concentration, but at a slower 
rate, reaching its equilibrium levels in weeks. As a result, measurement of Amadori 
products (e.g. hemoglobin A1C) can reflect the degree of glucose control over several 
weeks. Subsequently, over a period of weeks to months, some of Amadori-type early 
glycation products undergo further complex rearrangement reactions and form stable 
and irreversible cross-linked compounds, called advanced glycation end products 
(AGEs) (Brownlee, Cerami, and Vlassara 1988). In the setting of hyperglycemia, 
accumulation of AGEs in vessel walls is known to be implicated in the 
atherosclerotic process through various mechanisms, which can be mediated by a 
receptor or progress without receptor mediation. 
 
 
 
 Figure 12. The formation of advanced glycosylation end products (Aronson 
and Rayfield 2002) 
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Activation of the pentose phosphate pathway by high dose thiamin and subsequent 
elimination of excess G3P from the cytoplasm was also shown to decrease AGE 
formation in bovine retinal and umbilical vein endothelial cells cultured in high 
glucose concentrations (La Selva et al. 1996). This effect was confirmed by 
Thornalley et al. (2001) who showed that the addition of thiamin to human red blood 
cells incubated in high glucose is able to decrease methylglyoxal, a key intermediate 
in the glycation process arising from non-enzymatic fragmentation of glyceraldehyde 
phosphate (Degenhardt, Thorpe, and Baynes 1998) (see Figure 8). Moreover, high 
dose thiamin therapy was indicated to decrease methylglyoxal, glyoxal and 3-
deoxyglucosone concentrations in STZ diabetic rats (Babaei-Jadidi et al. 2003). The 
inhibitory effects of thiamin on AGE formation were described in both initial 
(Beltramo et al. 2002) and late (post-Amadori) stages (Booth, Khalifah, and Hudson 
1996) of glycation. 
 
Oxidative stress  
There is abundant evidence supporting the pivotal role of oxidative stress in the 
pathogenesis of hyperglycemic complications (Baynes and Thorpe 1999; Baynes 
1991; Nishikawa et al. 2000). Hyperglycemia has been shown to be involved in ROS 
formation through several mechanisms (Figure 7, pathways 1-6). The formed ROS 
include superoxide, hydrogen peroxide, nitric oxide, and hydroxyl radicals (Aronson 
and Rayfield 2002; Robertson et al. 2003; Robertson 2004). 
 
It is known that oxidation of excess glucose can increase production of electron 
donors, such as NADH and FADH2, resulting in the overproduction of the 
superoxide anion by the mitochondrial electron transport chain, particularly in 
endothelial cells. Increased mitochondrial superoxide production has been postulated 
to be the main source of oxidative stress induced by hyperglycemia (Nishikawa et al. 
2000). 
 
The transition metal- catalysed autoxidation of free glucose is shown to be an 
additional mechanism involved in oxidative stress. Through this pathway and in the 
presence of heavy metals, α-hydroxyaldehyde products of glucose (such as 
glyceraldehyde) can enolize and, via enediol radical anion production, generate 
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hydrogen peroxide (H202) and reactive intermediates, such as the highly toxic 
hydroxyl radical as well as α-ketoaldehydes (Wolff and Dean 1987; Wolff 1993).  
 
Another mechanism involves the transition metal- catalysed autoxidation of protein-
bound Amadori products, generating superoxide and hydroxyl radicals as well as 
highly reactive dicarbonyl components, such as 3-deoxyglucosone and 
methylglyoxal (Baynes and Thorpe 1999). 
 
Finally, hyperglycemia is associated with increased oxidative products mediated by 
AGEs. As mentioned above, binding of AGEs to their specific receptors (RAGE) can 
result in the up regulation of oxidative stress response genes and increase oxidative 
stress (Yan et al. 1994). 
 
There is convincing evidence that the tissue damage mediated by oxidative products 
may be exaggerated in diabetic patients because of compromised natural antioxidant 
defences associated with hyperglycemia (Aronson and Rayfield 2002). Free radicals 
are normally neutralized by antioxidants such as reduced glutathione, vitamin C and 
vitamin E. However, the levels of these antioxidants in diabetics have been reported 
to be significantly lower than normal individuals (Chen et al. 1983; Dominguez et al. 
1998; Karpen et al. 1985; Sano et al. 1998; Yoshida et al. 1995; Yue et al. 1989). 
It is shown that there is a close pathological relationship between oxidative stress 
generation and other pathways implicated in hyperglycemia complications, including 
the hexosamine and the polyol pathways, PKC activation and AGEs formation 
(Brownlee 2001; Garcia Soriano et al. 2001) [Figure 13]. In fact, the aberrations 
induced by hyperglycemia have been suggested to result from a single "unifying 
mechanism", which involves accelerated generation of reactive oxygen species 
(ROS) (Brownlee 2001). It is suggested that increased ROS formation induces DNA 
single-strand breakage resulting in the activation of nuclear enzyme poly (ADP-
ribose) polymerase (PARP). Activation of PARP in turn, contributes to ribosylation 
and inactivation of glyceraldehyde 3-phosphate dehydrogenase (GAPDH), and 
subsequent accumulation of glycolytic metabolites, particularly glyceraldehyde 3-
phosphate (G3P) upstream. 
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Figure 13. Relationship between rates of oxidant generation, antioxidant 
activity, oxidative stress, and oxidative damage in diabetes. [O2]* represents 
various forms of reactive oxygen species [ROS]. The overall rate of formation of 
oxidative products leading to oxidative tissue damage is dependent on ambient levels 
of both [O2]* and substrate. Increased generation of [O2]* depends on several 
sources including glucose autoxidation, increased mitochondrial superoxide 
production, and as a result of the receptor for advanced glycosylation end products 
activation. [O2]* deactivation is reduced because antioxidant defences are 
compromised in diabetes. Note that oxidative stress also promotes other 
hyperglycemia-induced mechanisms of tissue damage. Oxidative stress activates 
protein kinase C (PKC) and accelerates the formation of advanced glycosylation 
endproducts (AGEs) (Aronson and Rayfield 2002). 
 
Finally, this process can increase mitochondrial superoxide production and also 
diversion of excess glycolytic intermediates to alternative pathways (Du et al. 2003; 
Garcia Soriano et al. 2001; Reusch 2003). 
 
Reciprocally, as discussed before, activation of PCK (Brownlee 2001), AGEs 
formation (Yan et al. 1994), increased levels of sorbitol through the polyol pathway 
(Robertson 2004) and the hexosamine pathway activity (Kaneto et al. 2001; 
Robertson 2004) can promote oxidative stress [Figure 7]. Accordingly, if thiamin 
could have an inhibitory effect on each of hyperglycemia-dependent alternations, 
supplementation with thiamin would reduce oxidative stress markers. 
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Apart from re-directing the accumulated glycolytic intermediates toward the pentose 
phosphate pathway, the antioxidant properties of thiamin can be also considered as 
another likely explanation for the positive effects of thiamin on oxidative stress 
generation (Lukienko et al. 2000). Additionally, thiamin was suggested to act as an 
antioxidant indirectly by involving in the production of NADPH deriving from the 
pentose phosphate shunt. NADPH is a necessary cofactor for converting oxidised 
glutathione to its reduced form, required for neutralising oxidative stress. Over 
production of free radicals increases the demands for reduced glutathione and 
subsequently NADPH. This in turn, results in enhancing flux through the pentose 
phosphate shunt, requiring more thiamin (Bakker, Heine, and Gans 1997). The 
decreased levels of reduced glutathione were reported in the erythrocytes and tissues 
(heart and brain) of thiamin- deficient animals (Hsu and Chow 1960; McCandless, 
Schenker, and Cook 1968).  
 
Importantly, given the reduced thiamin levels reported in diabetic patients 
(Thornalley et al. 2007) and also its critical role as an antioxidant, thiamin 
supplementation may improve the compromised natural antioxidant defences in 
individuals with hyperglycemia. 
 
Inflammation 
It is now established that low grade chronic inflammation plays a central role in 
mediating all stages of atherosclerosis (Libby 2002) (see Section 2.2.1). Prospective 
epidemiological studies have  shown that the increased levels of cytokines such as 
IL-6 and TNF-α (Harris et al. 1999; Ridker, Hennekens, et al. 2000; Ridker, Rifai, 
Stampfer, et al. 2000; Ridker, Rifai, Pfeffer, et al. 2000), cell adhesion molecules 
such as soluble ICAM-1, P selectin, and E selectin (Hwang et al. 1997; Ridker, 
Hennekens, et al. 1998; Ridker, Buring, and Rifai 2001), and circulatory acute-phase 
reactants such as CRP, fibrinogen, and serum amyloid A (Danesh et al. 2000; 
Haverkate et al. 1997; Koenig et al. 1999; Kuller et al. 1996; Ridker, Hennekens, et 
al. 2000; Ridker et al. 1997; Ridker, Buring, et al. 1998; Tracy et al. 1997) may mark 
future risk for cardiovascular events. Moreover, elevation in inflammatory markers 
such as C-reactive protein has been proven to be associated with the adverse short-
59 
 
term prognosis of acute coronary syndromes (Berk, Weintraub, and Alexander 1990; 
Biasucci et al. 1999; Liuzzo et al. 1994; Rebuzzi et al. 1998; Toss et al. 1997). 
 
As previously mentioned, hyperglycemia has been shown to promote inflammation 
via the AGEs formation. Through this mechanism, binding of AGE-modified 
proteins with their specific receptors on the surface of several cell types can augment 
the production of pro-inflammatory cytokines and other inflammatory mediators 
involved  in vascular damage (Kirstein et al. 1990; Kirstein et al. 1992; Ross 1999; 
Schmidt et al. 1995; Schmidt et al. 1993; Vlassara et al. 1988; Vlassara et al. 1992; 
Wautier et al. 1994; Yan et al. 1994). In addition to the AGE formation, other 
mechanisms implicated in hyperglycemia can contribute to the inflammatory 
response mediated by reactive oxygen species (Brownlee 2001; Garcia Soriano et al. 
2001; Yan et al. 1994). Moreover, hyperglycemia has been implicated in promoting 
intracellular oxidative stress in adipocytes, resulting in the induction and secretion of 
acute phase reactants (Lin et al. 2005). The elevated levels of  inflammatory markers 
such as CRP and  interleukin-6  have been identified in both type 1 and type 2 
diabetic patients (Aronson et al. 2004; de Rekeneire et al. 2006; Devaraj et al. 2006) 
as well as those with pre-diabetic ranges of hyperglycemia (Lin et al. 2009; Tan et al. 
2003). 
 
With regard to the potential role of thiamin in suppressing the key pathologic 
pathways contributing to inflammatory process discussed above (Beltramo et al. 
2002; Booth, Khalifah, and Hudson 1996; Degenhardt, Thorpe, and Baynes 1998; La 
Selva et al. 1996; Thornalley, Jahan, and Ng 2001), supplementation with thiamin 
may have beneficial effects on the level of inflammatory markers, and improve 
outcomes in individual who are at the risk of hyperglycemia vascular complications. 
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2.5.10   The potential effects of thiamin in preventing hyperglycemia 
complications: from clinical aspects 
 
2.5.10.1    Glycemic control 
Effective control of blood glucose is a main goal in the management of 
hyperglycemia. Given the evidence suggesting a potential role for thiamin in 
preventing hyperglycemic complications discussed before (Babaei-Jadidi et al. 2003; 
Beltramo et al. 2002; Berrone et al. 2006; Booth, Khalifah, and Hudson 1996; La 
Selva et al. 1996; Thornalley, Jahan, and Ng 2001) (see Section 2.5.9), some 
experiments were undertaken to examine the effects of thiamin on blood glucose 
levels in vivo. Several animal and human studies examining the effects of thiamin on 
hyperglycemia are summarised in Table 10.  
 
Babaei-Jadidi et al. (2004) showed that administration of high doses of thiamin (7 
and 70 mg/kg/day) for 24 weeks had no effect on fasting blood glucose levels of the 
streptozotocin (STZ) - induced diabetic rats. This was consistent with the results of a 
clinical trial conducted by Rabbani et al. (2009) who showed no significant change in 
the fasting glucose of subjects with type 2 diabetes receiving either placebo or 
thiamin (300 mg/d) treatment for 3 months. These subjects had been diagnosed with 
diabetes for at least 5 years. Also, except one subject who achieved glycemic control 
with diet only, all other patients were on treatment with antihyperglycemic 
medications. However, since commencing this thesis, Gonzalez-Ortiz et al. (2011) 
have published a study on 24 Mexican overweight/obese subjects with type 2 
diabetes. In this study, supplementation with 150 mg thiamin (once daily) for 1 
month was shown to decrease the fasting plasma glucose (6.7 ± 1.0 mmol/L vs. 6.0 ± 
1.0 mmol/L, p = 0.024 ) before and after intervention respectively. These subjects 
had fasting plasma glucose concentrations < 11.0 mmol/L and HbA1C level < 8%, 
and were not treated with medications. These results suggest that thiamin therapy 
may be more effective on the fasting plasma glucose of patients with hyperglycemia 
at early stages.      
   
As discussed earlier, diabetic patients are at risk of thiamin deficiency because of  
decreased absorption (Patrini et al. 1996) and increased excretion of thiamin in the 
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urine (Thornalley et al. 2007). Animal studies indicate that thiamin deficiency can in 
turn, reduce overall glucose utilisation in the tissues (Hakim, Carpenter, and Pappius 
1983; Hakim and Pappius 1981) and thus increase fasting blood glucose 
(Rathanaswami and Sundaresan 1988). This is also associated with a decreased 
fasting insulin concentration (Rathanaswami and Sundaresan 1988). Basal secretion 
of insulin and insulin secretion in response to glucose and tolbutamide were also 
decreased in isolated pancreatic islets of thiamine deficient rats (Rathanaswami, 
Pourany, and Sundaresan 1991). Moreover, thiamin was shown to reduce 
hyperglycemia in a mouse model of TRMA (thiamin-responsive megaloblastic 
anemia syndrome) in which developed diabetes mellitus was associated with 
decreased insulin secretion (Oishi et al. 2002), These findings led to the conclusion 
that apart from the activation of thiamin-dependent enzymes and increased glucose 
utilisation, improvement of β-cell function and insulin secretion may be implicated in 
the beneficial effect of thiamin on glycemic control (Thornalley 2005). This was also 
considered as a possible explanation for the lack of significant effect of thiamin 
therapy on glycemic control in diabetic rats (Babaei-Jadidi et al. 2004), where 
permanent insulin deficiency was induced by streptozotocin (STZ) destroying most 
pancreatic β-cells (Thornalley 2005), and patients with long-term diabetes mellitus 
(Rabbani et al. 2009).  
 
Thiamin deficiency was also shown to induce glucose intolerance in animals 
(Rathanaswami and Sundaresan 1989). A potential association between thiamin 
status and glucose tolerance in human was identified by Bakker et al. (1998) who 
showed that thiamin intakes of 2196 men and women, 50-75 years old without 
diabetes, were inversely correlated to 2-h postprandial glucose concentrations,  
suggesting that thiamin supplementation may have an important role in improving 
glucose tolerance. However, to date there has been no published study to confirm this 
effect in individuals with impaired glucose tolerance. Only in one publication, 
thiamin supplementation (50 mg/d for 30 days)  was shown to improve glucose 
tolerance in 25 patients with hepatic cirrhosis (Hassan, Qureshi, and Zuberi 1991). 
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2.5.10.2 Lipids and lipoproteins 
It is now well established that both fasting and postprandial dyslipidemia are 
independent predictors of future cardiovascular events (Eberly, Stamler, and Neaton 
2003; Gaziano et al. 1997) . The association of hyperglycemia at the levels below the 
current diagnostic thresholds for diabetes with dyslipidemia has been increasingly 
recognized (Blake et al. 2004; Lim et al. 2000; Meigs et al. 1998; Novoa et al. 2005; 
Rodriguez et al. 1996). Evidence indicates that the adverse effects of postprandial 
hyperglycemia may be potentiated when it is associated with hyperlipidemia 
(Anderson et al. 2001).  
 
While the pathogenesis of hyperlipidemia associated with impaired glucose 
metabolism is unknown, a switch from lipid oxidation to lipogenesis in the liver has 
been considered as a possible mechanism (Taskinen 2003).  This is linked to an 
increase in the production of apolipoprotein B-100 (apo B100) (Packard and 
Shepherd 1997) and alteration in the assembly of very low density lipoprotein 
(VLDL) in the liver (Adiels et al. 2006). As indicated in Section 2.5.9, an increase in 
the hepatic hexosamine pathway in the liver due to hyperglycemia has been linked 
with lipogenesis (Rumberger et al. 2003; Veerababu et al. 2000) and it is proposed 
that supplementation with thiamin may alter this effect.  
 
High dose thiamin therapy (70 mg/kg/d) was shown to normalise food intake and 
prevent diabetes-induced increases in plasma triglycerides and cholesterol in diabetic 
rats, but there was no effect on the decrease of HDL (Babaei-Jadidi et al. 2004). 
These positive effects on diabetic dyslipidemia were due to thiamin repletion and 
increase in transketolase activity in the liver of rats. This was associated with a 
significant reduction in hepatic UDP-N-acetylglucosamine and fatty acid synthase 
activity.  These effects were not confirmed by the studies carried out in humans. In 
the study conducted by Rabbani and her colleagues (2009), supplementation with 
high dose thiamin (300mg/day) for 3 months had no significant effect on 
dyslipidemia in type 2 diabetic patients (n= 20) with microalbuminuria, compared 
with controls (n=20). Similarly, Gonzalez-Ortiz et al. (2011) reported no changes on 
serum total cholesterol, HDL, LDL, VLDL and triglyceride of patients with type 2 
diabetes receiving thiamin orally (150 mg/day) for 1 month (n=12) with respect to 
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placebo (n=12).  There has been no published literature so far to investigate the effect 
of serum lipid profile of individuals with pre-diabetic range of hyperglycemia.      
 
2.5.10.3  Endothelial function  
Evidence from more recent studies has shown endothelial dysfunction in patients 
with diabetes or IGT, and in healthy subjects with transient increases in plasma 
glucose, indicating that hyperglycemia even in the absence of overt diabetes is a 
cardiovascular risk factor (Akbari et al. 1998; Kawano et al. 1999; Salomaa et al. 
1995; Tooke and Goh 1999). 
 
In contrast to most cell types, vascular endothelial cells are unable to down regulate 
glucose transport in the presence of  hyperglycemia, leading to an increased 
intracellular glucose concentration (Kaiser et al. 1993). As a result, endothelial cells 
are among the first targets of glucose-mediated damage.  
 
The exact mechanisms responsible for endothelial dysfunction under hyperglycemic 
status are not fully understood. However, reduced release and/or synthesis of 
endothelium-derived nitric oxide (NO) resulting from the overproduction of ROS, 
and an imbalance between NO release and superoxide anion formation (Bucala, 
Tracey, and Cerami 1991; Cersosimo and DeFronzo 2006; Giugliano et al. 1997; 
Srinivasan et al. 2004)  have been suggested as likely mechanisms.  
 
Thiamin has been shown to improve endothelial and smooth muscle cell function in 
vitro (Chen, Okada, and Okeda 1997; La Selva et al. 1996). Additionally, it was 
shown to protect against glucose and insulin-mediated proliferation of human 
vascular smooth muscle cells (Avena et al. 2000). Thiamin was also demonstrated to 
mitigate or delay hyperglycemia-induced endothelial dysfunction through the 
improvement of endothelial cell migration, and reversing the increased secretion of 
the von Willebrand factor in cultured endothelial cells (Ascher et al. 2001).   
 
The potential effect of thiamin on vascular function in humans was initially 
investigated in patients with beriberi heart disease, in which  hemodynamic function 
and systemic vascular resistance were significantly improved following intravenous 
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administration of thiamin (Attas et al. 1978; Ayzenberg, Silber, and Bortz 1985). 
Recently, the same effect was reported by Arora et al. (Arora et al. 2006) who 
showed that administration of 100 mg intravenous thiamin improved endothelium 
dependent vasodilatation (EDV) in the presence of hyperglycemia. Little is known, 
however, about the inhibitory role of thiamin on hyperglycemia-induced ROS 
production, and if its antioxidant properties contribute to these vasomotive effects 
(Bakker, Heine, and Gans 1997; Lukienko et al. 2000). 
 
2.5.10.4   Renal function 
Nephropathy is a known complication of diabetes and cardiovascular diseases 
(Sharma 2003; Stratton et al. 2000; The Diabetes Control and Complications Trial 
Research Group 1993). However, there is emerging evidence that hyperglycemia in 
non-diabetic ranges (IGT) is also associated with renal injury (Gabir et al. 2000; 
Metcalf et al. 1993; Pan et al. 1993). In a cross- sectional study on more than 5,000 
Maori and European subjects, microalbuminuria was recognised in 21% of those 
with diabetes and 16% of those with IGT, but only 4% of normoglycemic individuals 
(Metcalf et al. 1993). In another large population-based study in China, the rate of 
albumin excretion was significantly higher among IGT subjects compared with the 
non-diabetic control group (7.2 ± 5.7 vs. 4.5 ± 2.8) (Pan et al. 1993). 
 
The increased level of plasma glucose can cause a high cytosolic glucose 
concentration in renal endothelial cells and pericytes. This in turn can result in the 
biochemical dysfunctions of:  protein kinase C, hexosamine and polyol pathways 
activations; metabolic pseudohypoxia; oxidative stress production; and advanced 
glycation end products (AGEs) formation (Brownlee 2001).  
 
Given the potential role of thiamin under hyperglycemic status (see Section 2.5.9), 
accumulating evidence has demonstrated the suppressive effect of thiamin on the 
multiple key pathogenic pathways involved in diabetic nephropathy in vitro (La 
Selva et al. 1996). Additionally, it was shown that the high dose of thiamin inhibits 
the development of incipient nephropathy (the initial stage of development of 
nephropathy) in the streptozotocin (STZ)-induced diabetic rats, and increases the 
thiamin-dependent enzyme transketolase activity in renal glomeruli (Babaei-Jadidi et 
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al. 2003). In the same work, these effects were associated with deceases in cytosolic 
and membrane fraction PKC activities, markers of glycation (AGEs in glomerular 
protein) and oxidative stress (plasma protein thiols), and concentrations of dicarbonyl 
compounds of methylglyoxal, glyoxal and 3-deoxyglucosone. More recently, the 
beneficial effect of high dose thiamin supplementation on microalbuminuria was 
confirmed in human subjects with type 2 diabetes mellitus (Rabbani et al. 2009; 
Riaz, Skinner, and Srai 2011). However, there has been no literature so far 
investigating the chronic effect of thiamin on the renal function of individuals with 
pre-diabetic range of hyperglycemia. 
 
2.5.10.5   Body weight & energy expenditure  
Only a few studies have investigated the effect of thiamin on body weight.  Tanaka et 
al. (2010) showed that thiamin intervention prevents obesity in Otsuka Long-Evans 
Tokushima Fatty (OLETF) rats, displaying obesity and metabolic abnormalities 
similar to those found in humans. In Tanaka et al’ study, OLETF rats were given free 
access to water (control group) or water containing 0.2% thiamin (thiamin group) for 
21 and 51 weeks. In a clinical trial conducted by Wilkinson et al. (1997), the weight 
of subjects with persistent subclinical thiamin deficiency receiving thiamin 
supplement (10 mg daily) decreased significantly after 3 months. No exact 
explanation has been offered by Wilkinson et al. for this finding. They explained a 
likely improvement in the heart failure of participants taking Furosemide (n=3, 17%) 
and a subsequent weight loss indicating diuresis as a notable point.  However, there 
is no information in the article indicating whether this significant reduction in body 
weight has been limited to these subjects. Also, no data about the energy intake of 
subjects in this study has been provided. By contrast, Smidt et al.(1991) reported that 
supplementation with 10 mg/d thiamin for 6 weeks resulted in a considerable 
increase in the body weight of elderly subjects with marginal thiamin deficiency. 
This change was associated with significant improvements in their appetite, and 
energy intake assessed by weekly 24-hour recalls. There has been no significant 
change in physical activities of subjects participating in either Smidt et al’s or 
Wilkinson et al’s study.  
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In general, changes in body weight result from an imbalance between the energy 
intake and energy expenditure. Total energy expenditure is comprised of three main 
components: basal metabolic rate (BMR), diet-induced thermogenesis (DIT) and 
energy expenditure physical activity. BMR represents the minimal rate of energy 
required for normal body function in a resting and awake state, accounting for 
approximately 50% to 70% of total energy expenditure (Ravussin and Bogardus 
1992). 
 
BMR is mainly dependent on the body size and composition (Tzankoff and Norris 
1977). Existing evidence indicates that body composition and subsequently energy 
expenditure can be influenced by the change in macro and micronutrient intake. 
Some studies have shown that administration of thiamin increases muscle mass and 
energy expenditure in experimental animals (Hamano, Okada, and Tanaka 1999; 
Huang et al. 2010). There has been no published study so far to evaluate the effect of 
thiamin on the energy expenditure in humans. 
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2.6   Summary 
Impaired glucose regulation plays a critical role in the pathogenesis of type 2 
diabetes mellitus and its cardiovascular complications. Thiamin is a water soluble 
vitamin playing a key regulatory role as a co-enzyme in metabolic pathways 
involving glucose. According to the findings of recent studies, people with 
hyperglycemia in the diabetic range are prone to thiamin deficiency. For example, 
the findings of Thornalley and his colleagues indicate that due to an increased 
excretion of thiamin in the urine, thiamin concentration in blood plasma was 
decreased by 76 per cent in type 1 and by 75 per cent in type 2 diabetic patients 
(Thornalley et al. 2007). In addition to the increased thiamin renal clearance, a 
reduced intestinal absorption was also suggested to contribute to the thiamin-
deficient state reported in diabetics (Patrini et al. 1996).  
 
In spite of these findings and also the essential role of impaired glucose metabolism 
in the pathogenesis of biochemical abnormalities associated with diabetes, there has 
been no published study to investigate thiamin status in individuals with pre-diabetic 
range of hyperglycemia.  
 
Studies also showed the presence of impaired glucose tolerance in thiamin-deficient 
laboratory animal (Oishi et al. 2002), suggesting that thiamin deficiency could be 
considered as both cause and effect of hyperglycemia. Therefore, supplementation 
with thiamin may break this vicious circle and improve glucose tolerance. 
 
In vitro studies reveal that thiamin can inhibit certain biochemical pathways that lead 
to abnormalities associated with hyperglycemia (Berrone et al. 2006; La Selva et al. 
1996; Thornalley, Jahan, and Ng 2001). The mechanism of action seems to involve 
the diversion of "excess" metabolic load (glycolytic intermediates) away from 
glycolysis and toward the so-called reductive pentose pathway, a secondary pathway 
for glucose catabolism.  
 
Given these findings some studies have been undertaken to examine the effects of 
thiamin on hyperglycemia complications in vivo. Thiamin supplementation was 
shown to improve cardiovascular risk factors in diabetic rats (Babaei-Jadidi et al. 
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2003) and increase muscle mass and energy expenditure in experimental animals 
(Hamano, Okada, and Tanaka 1999; Huang et al. 2010). Recently, a clinical study 
investigating the effects of thiamin on hyperglycemia showed that supplementation 
with thiamin decreased the fasting plasma glucose of diabetic patients with fasting 
plasma glucose concentration <11 mmol/L and HbA1C level < 8% (Gonzalez-Ortiz et 
al. 2011). Thiamin supplementation was also shown to improve glucose tolerance in  
patients with hepatic cirrhosis (Hassan, Qureshi, and Zuberi 1991). Additionally, 
thiamin is found to have a beneficial effect on microalbuminuria in subjects with 
type 2 diabetes mellitus (Rabbani et al. 2009). However, to date there has been no 
published study to confirm these effects in individuals with pre-diabetic range of 
hyperglycemia (IGT). 
 
Therefore, the present research work was designed in two studies, to assess the status 
and effects of thiamin on some cardiovascular risk factors in subjects with abnormal 
glucose metabolism.     
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3.  The cross - sectional study 
As mentioned before (see Section 2.5.6), recent studies indicate that individuals with 
hyperglycemia in the diabetic range are at higher risk of thiamin deficiency 
(Jermendy 2006; Thornalley et al. 2007; Valerio et al. 1999), because of an increased 
excretion of thiamin in the urine (Thornalley et al. 2007) and possible decreased 
absorption (Patrini et al. 1996). For example, Thornalley and his colleagues (2007) 
showed that thiamin concentration in blood plasma was decreased by 76 per cent in 
type 1 and by 75 per cent in type 2 diabetic patients relative to control subjects. 
However, there has been no published study to investigate thiamin status in 
individuals with other degree of abnormal glucose levels.  
 
Given this gap and also the essential regulatory role of thiamin in metabolic 
pathways involving glucose metabolism, it was hypothesised that the level of thiamin 
is also decreased in people with pre-diabetic range of hyperglycemia.  
 
3.1   Study design 
Our first hypothesis was addressed through a cross - sectional study, evaluating 
thiamin status in individuals with abnormal glucose regulation (IFG and IGT) 
relative to healthy subjects. Subsequently, potential associations between thiamin 
status and different cardiovascular risk factors were investigated. As indicated below, 
we were only able to evaluate thiamin status by RBC thiamin. 
  
3.2   Subjects 
Subjects were recruited by advertising in community and The West Australian 
newspapers, WA Practice Nurse Association newsletter, Curtin University web site 
and radio as well as outpatient clinics and divisions of general practice. Additionally, 
printed information sheets and flyers [Appendix 1] were sent to Community Diabetes 
Education Services for distributing among the people attending the educational 
programs for prevention of diabetes.   
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Following recruitment, potential volunteers were asked to complete an online 
screening questionnaire available on the web site of Curtin University  
 
The prospective subjects who didn’t have access to the internet were screened via 
telephone. Both on-line and telephone screening questionnaires began with some 
questions related to the subjects' general information, such as sex, age, address, 
weight and height. The second part of the forms consisted of the questions relating to 
the study's inclusion criteria [Appendix 2].  
Volunteers were excluded based on the following criteria:  
 Smoking 
 Known impaired renal or liver function  
 Major gastrointestinal disorders  
 Hypo and hyperthyroidism 
 Known diabetes mellitus 
 Cardiovascular event over the last 6 months 
  Known allergy or intolerance to thiamin 
 Females who are pregnant or lactating 
  Use of steroids, thyroxin or other supplements and medications that affect 
glucose metabolism 
 Taking diuretics with possible effects on urinary excretion of thiamin. 
 
Subjects who were taking supplements containing thiamin (e.g. multivitamins 
preparations) or consuming more than 2 standard alcoholic drinks per day, but met 
other inclusion criteria, were asked to undergo a washout period of at least 4 weeks 
before attending the clinical day.  
 
The sample was based on an expected 15% reduction in plasma thiamin 
concentration in the hyperglycemic group relative to the healthy group. Based on the 
results of previous studies (Thornalley et al. 2007), a sample size of 50 subjects (25 
subjects in each group) could provide 80% power at the 5% significance level using 
a two-sided independent groups t-test.  
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An initial seventy five subjects (31 males and 44 females) were recruited to allow for 
drop out/non-compliance. Of these, six female subjects dropped out, because of 
difficulties in undergoing a 4-week wash - out period for multivitamin supplements 
before attending the clinical visit and also an inability to commit the time. In 
addition, given the main objectives of this study, data of 1 known case of pre-
diabetic who became normal based on her results in our study, and four other 
subjects (2 males, 2 females), being identified as new cases of diabetes mellitus 
based on their plasma glucose concentrations, were excluded for final analysis.  
 
For evaluating the main objective of this study (see Section 3.1), data  of sixty four 
subjects (29 men and 35 women) were analysed, except for vascular function 
measurements which included data of forty four subjects (21 males and 23 females) . 
Also, data of 61 subjects (26 men, 35 women) were used for assessment of glucose 
tolerance by comparing two sampling systems of venous whole blood and venous 
plasma (see Section 3.5). 
 
The sixty four subjects consisted of thirty nine normal healthy volunteers (14 males, 
25 females) and twenty five hyperglycemics (15 males, 10 females) with blood 
glucose levels at pre-diabetic ranges (16 IGT, 9 IFG ), who were classified as normal 
and hyperglycemic based on venous plasma glucose measurements (FPG & 2 h-
GTT), the recommended tests for detecting all stages of hyperglycemia (Diabetes 
Australia Western Australia 2005; World Health Organization 2006). Two of IGT 
subjects were on long term cholesterol- lowering medicine (Zocor& atorvastatin) and 
one IGT subject was taking medication for hypertension.  
 
Participation in this study was completely voluntary and subjects were informed that 
they were able to withdraw from the study at any point in time, without prejudice. 
This study was approved by the Curtin University Human Research Ethics 
Committee (Approval number HR 118/2008) and a written consent form [Appendix 
3] was obtained from the subjects during the introductory short visit. 
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3.3   Methods 
3.3.1 Introductory short visit 
After an initial screening, the subjects who met inclusion criteria attended an 
introductory short visit to receive the study’s procedure and protocol in details and to 
provide written consent [Appendices 3&4]. 
 
In addition, during the short visit, participants were given a standard light-resistant 
container (greiner bio-one GmbH, Kremsmunster, Austria) to collect their urine for 
24 hours, starting the morning before the clinical day. A light-resistant urine 
container was provided because of the light sensitivity of thiamin  (Interdepartmental 
Committee on Nutrition for National Defense 1963). Boric acid (3 g) was added to 
the collection containers as a preservative to ensure thiamin stability (Tasevska et al. 
2008). It is known that thiamin is easily destroyed at pH 8 or above, particularly in 
high-temperature environments (Brody 1999). 
 
Subjects were instructed to discard their first urine of the day and record the time on 
the container label. From then, they should collect all urine for the next 24 hours, 
including the first urine of the following day (clinical day) at the same time as the 
recorded commencement time [Appendix 5]. The urine samples collected in a 
collection time outside the range of 23-25 h, or with a ratio of urinary creatinine 
(mg/d) to body weight (kg) outside the range of 10.8-25.2,  calculated based on the 
strategy developed by WHO (World Health Organization 1984), were considered as 
incomplete collections and excluded.  
 
3.3.2   Meal standardisation  
Participants were asked to be on an unrestricted carbohydrate diet of at least 150-200 
g of carbohydrate daily, during three days prior to the test as recommended by WHO  
(Alberti and Zimmet 1998) [Appendices 5&6]. Moreover, on the evening before the 
clinical day, they were required to consume a standard meal provided by 
investigators. These requirements were to ensure subjects were consuming a 
reasonable amount of carbohydrate before the glucose tolerance test. Studies have 
shown that fasting and 2-hour blood glucose levels can be influenced by the source 
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and amount of carbohydrate consumed the evening prior to the test (Alberti and 
Zimmet 1998; Wolever et al. 1988).  
 
The evening meal was Vegetable Korma with rice (Crafty Chef  Pty. Ltd., NSW, 
Australia), containing about 1720 kJ  with a macronutrient composition of 68% of 
energy from carbohydrate, 10% from protein and 21% from fat [Table 11]. 
Following consumption of the standard evening meal, subjects were required to fast 
overnight.  
 
Table 11. Information from Nutrition Information Panel for Vegetable Korma  
                                                                                                                                                                                                                                             
 Per 100 g Per meal (375g) 
Energy (kJ) 459  1721  
Protein (g) 2.5 9.4 
Fat (g) 
                    Total 
                    Saturated 
 
2.5 
1.5 
 
9.4 
5.6 
Carbohydrate (g) 
                    Total 
                    Sugars 
 
18.2 
0.8  
 
68.3 
3.0  
Sodium (mg) 217  814  
            
3.3.3   Experimental protocol 
On the morning of clinical day, subjects attended the out-patient clinic, School of 
Public Health, Curtin University, following an overnight fast of 10-14 hours and 
brought their completed 24 - hour urine collection.   
 
Upon arrival, participants were asked to empty their bladder and collect a midstream 
urine sample. The 24-h urine volume was measured and recorded. Twenty mL of 
collected midstream urine sample and 30 mL of 24-h urine sample were stored in 
separate 5 mL plain plastic vials at -70°C until being analysed for urinary thiamin, 
albumin and creatinine.  
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Anthropometric measurements were taken with subjects dressed in a gown  with no 
shoes and empty bladder. Body weight was measured using a calibrated body 
composition monitor (Model BC 541, Tanita Corporation, China) to the nearest 0.1 
kg, and height was measured with a portable stadiometer (Mentone Education 
Centre, design number 1013522, Victoria, Australia) to the nearest 0.5 cm. 
 
Waist circumference was measured at mid-exhalation, midpoint between the lateral 
lower rib margin and the ileac crest in the standing position (Gibson 2005; Jones et 
al. 1986) and hip circumference measurement was taken at the widest point over the 
buttocks (Lohman, Roche, and Martorell 1988). The average of two readings was 
recorded. Participants were then asked to rest 30 minutes prior to the measurements 
of blood pressure and vascular endothelial function, and blood sampling (see 
Sections 3.3.4& 3.3.5).  
 
After taking fasting measurements, subjects were required to consume the full bottle 
of a standard glucose tolerance test beverage (Glucaid: Fronine Pty. Ltd., NSW, 
Australia), containing 75 g of glucose (75 g/300 mL). The glucose beverage was 
lemon - flavoured and kept refrigerated prior to ingestion, to increase palatability. 
Subjects were instructed to drink the test load as rapidly as they comfortably could, 
but no more than 5 minutes. Following consumption of the beverage, subjects 
remained at rest during the test. They were allowed to drink water either before or 
during the test. Two hours after ingesting the beverage, another blood sample was 
collected for measuring glucose level ( glucose tolerance test).  
 
3.3.4   Blood pressure & vascular function measurements 
 
Following a mandatory rest period of 30 minutes, systolic and diastolic blood  
pressures were measured on subjects' right arms  in supine position, using a vital 
signs patient monitor (Cardiocap II, Datex, Helsinki, Finland) with a standard cuff 
for adults. Three blood pressure measurements, with 2 minutes intervals, were 
recorded in the fasting state and the average value was reported. 
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Vascular endothelial function was 
assessed by a Pulse Trace machine 
(PCA2, Micro Medical Ltd., UK) 
[Figure 14]. Pulse Trace PCA2 is a non- 
invasive device used to assess 
endothelium function and  vascular 
stiffness by recording digital volume 
pulse (DVP). The technique of DVP is 
based on measuring infra-red light 
transmission through the finger 
(photoplethysmography) (Chowienczyk 
et al. 1999).  
 
After an initial 30-minute rest, a photoplethysmography sensor transmitting infra-red 
light was placed on the index finger of subjects. The digital volume pulse 
measurements were recorded with subjects supine in a temperature-controlled room 
(22±2°C). Two readings, with at least 2 minute apart, were taken in fasting state. 
Each of these measurements was the average of three recordings with intervals of 30 
seconds. The average of six measurements was reported as baseline value. In 
addition to the fasting measurement, postprandial endothelial function changes were 
assessed intermittently at 30, 60, 90 and 120 minutes after ingestion of  the test load. 
 
3.3.5   Biomedical measurements 
Fasting blood samples were collected via venipuncture into serum, heparin and 
EDTA tubes (BD Vacutainer®, NJ, USA). After taking blood samples, the tubes 
were inverted gently between 8-10 times, with no delay. The serum tube containing 
clot activator was then left at room temperature for 20-30 minutes to clot before 
centrifugation. The blood collected into EDTA was centrifuged at 1100 g for 10 
minutes at 4°C immediately (within minutes). The isolated plasma was stored in 
separate 1.5 mL microcentrifuge tubes at  -80 °C until analysed for glucose and 
insulin concentrations. The same protocol was also administrated for the blood 
sample collected 2 hours after ingestion of glucose beverage repeating the plasma 
glucose measurement. 
   Figure 14. Pulse Trace PCA2 machine 
   used to assess endothelium function 
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Venous blood collected into the tube containing lithium heparin was used to assess 
thiamin status. For the measurement of thiamin in plasma, the collected blood was 
centrifuged immediately (1100 × g, 10 min, 4°C) and the separated plasma was 
frozen at temperature of -70 °C until analysis. The erythrocytes were prepared for 
thiamin analysis. After separating the plasma, buffy coat layer was removed from the 
erythrocytes and discarded. The packed red blood cells (RBC) were then washed 
three times with normal saline (9 g/L NaCl). For hemolysing the cells, 1 mL of de-
ionised water was added to 1 mL of washed RBC and mixed by vortex mixer 
(Australian Scientific, Australia) for 1 min (Talwar et al. 2000). The mixture was 
then aliquoted and frozen at  -80 °C until assayed. After a period of about half an 
hour from collecting fasting blood samples, the blood clotted into serum tube was 
centrifuged. The separated serum was then stored at -80 °C until analysis for total 
cholesterol, HDL-cholesterol, LDL cholesterol, triglyceride, hs-CRP and creatinine. 
 
In addition to measuring glucose in plasma, fasting and postprandial glucose levels 
were assessed in whole blood by using a blood glucose meter (Accu-Chek Active, 
Roche Diagnostics , NSW, Australia). To measure glucose level in whole blood, 
immediately after taking fasting blood samples, one drop of fresh whole blood left-
over from the used blood collection set was placed in the test zone of a glucose meter 
strip. This test was repeated with no delay. The average of two readings was 
recorded. The concentration of glucose in whole blood reported for 2-h post glucose 
load was determined according to the same procedure. 
 
3.3.6   Blood and urine analysis 
Aliquot of plasma (separated from the blood collected into EDTA tube), serum and 
spot urine samples were sent to Royal Perth Hospital for analysing glucose, insulin, 
total cholesterol, HDL-cholesterol, LDL cholesterol, triglyceride, highly sensitive C-
reactive protein, serum and urine creatinine, and urinary albumin. 
 
Plasma glucose levels were determined with the hexokinase method. Insulin levels 
were measured by the Architect insulin assay. Enzymatic colorimetic assays were 
used to determine the levels of serum triglyceride, total cholestrol and creatinine. 
Concentrations of HDL cholestrol were directly measured in the serum samples by 
78 
 
the Ultra HDL assay. These analyses were performed using the Abbott diagnostic 
kits (Abbott Laboratories, IL, USA) with a within- and between-run coefficient of 
variation of < 4.3%. LDL cholesterol was calculated using a modified version of 
Friedewald equation (Friedewald, Levy, and Fredrickson 1972) with quanitites in 
mmol/L:  
 
     LDL- cholesrerol = total cholesterol – (0.46 × triglyceride) – HDL- cholesrerol 
 
Serum hs-CRP was measured by nephelometry using a BNII system (Siemens 
Healthcare Diagnostic inc. Newwark, DE, USA) with between- and within-run 
coefficient of variation of 8.35% and 5.7% respectively. The levels of albumin in 
urine were assessed by the Abbott Microalbumin assay, a turbidimetric immunoassay 
using polyclonal antibodies againt human albumin, with between- and within-run 
coefficient of variation of 12.19% and 0.74% (Wako Pure Chemical Industries, Ltd. 
Osaka, Japan).  
 
Blood glucose was also determined in whole blood using the blood glucose meter 
(Accu-Chek Active, Roche Diagnostics , NSW, Australia), immediately after 
collecting blood samples (fasting & 2-h post glucose load) as described before. 
 
The results of fasting plasma glucose and insulin were also used to estimate the 
hemostatic model assessment (HOMA) score, as an index of insulin resistance by the 
following equation (Bonora et al. 2000): 
 
 
                                Fasting insulin (mIU/L) × fasting glucose (mmol/L) 
                                                                   22.5 
A HOMA score > 2.5 indicates low insulin sensitivity (IR) in adults (Keskin et al. 
2005).  
 
In the present study, subjects were screened for albuminuria by determing 
albumin/creatinine ratio in the collected fasting spot urine sample. Microalbuminuria 
was detected in the presence of an albumin excretion ≥ 30 and < 300 mg/g creatinine. 
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An albumin/creatinine ratio ≥ 300 mg/g represents clinical albuminuria  (Molitch et 
al. 2004).  
 
Renal function was also assessed by estimating GFR (glomerular filtration rate), 
using Cockroft- Gault formula adjusted for BSA (body surface area) (Cockcroft and 
Gault 1976): 
  
                                                         [140 - age (years)] × weight (kg) × K × C 
         eGFR (ml/min/1.73 m
2
) =                   
                                                                  Serum creatinine (μmol/L) 
 
Where K is 1.23 for men and 1.04 for women, and C corrects for BSA, equal to 
1.73/BSA. BSA was calculated by using DuBois formula (Du Bois and Du Bois 
1989):                       
                   BSA(m
2 
) = [weight (kg)] 
0.425
× [height(cm)] 
0.725
× 0.007184 
 
Concentration of creatinine is commonly used for measuring GFR. However, it is 
known to be influenced by muscle mass and diet. Accordingly, Cockroft- Gault 
formula is recommended as a useful surrogate tool, which employs patient's age, 
weight and serum creatinine to estimate glomerular function (Chudleigh et al. 2008; 
Guimaraes et al. 2007; Perlemoine et al. 2003).    
 
In this study, assessment of thiamin status was attempted in urine and plasma. 
However, there were some technical problems in establishing the methods for this 
analysis at Curtin University. The washed red blood cells separated from the blood 
collected into the heparin tube were sent to Royal Perth Hospital (RPH) to be 
analysed for thiamin.  
 
Thiamin (TPP) status was determined by high-performance liquid chromatography 
(HPLC) with fluoresecent detection (pre-column derivatisation) using the 
Chromsystems reagent kit (Chromsystems Instruments and Chemicals GmbH, 
Munich, Germany). The retention time, limit of quantification and recovery values 
for TPP were: 5.3 min, 0.7 nmol/L and 88-97%, respectively.    
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3.3.7   Assessment of dietary intake 
Dietary intake of thiamin and alcohol were assessed by the validated semi-
quantitative food frequency questionnaire of the Anti-Cancer Council Victoria (Giles 
and Ireland 1996; Hodge et al. 2000), containing 74 food items with 10 frequency 
response options ranging from ‘Never’ to ‘3 or more times per day’ [Appendix 8]. 
The used food frequency questionnaire also included 3 photographs of scaled 
portions for four foods (to calculate a portion size calibrator), questions on the 
overall frequency of consumption of fruits and vegetables (to calibrate the 
overestimation of these foods in the food list), and questions on consumption of 
foods such as bread that could not be simply grouped by the used frequency format. 
The intake of alcoholic beverages was assessed by a separate set of questions. The 
output of the questionnaire compromised 35 nutrients (Cancer Council Victoria 
2009). 
 
On the assessment day, after taking fasting measurements, subjects were instructed 
how to complete the questionnaire (self-administrated method). Subsequently, the 
completed questionnaires were checked by the study investigator for completeness, 
and any probable errors were corrected on the spot.  The collected forms were then 
optically scanned, and nutrients were computed by the Cancer Council Victoria, 
based on Australian food composition data from NUTTAB 95 (Cancer Council 
Victoria 2009; Lewis, Milligan, and Hunt 1995).  
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3.4   Statistical analysis  
Statistical analysis was done using SPSS for Windows (version 16, SPSS Inc., USA). 
Data were assessed for normality to ensure that the assumptions for the analysis are 
met and transformations were used if required. Two different sampling systems for 
assessment of glucose tolerance were compared using a paired samples t-test and 
Bland-Altman analysis. An independent sample t-test was used to compare 
anthropometric and metabolic measurements of the hyperglycemic subjects with 
those of normal group. Data are presented as mean ± standard deviation (SD) (in the 
text and tables) and mean ± standard error of mean (SEM) (in charts). Statistical tests 
were two-tailed and a p<0.05 was considered as statistically significant. 
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3.5   Results 
Assessment of glucose tolerance - a comparison of methods 
In this study, participants were assessed for glucose tolerance through two different 
sampling systems, namely venous plasma  analysed  by the WHO reference glucose 
oxidase method (Royal Perth Hospital), and venous whole blood measured using a 
blood glucose meter (Accu-Chek Active, Roche Diagnostics , NSW, Australia) 
(methods - see Section 3.3.5). 
 
Data of 61 subjects [26 (43%) men, 35 (57%) women] with a mean (± SD) age of 
47.7 (±14.6) and a BMI of 27.54 (± 4.3) kg/m2 were analysed for comparing two 
sampling systems of venous whole blood and venous plasma used for assessment of 
glucose tolerance. 
 
As shown in Table 12, the minimum fasting and 2-h post glucose load (2-h PG) 
blood glucose measured in venous whole blood were 4.50 and 3.20 mmol/L, while 
those of venous plasma were 4.70 and 3.40 mmol/L. The maximum fasting and 2-h 
PG blood glucose values were 6.35 and 12.50 mmol/L in venous whole blood, and 
6.70 and 13.80 mmol/L in plasma samples, respectively. 
 
The mean (± SD) of fasting whole blood glucose (FWBG) (5.33± 0.40 mmol/L) was 
found to be significantly lower than the mean of fasting plasma glucose (FPG) (5.51 
± 0.54 mmol/L) using a paired samples t-test (p-value < 0.001). This finding was 
consistent with the results of comparing the mean values of 2-h PG blood glucose 
measured in venous whole blood and plasma samples (6.69± 1.63 vs. 6.87 ± 1.83 
mmol/L, p = 0.007).  
 
There was a strong positive linear relationship between venous whole blood and 
plasma glucose concentrations measured in both fasting state (r = 0.85, p < 0,001) 
and 2-h post glucose load (r = 0.97, p < 0,001) [Figure 15].   
 
 
 
 
83 
 
Table 12. Descriptive statistics of venous whole blood glucose and venous 
plasma glucose concentrations 
 
 
 
Parameters 
Venous whole blood glucose 
concentrations (n=61) 
Venous plasma glucose 
concentrations (n=61) 
Fasting  2-h Post glucose 
load  
Fasting 2-h Post 
glucose load 
Minimum (mmol/L) 4.50  3.20 4.70 3.40 
Mean  5.33  6.69  5.51 6.87  
Maximum (mmol/L) 6.35 12.50 6.7 0 13.80 
Standard deviation (SD) 0.40 1.63 0.54 1.83 
 
 
Agreements between the two sampling methods for both fasting and 2-h post glucose 
load measurements were assessed by Bland-Altman analysis. For the fasting values, 
the bias (mean difference score between whole blood and plasma glucose values, 
FPG minus FWBG) was calculated 0.19 and 95% limit of agreement (mean 
difference scores ± 2SD) was obtained as - 0.39 to 0.77mmol/L. [Figure 16].  
 
The bias decreased slightly to 0.17, and 95% limit of agreement was - 0.79 to 1.13 
mmol/L, when the results of 2h-PG blood glucose values measured in two different 
sampling systems were compared.  
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Figure 15. Scatter plots of venous whole blood and plasma glucose 
concentrations (mmol/L) measured (a) in fasting state and (b) at 2-h post 
glucose load. 
 
 
 
 
 
Figure 16. Bland-Altman graphs of difference scores for venous whole blood 
and plasma glucose concentrations (mmol/L) measured (a) in fasting state and 
(b) at 2-h post glucose load. 
 
 
In this study, the mean of plasma /whole blood glucose ratio was 1.03 with a range of 
0.93 - 1.15 in fasting samples, which was in line with 2-h post glucose load 
measurements (mean ratio: 1.02, range: 0.87-1.17, p = 0.15).    
 
- 2 SD 
a b 
+2 SD 
a 
b 
Mean 
+2 SD 
- 2 SD 
Mean 
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After converting glucose concentrations in venous whole blood to the equivalent 
concentrations in participants' plasma, using the conversion factor of 1.11 
recommended by the International Federation of Clinical Chemistry (IFCC), the 
mean (±SD) values of converted fasting plasma glucose values were still 
significantly different from fasting plasma glucose concentrations measured in the 
laboratory (5.91 ± 0.45 vs. 5.51 ± 0.54 mmol/L, p < 0.001), with a bias of - 0.40 and 
95% limit of agreements of - 0.96 to 0.16. This significant difference was also found 
for 2-h PG glucose values (7.43 ± 1.81 vs. 6.87 ± 1.83 mmol/L, p <0.001). The bias 
from this was - 0.56 and 95% limit of agreements were -1.48 to 0.36.   
 
To evaluate the two different sampling systems for identifying various stages of 
hyperglycemia,  blood glucose measurements were stratified on the basis of WHO 
cut-off values for venous plasma and venous whole blood samples (Alberti and 
Zimmet 1998): namely, fasting venous plasma glucose concentrations into <6.1, 6.1 - 
6.9 and > 6.9 mmol/L, fasting venous whole blood glucose concentrations into <5.6, 
5.6 - 6.0 and > 6.0 mmol/L, 2-h PG venous plasma glucose concentrations into < 7.8, 
7.8 - 11.0 and >11.1 mmol/L, and 2-h PG venous whole blood glucose 
concentrations into < 6.7, 6.7- 9.9 and > 9.9 mmol/L.  
 
Accordingly, 72.1%, 24.6% and 3.3% of participants were categorised as 
normoglycemic, IFG and diabetic, respectively, based on the fasting whole blood 
glucose measurements. However, these percentages changed to 77%, 23% and 0% 
respectively, when individuals were classified with regard to the fasting plasma 
glucose concentrations. Furthermore, there was an increased discrepancy when only 
2-h post glucose load measurements were used as the basis of  classifications, 
namely 54.1%, 41.0 and 4.9% of individuals categorised as normoglycemic, IGT and 
diabetic according to 2-h PG whole blood measurement, compared to 75.4%, 21.3% 
and 3.3% based on 2-h PG plasma glucose concentrations.  When both fasting and 2-
h post glucose load measurements were considered for classification, 42% (13 out of 
31) of participants diagnosed as IFG or IGT according to WHO venous whole blood 
cut-off values, had normal plasma glucose concentrations and only one 
normoglycemic participant was misclassified as IFG. Furthermore, among the three 
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participants classified as diabetic, based on the venous whole blood values, one 
subject had plasma glucose concentration at the pre-diabetic level (IGT).  
 
Assessment of anthropometric and metabolic factors 
To achieve the main objective of this study, data of 64 subjects (29 men and 35 
women) with an overall mean (± SD) age of 48.2 (±14.3) years and BMI of 27.4 
(±4.2) kg/m
2
 were analysed, except for vascular function measurements which 
included data for forty four subjects (21 males and 23 females).  
 
According to the WHO classification [Appendix 7], 10 (6 men, 4 women) of 64 
subjects were identified as having metabolic syndrome, and 11 subjects (6 men, 5 
women) were insulin resistant based on the calculated HOMA score (HOMA score > 
2.5) (Keskin et al. 2005).    
.   
The sixty four subjects consisted of 39 normal healthy participants (14 men, 25 
women) and twenty 25 hyperglycemics (15 men, 10 women) with blood glucose 
levels at pre-diabetic ranges (16 IGT, 9 IFG). These classification were based on 
venous plasma glucose measurements (FPG& 2-h GTT), as recommended by WHO, 
IDF and ADS for detecting glucose intolerance.  
 
Of eleven participants classified as insulin resistant, 10 subjects were  hyperglycemic 
(6 IGT, 4 IFG) and 1 subject had normal blood glucose levels.  
   
As presented in Table 13, hyperglycemic subjects had an average (±SD) age of 
57.96±11.08 years which was significantly higher than the average age of 
normoglycemic group (41.92 ± 12.64, P<0.001).  
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Table 13. Anthropometric and metabolic characteristics of subjects in each 
group 
 
Subjects' 
characteristics 
Hyperglycemic  Group Normoglycemic Group  
P-Value 
Mean(SD) Range Mean(SD) Range 
Age (y)  57.96(11.08)  27-73 41.92(12.64) 22 - 71 <0.001 
Weight (kg) 83.0(12.55) 61.6-105.9 74.8(16.02) 51.6-105.4 0.03 
Body mass index 
(kg/m
2
) 
28.30(3.69) 21.1-36.4 26.88( 4.46) 19.9-35.8 0.19 
Waist 
circumference (cm) 
99.94(10.18) 86.0- 122.0 90.4(12.74) 68.0- 124.0 0.003 
Waist/hip ratio  0.94(0.07) 0.81- 1.06 0.85(0.11) 0.45-1.05 0.001 
Systolic blood 
pressure (mmHg) 
118.7(11.3) 97 - 142 109.9(11.93)  91 -140 0.005 
Diastolic blood 
pressure (mmHg) 
71.0(8.05)  60 - 91 63.5(7.62)  48 - 90 <0.001 
Fasting plasma 
glucose (mmol/L) 
6.04(0.37) 5.30 - 6.50 5.21(0.34) 4.7- 6.0 <0.001 
2-h plasma glucose 
(mmol/L)  
8.08(1.26)  6.1 - 11.0 5.93(1.01) 3.40 - 7.70 <0.001 
Fasting insulin 
(μIU/mL) 
8.74(4.78) 3.0 - 21.0 6.03(2.35) 0.9 - 11.40 0.01 
2-h insulin (μIU/mL) 81.03(55.78) 24.7- 233.0 52.84(36.12) 15.0 -205.0 0.02 
HOMA score 2.37(1.33) 0.83-6.07 1.40(0.56) 0.20-2.53 0.002 
Triglyceride 
(mmol/L) 
1.49(0.53) 0.84 - 3.02 1.38(0.79) 0.48 - 4.58 0.56 
Total cholesterol 
(mmol/L) 
4.90(1.15) 2.95 - 6.63 5.12(1.13) 1.44 - 8.88 0.40 
Fasting LDL  
( mmol/L) 
2.96(0.75) 1.40 - 4.62 3.07(0.92) 1.82 - 5.82 0.61 
Fasting HDL 
( mmol/L) 
1.22(0.24) 0.82 - 1.94 1.30(0.30) 0.81 - 6.03 0.30 
Fasting hs-CRP 
(mg/L) 
1.60(1.25) 0.16 - 3.93 1.60(1.43) 0.16 - 6.98 0.10 
eGFR *  
(ml/min/1.73 m
2
)  
93.47(20.7)) 52.4-146.8 112.6(20.8) 67.4-163.5 0.001 
* Estimated by using Cockroft - Gault formula adjusted for body surface area 
 
When all subjects were stratified into three age groups, namely:  < 45, ≥ 45 and < 65, 
and ≥ 65 years, the mean (± SD) values of fasting and postprandial glucose increased 
with age, peaking among those aged 65 years and older [Table 14]. Moreover, 
subjects aged 45-64 years and ≥ 65 years had higher insulin levels (fasting & 2-h PG) 
and HOMA score, compared to subjects who were younger than 45 years.   
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Table 14. Plasma glucose and insulin levels and HOMA score in different age 
groups 
 
Measurements - Mean(SD) < 45 years 
(n=24) 
≥45 and <64 years 
(n=27) 
≥ 65 years 
(n=8) 
Fasting plasma glucose (mmol/L) 5.18(0.39) 5.66(0.48) 6.08(0.47) 
2-h PG plasma glucose (mmol/L) 6.22(1.42) 7.05(1.58) 7.33(1.29) 
Fasting insulin (μIU/mL) 6.15(2.40) 7.82(3.86) 7.06(5.83) 
2-h PG insulin (μIU/mL) 53.57(37.14) 69.55(46.51) 71.91(69.17) 
HOMA score 1.42(0.57) 2.01(1.07) 1.96(1.72) 
 
  
Normal and hyperglycemic groups had mean BMI (± SD) of 26.88 (± 4.46) and 
28.30 (± 3.69) kg/m
2
, respectively. The tendency for an increased levels of fatness 
(indicated by BMI) in hyperglycemic subjects became significant when two groups 
were compared for waist circumference (P = 0.003) and waist/hip ratio (P = 0.001), 
as two indices of abdominal obesity. There were also significant correlation between 
waist circumference and plasma glucose levels (fasting: r = 0.41, p = 0.001; 2-h PG: 
r = 0.33, P = 0.007) as well as other cardiovascular risk factors: SBP (r = 0.32, P = 
0.009), HDL- cholesterol (r = - 0.29, P = 0.02), triglyceride (r = 0.27, P = 0.03) and 
CRP (r = 0.31, P = 0.01).  
 
Hyperglycemic subjects had a significantly higher HOMA score (2.37±1.33 vs. 
1.40±0.56, p=0.002), compared to the normoglycemic group. There were also 
significant associations between HOMA score and blood glucose measured in both 
fasting (r = 0.49, p<0.001) and postprandial (r=0.29, p<0.05) states, and between 
HOMA score and indices of central obesity [WC: r = 0.53, p < 0.001; W/H ratio: r = 
0.43, P <0.001]. 
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Figure 17: Systolic and diastolic blood pressure in hyperglycemic and normal 
groups. Compared to normal group, hyperglycemic subjects had a significantly 
higher systolic (p=0.005) and diastolic (p<0.001) blood pressure. Data are 
presented as mean ± SEM 
 
Subjects with impaired glucose regulation had also a significantly higher resting 
systolic (118.7±11.3 vs. 109.9±11.93 mmHg, P = 0.005) and diastolic (71.00±8.05 
vs. 63.5±7.62 mmHg, P< 0.001) blood pressure, relative to normal volunteers [Figure 
17].   
 
In comparison with normoglycemic group, hyperglycemic subjects had a tendency 
toward higher mean (± SD) value of triglyceride (1.51±0.57 vs. 1.38±0.78 mmol//L), 
associated with lower mean values of total cholesterol (5.08±1.07 vs. 4.90±1.37 
mmol//L), LDL-cholesterol (3.23±0.53 vs. 3.07±0.91 mmol//L) and HDL-cholesterol 
(1.40±0.70 vs. 1.52±1.06 mmol//L) [Table 13].  
  
Microalbuminuria (detected by albumin to creatinine ratio ≥ 30 μg/mg) was present 
in 12 % of those with hyperglycemia in pre-diabetic ranges (3 of 25 subjects), but 
7.7% of normal individuals (3 of 39 subjects). Moreover, there was a significant 
difference between glomerular filtration rate (GFR) estimated in hyperglycemic and 
normal participants (93.47±20.7 vs. 112.63±20.8 ml/min/1.73 m
2
, P = 0.001).  
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Subjects with metabolic syndrome had a tendency toward higher BMI (29.64±3.74 
vs. 27.03±4.19 kg/m
2
, P = 0.07), as well as significantly higher WC (103.30±12.37 
vs. 92.46±12.02 cm, P = 0.01), and W/H ratio (0.96±0.06 vs. 0.87±0.10, P = 0.01). 
Also, there was a significant association between metabolic syndrome and insulin 
resistance (χ2 = 23.23, p < 0.001).   
 
Arterial stiffness was assessed  in a subgroup of  participants including 27 normal 
and 17 hyperglycemic (12 IGT, 5 IFG) volunteers, by using a Pulse Trace machine 
recording RI and SI  as two main indicates derived from digital volume pulse (DVP). 
In the present study, in addition to the fasting measurement, post prandial vascular 
function was evaluated at 30, 60, 90 and 120 minutes after ingestion of the glucose 
load. Areas under the curves were calculated using the trapezoidal rule. Changes in 
SI and RI responses were expressed as SI Postprandial minus SI Fasting, and RI 
Postprandial minus RI Fasting, respectively. 
 
The mean value (±SD) of (Ln) fasting SI measured in hyperglycemic group was 
significantly higher than those measured in the normoglycemic group (2.19±0.32 vs. 
1.96 ±0.22 m/s, p = 0.005) [Figure 18]. The observed difference was borderline after 
adjustment for age as the main potential confonder (p=0.05). SI measured in fasting 
state was significantly correlated with age (r = 0.78, p<0.001), W/H ratio (r = 0.47, p 
= 0.001), SBP (r = 0.60, p < 0.001), DBP (r = 0.55, p<0.001), total cholesterol (r = 
0.32, p=0.04) and fasting plasma glucose (r=0.57, p<0.001).  
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Figure 18. Comparison between (Ln) Fasting SI measured in hyperglycemic and 
normal groups. (Ln) Fasting SI measured in hyperglycemic group was significantly 
higher than those measured in the normoglycemic group (p=0.005). Data are 
presented as mean ± SEM.    
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Figure 19. Change in postprandial RI observed in hyperglycemic and normal 
groups. Hyperglycemic subjects had tendency to a smaller change in the post-
glucose challenge RI values, when compared with normoglycemic group. Data are 
presented as mean ± SEM.    
  
 
Subjects with hyperglycemia also had a higher fasting RI (71.62% ±10.62 vs. 
68.96% ±10.50, p=0.42) relative to normoglycemic individuals, although it was not 
statistically significant. There was also a weak but significant correlation between 
fasting RI and age (r = 0.34, p<0.05).  
 
Furthermore, hyperglycemic subjects had tendencies to a smaller change in SI (-0.37 
± 2.93 vs. -0.80± 1.90 m/s, p=0.56) and RI (-9.61% ± 14.15 vs. -10.87% ±14.89, 
p=0.78) values  following the glucose callenge, when compared with normoglycemic 
group [Figure 19].  
 
Subjects participating in this study were also classified on the basis of HOMA score. 
According to our data, there were trends toward higher (Ln) fasting SI (2.22 ± 0.24 
vs. 2.01 ± 028 m/s) and fasting RI (73.14 % ± 8.08 vs. 69.39% ± 10.89), associated 
with  bunted changes in postprandial SI (-0.21 ± 2.7 vs. -0.72 ± 2.3 m/s ) and RI (-
10.26% ± 15.50 vs. -10.41% ± 14.48) in the insulin resistant group (n=7) relative to 
subjects without insulin resistance (n=37).  
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Assessment of thiamin status 
In the present cross-sectional study, dietary intake of thiamin was estimated by a 
validated semi-quantitative food frequency questionnaire (Anti-Cancer Council, 
Victoria). There was no significant difference between the mean (± SD) of thiamin 
intake in normal subjects and those who were diagnosed with hyperglycemia 
(1.37±0.72 vs. 1.46±0.51 mg/day, p=0.56) [Figure 20]. Also, there were no 
significant difference between females and males in thiamin intake (1.29±0.62 vs. 
1.54±0.66 mg/day, p=0.13). Thiamin intake was not significantly associated with 
BMI, WC, W/H ratio, SBP, DBP, FPG, 2-h plasma glucose, HOMA score, total 
cholesterol, HDL-cholesterol, LDL-cholesterol, triglyceride, hs-CRP, fasting SI and 
RI, and changes in postprandial SI and RI. Similarly, no significant correlations 
between thiamin intake and these variables found for each gender group. There was a 
strong and significant correlation between dietary intakes of thiamin and fibre (r = 
0.63, p<0.001). 
 
 
 
 
Figure 20: Dietary intake of thiamin in hyperglycemic and normal groups. 
There was no significant difference between thiamin intake in normal subjects and 
hyperglycemic group (p=0.56). Data are presented as mean ± SEM.    
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In this study, it was planned to assess thiamin status by measuring thiamin in urine, 
plasma and RBC samples. However, we encountered technical problems in 
establishing the HPLC methods for this analysis at Curtin University. Therefore, only 
the results of RBC thiamin (which were assayed at RPH) are presented.  
 
No significant difference was observed between the mean (± SD) of RBC thiamin 
levels measured in hyperglycemic and normal group (159.76±29.08 vs. 
142.59±39.58 nmol/L, p= 0.07). Also, when RBC thiamin levels were converted to 
nmol/g hemoglobin, no significant difference  was found between the hyperglycemic 
and normal groups (0.95±0.17 vs. 0.88±0.24 nmol/g Hb, p=0.22) [Figure 21]. The 
levels of RBC thiamin reported as nmol/g Hb were strongly associated with those 
reported as nmol/L (r=0.95, p<0.001). RBC thiamin level (nmol/g Hb) was not 
significantly correlated with BMI, WC, W/H ratio, SBP, DBP, HOMA score, total 
cholesterol, HDL-cholesterol, LDL-cholesterol, triglyceride, fasting insulin, hs-CRP, 
2-h plasma glucose, 2-h insulin, urinary albumin/creatinine ratio, , fasting SI and RI, 
changes in postprandial SI and RI, and thiamin intake [Figure 22]. There was a weak 
but significant correlation between RBC thiamin level (nmol/g Hb) and FPG (r=0.25, 
p=0.049).  
 
 
 
Figure 21: RBC thiamin levels in hyperglycemic and normal groups. No 
significant difference was observed between RBC thiamin levels measured in 
hyperglycemic subjects and normal group (p= 0.22) Data are presented as mean ± 
SEM.    
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Figure 22: Scatter plot of RBC thiamin levels and dietary intake of thiamin. No 
significant correlation was observed between RBC thiamin levels (nmol/g Hb) and 
thiamin intake (mg/d) (r=0.046, p=0.72). 
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3.6   Discussion 
Comparison of methods used for assessment of glucose tolerance 
Glucose concentration can be measured in plasma or whole blood. Concentration of 
glucose measured in whole blood is generally lower than its pertinent plasma 
(Holtkamp, Verhoef, and Leijnse 1975; Kempe et al. 1997), as confirmed by this 
study.  This is mainly due to a higher content of proteins ( i.e. hemoglobin) and 
cellular elements in whole blood, and a concomitant decrease in the water portion 
(Dungan et al. 2007; Marks 1996). Several factors have been shown to influence 
blood glucose concentrations in different sample types, including patients variables 
(i.e. feeding, hematocrit, temperature and drugs)  and the method of measurement 
(Dungan et al. 2007; Haeckel et al. 2002; Oberg and Ostenson 2005; Smith and 
Kilpatrick 1994). The significant difference detected in this study as well as a 
clinically poor agreement between plasma and venous whole blood values are in line 
with the finding of other authors who recommended avoiding the use of glucose 
concentrations measured in the two systems interchangeably (D'Orazio et al. 2005; 
Dungan et al. 2007).  
 
The Bland-Altman graphs [Figure 16] indicate that the difference scores for blood 
glucose measured in two sampling systems proportionally increased with the glucose 
concentrations. In the present study, the measured fasting and 2-h PG glucose 
concentrations were limited to the described ranges. Hence, it is not possible to 
discuss the impact of sampling type on detecting hyperglycemia beyound the 
mentioned values.   
 
Given the discussed discrepancy, the use of fixed factors for converting glucose 
concentrations from one sampling system to another has been suggested by some 
investigators (Cederholm and Wibell 1990; D'Orazio et al. 2005; Dungan et al. 2007; 
Stahl and Brandslund 2003). These conversion factors are determined based on the 
water content of different compartments, or derived from the statistical analysis 
(ratio of mean values or regression lines equation) of glucose concentrations 
measured in different systems (Haeckel et al. 2002).  
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Accordingly, considerable variation in suggested conversion factors may be 
attributable to a large discrepancy between the mean values of plasma/whole blood 
glucose ratio reported in previous studies (Holtkamp, Verhoef, and Leijnse 1975; 
Ingram et al. 1971; Lind et al. 1972; McDonald, Fisher, and Burnham 1964; 
Morrison and Fleck 1973; Tustison, Bowen, and Crampton 1966). To provide 
harmonised results, IFCC recommended a constant factor of 1.11 for converting 
whole blood glucose concentrations to equivalent plasma values, as was used here.  
 
The significant difference between glucose concentrations measured in venous 
plasma samples and the converted values observed in this study, together with a 
relatively wide limit of agreement, indicate that the conversion of glucose 
concentrations using a fixed factor may result in unpredictable rates of clinical 
misinterpretation. The findings of the present study are in agreement with previous 
studies that reject the practice of converting glucose concentration, and recommend 
to use a single system of venous plasma for all glucose measurements (Holtkamp, 
Verhoef, and Leijnse 1975; Morrison and Fleck 1973; Wiener 1995). Holtkamp et al. 
(1975) showed that the use of conversion factors can be helpful only when the 
samples are deproteinized.  
 
In this study, glucose concentrations measured in two different sampling systems 
were also compared for glucose tolerance assessment, using the cut-off values 
recommended by WHO. According to our findings, the percentage of individuals 
classified as having impaired glucose tolerance or diabetes using venous whole blood 
was higher compared to venous plasma  (χ 2 = 22.002, p < 0.001), and evaluating 
glucose tolerance using venous whole blood values caused misclassification in up to 
25% of the GTTs. In agreement with this, Neely et al. (1991) found that, based on 
the WHO criteria, the use of venous whole blood values may give a higher incidence 
of gestational impaired glucose tolerance relative to venous plasma glucose.  
 
By contrast, in an epidemiological survey conducted by Farrer et al. (1995), no 
significant difference was reported in the proportion of individuals classified as 
having impaired glucose tolerance or diabetes using venous whole blood glucose, 
when compared with venous plasma glucose. The inconsistency between the findings 
of Farrer et al. and the present study may be explained in part by the difference in the 
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method of glucose measurements. In the present study venous whole blood samples 
were analysed by means of a blood glucose meter (Accu-Chek Active, Roche 
Diagnostics), wheras in the study carried out by Farrer et al, venous whole blood 
samples were assayed using a bench top analyser. The Accu-Chek device used for 
this study was a glucose dehydrogenase-based meter, measuring glucose 
concentration in whole blood sample by the photometric metod. According to the 
information provided by the manufacturer, the Accu-Chek glucose meter works 
acceptably with both venous and capillary blood samples (Roche Diagnostics 
Corporation 2001). However, in general the applicability of glucose meters for 
detecting glucose intolerance is still a matter of debate (Tonyushkina and Nichols 
2009).  
  
At present, fasting plasma glucose and 2-h OGTT are recommended by WHO and 
IDF to identify all states of hyperglycemia (World Health Organization and 
International Diabetes Federation 2006). Also, for standardisation in Australia, 
venous plasma glucose was chosen as a recommended method of diagnosing diabetes 
and impaired glucose regulation state (IFG, IGT) by the Australian Diabetes Society 
(ADS)(Diabetes Australia Western Australia 2005; Welborn 1996). Moreover, 
according to the guidelines provided by National Health and Medical Research 
Council (NHMRC), venous plasma glucose measurements should be performed by 
an accredited laboratory, and blood glucose meters do not have sufficient accuracy 
required for definitive diagnosis (National Health and Medical Research Council 
2001; Poirier et al. 1998). 
 
Anthropometric and metabolic factors  
Based on the results of the present study, subjects with impaired glucose regulation 
were significantly older than healthy group. This was in line with previous studies, 
indicating that the prevalence of abnormal glucose tolerance and diabetes increases 
with age (Cowie et al. 2006; DECODE Study Group 2003). Additionally, in this 
study the mean of HOMA score (a measure of insulin resistance) increased with age. 
In keeping with this, the increased risk of hyperglycemia with age is thought to be 
mainly attributable to a decline in insulin-mediated glucose uptake by peripheral 
tissue, and a delay in insulin-induced suppression of hepatic glucose production 
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(Couet et al. 1992). Bryhni et al. (2010) also suggested a reduced secretion of insulin 
as the possible mechanism, which was not confirmed by our study (see table 13). The 
increased insulin levels showed in the current study could be as a result of 
compensatory hyperinsulinemia induced by insulin resistance. Consequently, 
changes with age could be due to a reduced capacity of pancreatic beta cells to 
secrete adequate insulin to compensate for insulin resistance, rather than the absolute 
decrease in insulin secretion.  
 
Hyperglycemic subjects participting in the current study also had a higher BMI 
relative to the normoglycemic group, although it was not signifiant. This tendency 
became significant when two groups were compared for the indices of abdominal 
obesity (waist circomfrence & W/H ratio). These findings confirm several studies 
showing a relationship between obesity and various cardiovasular risk factors 
including: hypertension (Berchtold et al. 1981; Blair et al. 1984),  dyslipidemia 
(Garrison et al. 1980; Olefsky, Reaven, and Farquhar 1974) and  in particular 
hyperglycemia (Hartz et al. 1983; Stern and Haffner 1986). This risk is known to be 
more significant in the presence of central obesity (National Institutes of Health 
1998). Moreover, in agreement with our study, excess adipose tissue has been shown 
to induce the production of cytokines such as CRP, suggesting that it contributes to 
the inflammatory atherogenic process independent of its effects on lipoprotein 
metabolism or insulin sensitivity (Yudkin et al. 1999). CRP is accepted as the 
strongest non-lipid predictor of cardiovascular events (Ridker, Hennekens, et al. 
2000), including  myocardial infarction (Ridker et al. 2002), stroke (Ridker et al. 
2002; Ridker 2003),  cardiac sudden death (Albert et al. 2002) and peripheral artery 
diseases  (Ridker et al. 2008), particularly in patients with diabetes mellitus 
(Linnemann et al. 2006; Pfutzner and Forst 2006). 
 
Hyperglycemic subjects participating in this study also had a significantly higher 
HOMA score compared to the normoglycemic group. There were also significant 
correlations between HOMA score and indices of central obesity. These results are in 
agreement with other studies (Despres 1993; Jellinger 2007; Westphal 2008) which 
indicate that abdominal obesity may play a key role in the pathogenesis of 
hyperglycemia via enhancing insulin resistance.  
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In this study, we also observed that not all of hyperglycemic subjects were IR as 
estimated by HOMA. This could be partly because of the method used for the 
assessment of insulin sensitivity. There are several measures of insulin resistance 
(DeFronzo, Tobin, and Andres 1979; Galvin et al. 1992; Harano et al. 1977; 
Matthews et al. 1985). Of these, hyperinsulinemic euglycemic clamp is considered as 
the gold standard method to quantify insulin resistance (American Diabetes 
Association 1998). Given that glucose clamp technique is difficult, time consuming 
and expensive, homeostasis model assessment (HOMA) of insulin sensitivity was 
proposed as an acceptable alternative measure of insulin resistance (Bonora et al. 
2000). However, HOMA measures liver resistance rather than peripheral resistance 
(Bonora et al. 2000).           
 
In the present study, more hyperglycemic subjects had microalbuminuria than normal 
group. This was accompanied by raised levels of serum lipids and blood pressure. 
Consistent with these results, impaired glucose metabolism was shown to be strongly 
asscociated with other lipid (Zhang et al. 2009) and non-lipid (hypertension, obesity 
and microabuminuria) risk factors (Deedwania 2011; Zelmanovitz et al. 2009). 
Consequently, to improve cardiovascular risk prediction, these risk factors are 
generally considered as a cluster, what is now known as the "metabolic syndrome". 
Statistical data indicate that metabolic syndrome occurs in approximately one out of 
four of the world’s adult population and those who have it are three times as prone to 
having a heart attack or stroke, compared with people without the syndrome (Alberti, 
Zimmet, and Shaw 2006; International Diabetes Federation 2006).  
 
According to our results, there was a significant correlation between metabolic 
syndrome and insulin resistance. Also, subjects with metabolic syndrome had 
significantly higher BMI, WC and W/H ratio relative to those who were without 
metabolic syndrome. These findings are in line with previous studies suggessting 
insulin resistance and obesity (specifically abdominal obesity) as the main 
underlying contributors to the development of metabolic syndrome (Despres et al. 
2008; Despres 1993). 
 
Arterial stiffness was another risk factor evaluated in the present study. According to 
our results, fasting SI was correlated more strongly with age, while there was a weak 
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relationship between fasting RI and age. In agreement with this, Millasseau et al. 
suggested SI as a more reliable index for evaluating vascular aging than RI 
(Millasseau et al. 2003).  Furthermore, Woodman and Watts indicate that the 
stiffness index derived from DVP analysis provides an estimation of large artery 
stiffness which is strictly linked to age-related changes (Woodman and Watts 2003).   
 
Although arterial stiffness occurs mainly as a pathological consequence of aging 
(Benetos et al. 2002), other risk factors including central obesity, hypertension, 
dyslipidemia and hyperglycemia can accelerate its progress (Henry et al. 2003; Liu et 
al. 1989; Safar, Czernichow, and Blacher 2006; Salomaa et al. 1995; Schram et al. 
2004; van Popele et al. 2006; Wilkinson et al. 2002; Xu et al. 2010). Hyperglycemia 
was shown to enhance arterial stiffness through several mechanisms (Henry et al. 
2003; Salomaa et al. 1995; Schram et al. 2004; van Popele et al. 2006; Xu et al. 
2010), causing endothelial dysfunction as well as alternations in the structure of 
vascular extracellular matrix.   
 
In the present study, fasting stiffness index measured in subjects with hyperglycemia 
was significantly higher than those measured in normoglycemic subjects. This result 
confirms a previous study indicating that hyperglycemia even in pre-diabetic ranges 
can augment arterial stiffness (Henry et al. 2003). It was also consistent with the 
findings of Gunarathne et al. (2008) who designated SI derived from digital volume 
as a potent discriminator of increasing cardiovascular complications in high- risk 
subjects including diabetics. The prevalence of hyperglycemia increases with age 
(Australian Bureau of Statistics 2006; Dunstan et al. 2001), which is also the main 
determinant of arterial stiffness, as discussed above.  Accordingly, in the present 
study, higher fasting SI value observed in hyperglycemic subjects could be partially 
explained by the age difference between the two groups. It was shown by the 
increase in the p-value after adjustment for age (see Section 3.5).  
 
We reported that hyperglycemic subjects had also a higher fasting RI value relative 
to normoglycemic subjects. The difference in fasting RI value between the two 
groups was not statistically significant, but it may be considered significant from a 
clinical view.    
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RI is mainly related to the tone of small arteries which can be altered in the presence 
of hyperglycemia (Gunarathne et al. 2009; Rizzoni, Porteri, Guelfi, Muiesan, 
Valentini, et al. 2001; Rizzoni, Porteri, Guelfi, Muiesan, Piccoli, et al. 2001; Rosei 
and Rizzoni 2010).  Nitric oxide released from endothelium can influence smaller 
arterioles and branch vessels more than larger arteries, due to a thinner media of 
smaller vessels (Cohn 1999; de Koning and Rabelink 2002). RI was also shown to be 
a reliable parameter for evaluating the effect of different vasoactive substances, such 
as glyceryl trinitrate, angiotensin II and salbutamol (Chowienczyk et al. 1999; 
Gopaul et al. 2001; Millasseau et al. 2003). However, there is no published literature 
so far to show the changes in RI after a glucose challenge in subjects with 
hyperglycemia. 
 
The effect of oral glucose (usually 75 g administrated in a standard OGTT) on 
endothelial function has been mainly assessed by the change in the flow-mediated 
vasodilation (FMD). FMD was shown to decrease within 1 hour after ingestion of the 
glucose load by healthy subjects as well as patients with IGT and diabetes (Akbari et 
al. 1998; Kawano et al. 1999). However, the change in the post-prandial FMD was 
more significant in diabetic or impaired glucose tolerant patients, compared to 
subjects with normal glucose metabolism.  
 
Several mechanisms are thought to account for the temporary impairment of 
endothelium-dependent vasorelaxation observed following an oral glucose challenge, 
including generation of oxidative stress (Kawano et al. 1999) and free radicals (Title 
et al. 2000), a transient loss of NO bioavailability (Title et al. 2000), and a reduction 
in antioxidant defence systems (Ceriello et al. 1998).  
 
According to our data, the insulin resistant group had tendencies toward higher SI 
and RI measured in fasting state, accompanied by reduced changes in postprandial 
responses, compared to individuals without insulin resistance. Consistent with these 
results, Gopaul et al.  (2001) showed that in diabetic patients, the blunted response of 
RI following inhalation of salbutamol was significantly correlated with insulin 
sensitivity and plasma 8-epi-prostaglandin F2 alpha (8-epi-PGF2α), a product of 
oxidative stress. Insulin has been suggested to cause arterial dilation through the 
release of NO (Scherrer et al. 1994). In the insulin resistant state, insulin-mediated 
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vasodilation may be impaired due to a decrease in NO bioavailability (Williams et al. 
1996), occurring temporarily after ingestion of an oral glucose load.    
  
In the present study, a tendency toward a blunted response of DVP-derived 
parameters (RI & SI) to the oral glucose challenge in subjects with impaired glucose 
metabolism (IFG & IGT) confirms an impaired endothelium-dependent vasodilation 
in these patients, as shown by others in the FMD assessments.  Moreover, in 
agreement with our results, Gopaul et al. (2001) reported a trend toward a reduced 
change in the RI derived from DVP analysis following inhalation of salbutamol in 
subjects with IGT, which became significant in newly diagnosed and established 
diabetes. Similarly, Chowienczyk et al. (1999) showed an attenuated response of RI 
to inhaled albuterol (salbutamol) in patients with type 2 diabetes mellitus, compared 
to control subjects. Given the evidence of changes in FMD following an oral glucose 
challenge in subjects with hyperglycemia as well as the reduction in 
photoplethysmographic digital volume pulse parameters under salbutamol inhalation, 
it can be expected that evaluating DVP analysis following an oral glucose challenge 
could provide additional information in the assessment of vascular function, 
particularly in diabetic patients. Further studies are required to confirm these findings 
in individuals with an increased risk of cardiovascular diseases. 
 
Thiamin status 
Hyperglycemic subjects participating in the present study had thiamin intakes similar 
to normoglycemic group as assessed by FFQ. The thiamin intake in both groups were 
greater than Australian Recommended Dietary Intakes (RDIs) (1.2 mg/d males, 1.1 
mg/d females) (National Health and Medical Research Council 2006), as expected. 
Subsequent to mandatory fortification of bread-making flour with thiamin in 
Australia which started in January 1991, almost all Australians were shown to have 
an intake of at least the recommended values (Baghurst et al. 1996; The National 
Health and Medical Research Council 1990). However, RDIs are set for healthy men 
and women, and the adequacy of thiamin intake at these levels is still a matter of 
debate about patients with diabetes (Vindedzis et al. 2008). Recent studies indicated 
that diabetic patients are at risk of thiamin deficiency, which is mainly due to an 
increased excretion of thiamin (Jermendy 2006; Thornalley et al. 2007).  
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In our study, the level of RBC thiamin in hyperglycemic subjects was not 
significantly different to the normoglycemic subjects. Also, the means of RBC 
thiamin in both groups were in the normal range (Schrijver 1991), although they 
were less than the values [mean value of 433 ng/g Hb (1.44 nmol/g Hb), with 95 % 
reference interval of 290-590 ng/g Hb (0.93-1.96 nmol/g Hb)] reported in another 
study using the same method (Talwar et al. 2000).  
 
The results of the current study are in line with the findings of Thornalley et al. 
(2007) who showed a normal concentration of RBC thiamin in diabetic patients 
(normal volunteers 0.318±0.028 pmol/mg Hb; type 1 diabetes 0.345±0.025 pmol/mg 
Hb; type 2 diabetes 0.328±0.137 pmol/mg Hb), despite a significant increase in their 
urinary thiamin excretion (fourfold and threefold in type 1 and type 2 diabetic 
subjects relative to normal participants). These authors found that the normal level of 
RBC thiamin in diabetic patients was accompanied by significant increases in 
erythrocyte membrane thiamin transporters THTR-1 and RFC-1, normal activity of 
erythrocyte transketolase, and severe decreases in plasma thiamin (76% and 75% in 
type 1 and type 2 diabetic subjects, respectively). This brings into question the 
recommendation of the concentration of TDP in erythrocytes as the most sensitive 
indicator of thiamin status (Baines and Davies 1988; Brin 1964; Howard 2000; 
Talwar et al. 2000). Thornalley et al. (2007) suggested plasma thiamin for evaluating 
thiamin status in diabetic patients, because erythrocyte thiamin levels and also the 
erythrocyte transketolase activity may be influenced by the increased levels of 
thiamin transporter protein.  
 
Measurement of plasma thiamin is less frequently used to evaluate tissue storage, 
because, contrary to erythrocyte thiamin (Brin 1964), the extracellular concentration 
of thiamin can be influenced largely by the recent intake. Also, approximately 10% 
of total blood thiamin is found in the plasma and 80% is in erythrocytes (Talwar et 
al. 2000). Therefore, plasma thiamin concentration is difficult to assay precisely 
without being contaminated by the leakage of thiamin from the blood cells during the 
preparation of samples (Bates 2009). With respect to these facts and also the findings 
of Thornalley and his colleagues (2007), whole blood may be the preferred specimen 
for thiamin assessment in individuals who are at risk of thiamin deficiency, including 
diabetics.       
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It was not possible to evaluate thiamin urinary excretion and plasma status in our 
participants. However, evidence indicates that hyperglycemia even in non-diabetic 
ranges is associated with some degrees of renal injury (Gabir et al. 2000; Metcalf et 
al. 1993; Pan et al. 1993), as confirmed in our study. Therefore, it can be predicted 
that patients with impaired glucose regulation (IFG, IGT) would be also prone to 
thiamin deficiency as judged by plasma levels, due to increased urinary excretion.  
Further analysis of plasma and urinary thiamin is required to confirm this prediction 
in patients with pre-diabetic hyperglycemia. 
 
In the current cross-sectional study, there was no significant correlation between 
RBC thiamin and thiamin intake. This could be partly due to the use of FFQ for 
estimating dietary intake of thiamin. FFQs are useful tools for ranking individuals’ 
usual dietary intakes. However, they may not be adequately accurate to determine the 
absolute intakes of energy and nutrients. The lack of correlation may also be as a 
result of the likely renal damage in some hyperglycemic subjects and subsequent 
variation in the loss of thiamin.  
 
In this study, thiamin intake was not significantly associated with other 
measurements of this study including the plasma glucose determined in postprandial 
state. In contrast with our results, Bakker et al. (1998) reported a strong correlation 
between thiamin intake and 2-h plasma glucose in the Hoorn Study. They 
hypothesised that the effect of fibre consumption on glucose tolerance is in part 
attributable to concomitant intake of thiamin. The Hoorn Study consisted of 
Caucasian men and women aged 50-74 years, with a mean (±SD) dietary thiamin 
intakes of 1.2±0.3 and 1.1±0.3 mg/d, respectively, assessed using a semi-quantitative 
food frequency questionnaire (Grootenhuis et al. 1995). In that study, the intake of 
dietary fibre was reported as 28.7±8.7 g/d in men and 26.2±6.9 g/d in women, which 
were greater than those observed in the present study (23.2±10.3 g/d in men, 
20.8±8.1 g/d in women). The inconsistency between the findings of Bakker et al. and 
our study may be explained partly by the considerable difference in the number of 
subjects participating in the Hoorn Study (n=2196) and the present study (n=64). 
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3.7   Conclusion 
In addition to diabetics, patients with the pre-diabetic range of hyperglycemia have 
been proposed to be prone to thiamin deficiency, due to increased urinary excretion. 
This hypothesis was not accepted in this study, when thiamin status of 
hyperglycemics was compared with normal subjects, based on the erythrocyte 
thiamin levels. On the other hand, we cannot reject it completely. Measurement of 
erythrocyte thiamin has already been recommended as the most sensitive indicator of 
thiamin status in individuals who are at risk of thiamin deficiency; however it may be 
less useful in patients with hyperglycemia, due to the possibility of changes in the 
levels of thiamin transporter proteins. Because of some technical limitations, it was 
not possible to analyse thiamin urinary excretion and plasma levels of our 
participants in this study. Further evaluation of plasma and urinary thiamin is needed 
to make better judgment about thiamin status in patients with impaired glucose 
regulation. This gives us an opportunity to extend our investigation in the future. 
 
In the current study, a subgroup of subjects was also evaluated for arterial stiffness 
via a Pulse Trace device. According to our findings, hyperglycemic subjects had 
higher levels of fasting DVP parameters (SI & RI), accompanied with tendencies 
toward blunted response to ingested glucose load relative to normoglycemic group. 
These results suggest that screening of individuals with hyperglycemia by using a 
Pulse Trace machine may be a means of recognising cardiovascular complications at 
early stages. Further research with a larger sample size is recommended to extend 
these interesting results. 
 
The results of this study also confirm that the use of different sampling systems as 
well as converting glucose concentrations from one system to another using fixed 
factors may lead to misclassification of hyperglycemia, particularly in cases where 
the blood samples are analysed by glucose meters. Glucose meters may be helpful to 
obtain an idea about patients' blood gluose or for an inital screening of 
hyperglycemia. However, glucose concentrations determined in venous plasma by a 
qualified laboratory should be consided in situations requiring an accurate glucose 
measurement for definite diagnosis of glucose intolerance or diabetes mellitus,  or for 
making treatment decisions. 
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4.  Intervention study 
As discussed previously (sections 2.5.9 & 2.5.10), in vivo studies suggest that 
thiamin supplementation can inhibit certain biochemical pathways leading to 
abnormalities associated with hyperglycemia (Berrone et al. 2006; La Selva et al. 
1996; Thornalley, Jahan, and Ng 2001). These findings were supported by some 
experiments undertaken in animals (Babaei-Jadidi et al. 2003; Babaei-Jadidi et al. 
2004; Oishi et al. 2002). For example, Babaei-Jadidi et al.(2003) showed that thiamin 
supplementation improves cardiovascular risk factors in diabetic rats. Despite these 
findings, there is limited literature investigating the effects of thiamin on metabolic 
outcomes in humans, particularly among individuals with hyperglycemia at early 
stages. In a clinical study investigating the effects of thiamin on hyperglycemia in 
humans, supplementation with thiamin decreased the fasting plasma glucose of 
diabetic patients with HbA1C level < 8%, who were not treated with medications 
(Gonzalez-Ortiz et al. 2011). Thiamin supplementation was also shown to improve 
glucose tolerance in patients with hepatic cirrhosis (Hassan, Qureshi, and Zuberi 
1991). To date there has been no published study to examine the effects of thiamin 
supplementation on glucose tolerance in individuals with impaired glucose 
metabolism.  
 
4.1   Study design 
A randomised, double blind, cross-over design study investigated whether in 
hyperglycemic adults, chronic consumption of thiamin improves glucose tolerance 
and some cardiovascular disease risk factors. The study design is illustrated in Figure 
23. Hyperglycemic subjects were randomly allocated into two groups (Groups A and 
B) by the investigator (Dr. Fariba Alaei), to consume either 100 mg (2 × 50 mg) 
thiamin hydrochloride or placebo three times a day (300 mg/d) before meals for six 
weeks (Part 1). Cardiovascular disease risk factors were assessed at weeks 0 
(baseline), 3 and 6. Following completion of the first part and a 14-week wash out 
period, subjects came back to receive alternative capsules for another six weeks (Part 
2). Subsequently, clinical measurements were repeated on another three separate 
visits at weeks 0, 3 and 6, according to the same protocol as the first part.  
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The allocation of treatments to Groups A and B was done by a person who did not 
know anything about the subjects or their data. Thus, the randomisation was double 
blind. 
 
4.2   Subjects 
Subjects were recruited as described for the cross - sectional study (see Section 3.2). 
The eligible subjects diagnosed as glucose intolerant during the cross-sectional study, 
were invited to participate in the intervention study as well. Seventeen of them 
agreed to participate.  
 
Volunteers were asked to complete the online screening questionnaire available on 
the web site of Curtin University. The prospective subjects who had no access to the 
internet were screened by using a telephone screening tool [Appendix 2]. Volunteers 
were included according to the criteria considered for the cross - sectional study, and 
if they could be available during the period of the study.   
 
Subjects who were taking supplements containing thiamin (i.e. multivitamins 
supplements) or consuming more than 2 standard alcoholic drinks per day were 
asked to cease the supplement and reduce the alcohol intake during their 
participation, starting 4 weeks before attending the first clinical day. One subject on 
long-term medication (Allopurinol) with no impact on the endpoints of the study was 
allowed to continue his medication.  
 
The power calculation was based on the predicted change of 20 %  in  blood glucose 
level measured 2 hours after ingestion of glucose syrup in an OGTT  (Hassan, 
Qureshi, and Zuberi 1991). A sample of 12 subjects in a cross-over design provides 
sufficient power (95%) to detect the predicted change in 2-h plasma glucose at a 5% 
significance level.  
 
For the intervention study, a total of seventeen subjects (7 males and 10 females) 
were recruited to allow for drop out/non-compliance.  
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Participation in this study was completely voluntary and subjects were informed that 
they were able to withdraw from the study at any point in time without prejudice. 
This study was approved by the Curtin University Human Research Ethics 
Committee (Approval number HR 161/2008) and a written consent form [Appendix 
9] was obtained. This trial was registered on the Australian New Zealand Clinical 
Trials Registry (ACTRN12611000051943). 
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4.3   Methods 
4.3.1 Preparation and characterization of capsules 
The thiamin supplement and placebo were provided in the form of capsules with 
similar physical characteristics [Table 15], and distributed in bottles of same shape 
and colour.  
 
        Table 15. Specifications of prepared thiamin and placebo capsules 
Capsule Specifications Thiamin Capsule Placebo Capsule 
Colour (cap/body) White/White White/White 
Closed length (mm) 15.40 - 16.00 15.40 - 16.00 
External diameter (mm)  
                               Cap 
                             Body 
 
5.84 - 5.87 
5.59 - 5.62 
 
5.84 - 5.87 
5.59 - 5.62 
Capsule weight (mg)  
                 Mean(SD) 
 
246.96(9.81) 
 
229.60 (15.66) 
 
 
To prepare supplement capsules, tablets of vitamin B1 (Betamin, Sanofi-Aventis 
Australia Pty Ltd., Australia) were ground into a powder using a coffee grinder. The 
vitamin tablets contained thiamin hydrochloride as active component as well as 
inactive ingredients of starch (wheat) and lactose. The vitamin B1 powder was then 
put into the empty white/white gelatine capsules (Capsuline®Inc, FL, USA) [Figure 
24] using a capsule filler machine (Capsuline®Inc, FL, USA), according to the 
manufacturer's instructions. The prepared 
thiamin capsule had a mean (± SD) weight 
of 246.96 ± 9.81 mg, containing 50.74 ± 
2.46 mg thiamin hydrochloride with a CV 
of 4.84%  in random samplings (n=25). 
 
The capsules provided as control were 
matched with the supplement, containing 
the inactive ingredients of thiamin 
capsules. Accordingly, for preparation of 
Figure 24. The used white/white 
gelatine capsules    
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placebo, the same empty gelatine capsules were filled with a mixture of wheat starch 
(Nursesfoods Pty Ltd., WA, Australia) and lactose (Ramprie Laboratories, WA, 
Australia) powders, with a ratio of 1:1. 
 
4.3.2   Introductory visit 
After an initial screening, eligible subjects were invited to attend a short introductory 
visit.  This visit occurred before commencement of the study to explain the study’s 
procedures and protocol in detail and how to complete a weighed food record for 
three consecutive days before baseline and week 6 clinical visits (see Section 4.3.8),  
and to obtain written consent [ Appendices 9&10]. 
 
During the introductory visit, participants were also given a standard light-resistant 
container to collect their urine for 24 hours, starting the day before the first clinical 
day. A light-resistant urine container was provided because of the light sensitivity of 
thiamin  (Interdepartmental Committee on Nutrition for National Defense 1963). 
Acid was not added to the container as a preservative because this urine was used to 
determine albumin excretion. Thus, subjects were instructed to keep the container 
refrigerated (or in an esky with ice) during the collection.  Subjects were instructed to 
discard their first urine of the day and record the time on the container label. From 
then, they should collect all urine for the next 24 hours, including the first urine of 
the following day (clinical day) at the same time as the recorded commencement 
time [Appendix 5].  
 
At the completion of the introductory visit, subjects were supplied with a standard 
frozen meal to consume the evening before attending in the first clinical visit (see 
below).  
 
4.3.3   Meal standardisation  
Participants were asked to follow an unrestricted carbohydrate diet of at least 150-
200 g per day for the three days before each the clinical visits [Appendix 5]. 
Additionally, on the evening before each of these six clinical visits, they were 
required to consume the standard meal provided. As described in Section 3.3.2, these 
were to ensure subjects were consuming a reasonable amount of carbohydrate prior 
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to the glucose tolerance test. Meal standardisation was also administrated to 
minimize variation in the composition of meals consumed by subjects on the evening 
before measurement. It is known that the composition of meal consumed the day 
prior to the test can affect the lipid profile determined on the clinical day as well as 
resting and postprandial energy expenditure measurements (Granata and Brandon 
2002; Karpe 1997). The evening meal provided was Vegetable Korma with rice 
(Crafty Chef Pty. Ltd., NSW, Australia), containing about 1720 kJ energy with a 
macronutrient composition of 68% energy as carbohydrate, 10% energy as protein 
and 21% energy as fat [Table 11]. 
 
4.3.4   Experimental protocol 
Before each clinical visit, subjects were required to fast overnight following the 
standard evening meal (10-12 hours). They were also asked to refrain from alcohol 
and strenuous exercise for the 24 h before visits. 
  
On the baseline (week 0) and week 6 clinical days, subjects attended at the out-
patient clinic, School of Public Health, Curtin University in the morning (by 9.00 
am) in fasting condition and brought their completed 24- hour urine collection. The 
24-h urine volume was measured and recorded. A 30 mL sample of 24-h urine 
collection was then stored in separate 5 mL plain plastic vials at -80°C until analysis 
for albumin.  
 
Upon arrival, participants were asked to empty their bladder and the time of urine 
passed was recorded. Height, weight and waist & hip circumferences were then taken 
with subjects dressed in a gown with no shoes and empty bladder as described in 
Section 3.3.3. BMI was calculated according to the standard equation (kilograms per 
meters squared). Subsequently, participants were asked to rest 30 minutes prior to 
measurements of blood pressure and energy expenditure, as well as taking fasting 
blood samples (see Sections 4.3.5, 4.3.6 & 4.3.7).  
 
Following the fasting measurements, subjects were instructed to void and collect 
their urine (baseline urine collection). They then consumed the full bottle of a 
standard glucose tolerance test (GTT) drink (Glucaid: Fronine Pty. Ltd., NSW, 
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Australia), containing 75 g of glucose (75 g/300 mL) over a minutes. After 
consuming the glucose load, participants were only allowed very lightly activity, 
such as listening to music or reading.  They were allowed to drink water either before 
or during the test.  
 
Postprandial energy expenditure was measured for a period of 20 minutes before the 
second blood sample taken 2 hours after ingestion of the glucose solution. At the end 
of the GTT, participants were asked to void and collect their urine for the second 
time (postprandial urine collection). The times and volumes of baseline and 
postprandial urines passed were recorded. A 15 mL sample of each baseline and 
postprandial urine collection was stored in separate 5mL plain plastic vials at -80°C 
until being analysed for urinary urea and creatinine. Fasting and postprandial energy 
expenditures were calculated from measurements of oxygen consumption, carbon 
dioxide production and nitrogen excretion using the equation of Ferrannini  
(Ferrannini 1988) (see Section 4.3.6).  
 
On the clinical visit in week 3, subjects were asked to come to the outpatient clinic in 
fasting condition. Height, weight and waist & hip circumferences were measured, 
with subjects dressed in a gown with no shoes and empty bladder.  After a mandatory 
30- minute resting period, fasting blood pressure and fat oxidation were measured, 
and a blood sample was taken as described for weeks 0 and 6.  
 
Before completing clinical visits in weeks 0 and 3, subjects were supplied with 
bottles of thiamin/placebo capsules as well as  the standard frozen meal for the 
evening prior to the next visit. Subjects were instructed to take two of the capsules, 
one hour before their breakfast, lunch and dinner (a total of 6 capsules per day) and 
return the bottles containing left-over capsules when they come back for the next 
clinical visit to assess subjects' compliance (see Section 4.3.9). 
 
Additionally, at week 3, participants were given the light-resistant urine container to 
collect their urine for 24 hour, starting the day before the clinical visit at week 6.  
 
Following completion of the first part and a 14-week wash out period, subjects came 
back to receive alternative capsules for another six weeks (second part). 
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Subsequently, clinical measurements were repeated on another three visits at weeks 
0, 3 and 6, according to the protocol described for the first part.  
 
4.3.5   Blood pressure measurement 
Systolic and diastolic blood pressures were measured on each subject's right arm in 
supine position, using a vital signs patient monitor (Cardiocap II, Datex, Helsinki, 
Finland) with a standard cuff for adults. Three blood pressure measurements, 
separated with 2-minute intervals, were recorded in the fasting state and the average 
value was reported.  
 
4.3.6   Energy expenditure determination 
The effect of thiamin supplementation on each subject's energy expenditure was 
assessed by indirect open-circuit calorimetry using a Deltatrac II machine (Datex, 
Helsinki, Finland). The principal of operation is illustrated in Figure 25.  
 
 
Figure 25. Deltatrac II machine used for indirect calorimetry. The subject inhales 
the atmospheric air entering the canopy via tube 1. The expired gases are then 
transferred to  the monitor by the collecting tube 2. The system also takes a sample 
from the atmospheric air via a separate sampling line (tube 3). 
 
1 
 3 
 2 
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The Detatrac Metabolic Monitor is attached to a ventilator canopy with a constant 
flow rate of 46.5 L/min (determined for adult patients). The subject inhales the 
atmospheric air entering the canopy via tube1. The expired gases are then transferred 
to the mixing chamber of the monitor through the canopy hose (tube 2), to be 
analysed for O2 and CO2 concentrations by a paramagnetic sensor and an infra-red 
analyser, respectively. The system also takes a sample from the atmospheric air via a 
separate inspiratory sampling line (tube 3). Following analysis of gas samples, data 
collected minute by minute is displayed on the monitor, showing rates of carbon 
dioxide production (VCO2) and oxygen consumption (VO2), and  respiratory quotient 
( RQ = VCO2/ VO2). 
 
  
                          
 
 
 
 
 
 
 
 
The performance of the Deltatrac II Metabolic Monitor can be checked by analysing 
the gases produced from the burning of pure ethanol (Alcohol burning test) [Figure 
26]. According to the manufacturer's instructions, the test should continue for at least 
30 minutes. Accordingly, four alcohol burning tests were carried out intermittently 
during the period of the study, with the mean (±SD) RQ value of 0.66 (± 0.02) for 
the last 15 minutes and a CV of 3.03 %, being in the range recommended by the 
Datex company (0.64-0.69). 
 
After warming up of the Deltatrac II monitor on the morning of each clinical visit, 
gas calibration was manually performed, using a calibration gas mixture of 95% 
oxygen and 5% carbon dioxide (GE Healthcare Finland Oy, Finland). The system 
was also calibrated for the ambient pressure using a standard barometer (Regen 
Figure 26. Alcohol burning test set up 
(....) 
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Veranderlich Schon Barometer, Germany). Energy expenditure measurements were 
then conducted under standardised conditions (Henry 2005; Piers et al. 1992).    
 
As previously mentioned, total energy expenditure consists of three main 
components: basal metabolic rate (BMR), diet-induced thermogenesis (DIT) and 
energy expenditure physical activity. BMR represents the minimal rate of energy 
required for normal body function in a resting and awake state, accounting for 
approximately 50% to 70% of total energy expenditure (Ravussin and Bogardus 
1992). The individual's BMR is best measured just after waking in the morning, 
when he/she is in a post absorptive state. Where overnight facilities are not available, 
resting metabolic rate (RMR) is usually determined instead of BMR (Gropper, 
Smith, and Groff 2009). RMR is termed resting energy expenditure (REE) when it is 
expressed in units of kcal/24 h (Food and Nutrition Board 2002).  
 
In the present study, RMR was measured following the initial mandatory rest and 
measurement of blood pressure. The Deltatrac canopy was placed over the head of 
the subject lying in supine position in a temperature-controlled room (22±2°C). The 
edges of the canopy's plastic flaps were then tucked under the pillow. The fasting 
measurement was continued for 30 minutes and the average for the last 25 minutes 
was recorded. Each subject then collected the urine before drinking the test load 
(baseline urine collection).  
 
In this study, the Deltatrac II metabolic monitor was also used to assess the impact of 
chronic thiamin supplementation on the thermogenic effect of the glucose solution. 
During the clinical visits at weeks 0 and 6, postprandial energy expenditure was 
determined for a period of 20 minutes just before taking the second blood sample; 
the average for the last 15 minutes was recorded. At the end of the measurement, 
participants were asked to collect their urines for the second time (postprandial urine 
collection). The times and volumes of baseline and postprandial urines passed were 
recorded. A 15 mL of each baseline and postprandial urine sample was stored in 
separate 5 mL plain plastic vials at -80°C until analysis for urinary urea and 
creatinine.  
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REE (kcal/24 h) was predicted from measurements of oxygen consumption, carbon 
dioxide production and nitrogen excretion (derived from urea analysis) using the 
equation of Ferranni:  
 
[(3.91× rate of O2 consumption in L/min) + (1.1× rate of CO2 production in L/min) - 
(3.34 × rate of nitrogen excretion in g/min)] × 60 (Ferrannini 1988). 
 
In the present study, total urinary nitrogn was estimated using urinary urea nitrogen 
and urinary creatinine nitrogen. Urinary urea nitrogen alone accounts for 86-90% of 
total urinary nitrogen and the combination of urinary urea nitrogn plus urinary 
creatinine nitrogn accounts for  90-94.5% of total urinary nitrogen (Gibson 2005; 
Manore et al. 2009).  
 
 Diet-induced termogenesis (DIT) was calculated by dividing increase in energy 
expenditure relative to fasting value by the energy content of ingested glucose load 
(Westerterp 2004):                              
                                        Post glucose load EE - Fasting EE  
kcal in glucose load 
 
4.3.7   Biomedical assessments 
Fasting blood samples were collected via venipuncture into serum, heparin and 
EDTA vacutainer tubes (BD Vacutainer®, NJ, USA). The plasma vacutainers  were 
centrifuged  at 1100 g for 10 minutes at 4°C immediately (within minutes), while the 
serum tube was left at room temperature for 20-30 minutes to clot before 
centrifugation. Subsequently, the isolated plasma and serum samples were stored in 
separate 1.5 mL microcentrifuge tubes at -70 °C until analysis. The same storage 
protocol was administrated to the blood sample collected 2 hours after ingestion of 
glucose beverage for measuring plasma glucose. 
  
After separating plasma and removing buffy coat layer, extracted RBCs were washed 
three times using the protocol described for the cross-sectional study phase 1 (Talwar 
et al. 2000) (see Section 3.3.5). The samples prepared were then aliquoted and frozen 
at -80 °C until analysed.  
× 100 
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Aliquotes of plasma (separated from the blood collected into EDTA tube), serum, 
washed RBC and urine samples were sent to Royal Perth Hospital for analysing of 
thiamin, glucose, insulin, total cholesterol, HDL-cholesterol, LDL-cholesterol, 
triglyceride, hs-CRP, creatinine, and urinary albumin, creatinine and urea (see 
Section 3.3.6). 
 
The results of fasting plasma glucose and insulin were also used to estimate the 
HOMA score, as an indix of insulin sensitivity as described for the cross-sectional 
study (see Section 3.3.6).  
 
In addition to measuring glucose in plasma, fasting and postprandial glucose levels 
were determined in whole blood by using a blood glucose meter (Accu-Chek Active, 
Roche Diagnostics, NSW, Australia) as well. After taking fasting blood samples, one 
drop of fresh whole blood left-over in the used blood collection set was placed on the 
glucose meter strip. This test was repeated immediately. The average of two readings 
was reported. 
 
In this study, albumin excretion was determined in the sample of 24-h urine 
collection. Detection of albumin in a timed urine collection and determining 
protein/creatinine ratio in random urine are known as acceptable methods for 
screening of microalbuminuria. However,  measuring albumin excretion  in a 24-h 
urine collection is still the gold standard method when more precision is required 
(Weber 2001). Microalbuminuria was recognised in the presence of a urinary 
albumin excretion ≥ 30 and < 299 mg/24h. An albumin excretion ≥ 300 mg/24h 
represents clinical albuminuria  (Molitch et al. 2004). Renal function was also 
assessed by estimating GFR (glomerular filtration rate), using Cockroft- Gault 
formula adjusted for BSA (body surface area), as described in Section 3.3.6.   
 
4.3.8   Physical activity & dietary intake assessments 
Over the course of the intervention, subjects were asked to maintain their usual diet 
and level of physical activity.  To monitor participants' dietary habits,  they were 
instructed to record all food and drinks consumed over three consecutive days, 
including two week-days and one weekend day,  before baseline and week six 
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clinical visits [Appendix 11]. The completed 3-days food & drink diaries were then 
analysed using FoodWorks - Premium version 2009 [Xyris Software (Australia) Pty 
Ltd].   
 
The international physical activity questionnaire (IPAQ) - short version was used to 
evaluate participants' physical activity levels (Booth 2000), being completed for 
clinical visits at baseline and week six [ Appendix 12]. Data collected from IPAQ 
were then analysed based on both categorical and continuous scoring protocol 
available on the IPAQ website.        
 
4.3.9   Compliance evaluation 
As a part of the intervention protocol, on clinical visits at week 0 and 3, subjects 
were supplied with containers of prepared capsules for three weeks. They were 
instructed  to take two capsules [thiamin (50 mg/capsule) or placebo], one hour 
before their breakfast, lunch and dinner (a total of 6 capsules per day), and return the 
bottles containing left- over capsules when they come back for the next clinical visit.   
Compliance for each part of the intervention was then evaluated using  the formula 
below: 
 
Total known number of capsules provided for six weeks - Total number of left over capsules 
                                 Total known number of capsules provided for six weeks 
 
Moreover, participants were asked to tick the box related to each meal on the 
provided sheet [Appendix 13 - a sample of the sheet], just after taking the capsules 
and bring back the completed sheets on the clinical visit at week six in each part. 
Subsequently, subject compliances was also assessed by checking the sheets and 
calculated by the formula: 
                                          The number of capsules taken 
The number of capsules expected to be taken for the certain period of six weeks   
 
If there was any discrepancy between the subjects' compliances calculated though the 
two described ways, the lesser value was reported as the participant's minimum 
compliance.  
 
×   100 
×   100 
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4.4   Statistical analysis  
The main endpoint of this study was to investigate any significant changes in 2-h 
plasma glucose following consumption of thiamin supplement for 6 weeks relative to 
control. Given the cross-over design of this study, the effects of treatments 
(supplement and placebo) on cardiovascular risk factors were assessed at weeks 0, 3 
and 6 using a linear mixed-model analysis, with treatment, week and treatment*week 
interaction as fixed effects. The metabolic characteristics of each group A&B at the 
baseline of each treatment were compared using a paired t-test, to assess the order 
effect. All statistical analyses were performed using SPSS for windows (version 16, 
SPSS Inc., USA). Data are presented as mean ± standard deviation (SD) (in the text 
and tables) and mean ± standard error of mean (SEM) (in charts). All tests were two-
tailed and a p<0.05 was considered as statistically significant.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
122 
 
4.5   Results 
For the intervention study (cross-over design), 17 hyperglycemic subjects (7 men and 
10 women) were recruited initially. Of these total numbers, four subjects (2 females 
and 2 males) dropped out after completing the first part (2 subjects from each group 
A&B), because of the time involved or starting the medication for treatment of 
hyperglycemia as advised by their general practitioner.  Data of another subject (1 
female) were excluded later, due to the lack of compliance during the study. Thus, 
data of 12 subjects (5 men and 7 women) were used for the final analysis, except for 
fasting measurements at week 3 in the supplement arm that include data of 11 
subjects. 
 
 These 12 subjects consisted of 10 cases of impaired glucose tolerance (IGT) and 2 
new cases of diabetes. Mean (± SD) age was 57.16 ± 12.88 years and BMI 28.85± 
4.43 kg/m
2
. The subjects had a mean of total cholesterol, triglyceride, HDL-chol and 
LDL-chol within the normal ranges, based on the National Heart Foundation 
(National Heart Foundation and Australian Institute of Health 1990) and the 
Australian Diabetes Society (Australian Diabetes Society 1994) recommendations. 
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Table 16. Metabolic characteristics of subjects at the baseline of treatment 1 and 
treatment 2 in groups A & B  
 Group A  Group B 
 
Parameters 
Week 0. 
Treatment 1 
Mean(SD) 
Week 0. 
Treatment 2 
Mean(SD) 
P-  
value 
Week 0. 
Treatment 2 
Mean(SD) 
Week 0. 
Treatment 1 
Mean (SD) 
P -
value 
Weight (kg) 80.30(11.44) 81.06(11.20) 0.50 85.25(17.09) 85.15(17.89) 0.89 
RBC thiamin 
(nmol/gHb)  
0.97(0.14) 0.99(0.17) 0.53 0.89(0.16) 0.94(0.18) 0.22 
FPG (mmol/L) 6.18(0.55) 6.38(0.74) 0.30 5.77(0.56) 5.66(0.63) 0.14 
2-h PG 
(mmol/L) 
9.92(2.45) 10.86(2.94) 0.18 9.20(2.10) 9.11(1.77) 0.90 
SBP (mmHg) 122.80(10.43) 120.60(13.41) 0.32 120.71(17.62) 113.57(10.31) 0.10 
DBP (mmHg) 71.00(7.38) 71.20(5.54) 0.94 71.57(8.96) 68.43(9.18) 0.24 
Fasting insulin 
(uIU/mL) 
5.48(3.42) 7.62(4.64) 0.03 7.17(4.59) 7.47(3.48) 0.62 
2-h insulin 
(uIU/mL) 
40.36(34.42) 62.04(58.67) 0.14 54.24(29.29) 76.34(46.28) 0.14 
Total cholesterol 
(mmol/L) 
4.92(1.02) 5.29(1.00) 0.009 4.50(0.85) 4.64(0.60) 0.35 
Triglyceride 
(mmol/L) 
1.03(0.20) 1.26(0.68) 0.37 1.17(0.72) 1.43(1.32) 0.36 
Serum HDL 
(mmol/L) 
1.24(0.22) 1.31(0.23) 0.09 1.11(0.25) 1.11(0.27) 0.97 
Serum LDL 
(mmol/L) 
3.20(1.03) 3.40(0.80) 0.35 2.83(0.63) 2.85(0.55) 0.91 
hs-CRP (mg/L) 1.50(1.21) 1.98(1.54) 0.13 2.96(2.11) 6.17(6.36) 0.19 
eGFR* 
(ml/min/1.73 m
2
) 
89.93(14.23) 90.94(13.58) 0.79 99.58(32.64) 103.03(40.35) 0.34 
Urine albumin 
(mg/d) 
9.01(5.60) 6.34(4.31) 0.20 11.23(13.46) 40.68(70.65) 0.33 
Dietary thiamin 
(mg/d) 
2.22(0.51) 2.11(0.89) 0.85 1.41(0.83) 1.67(1.64) 0.54 
  * Estimated by using Cockroft - Gaulat formula adjusted for body surface area 
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Table 17. Comparison between metabolic characteristics of subjects in placebo 
and supplement arms at the baseline (week 0) 
Parameters Placebo arm 
Mean (SD) 
Supplement arm 
Mean (SD)  
P- 
value 
Weight (kg) 83.13(15.12) 83.51(14.48) 0.53 
RBC thiamin  
(nmol/g Hb)  
0.95(0.16) 0.93(0.17) 0.43 
Fasting plasma glucose 
(mmol/L) 
5.87(0.63) 6.02(0.69) 0.07 
2-h plasma glucose 
(mmol/L) 
9.45(2.01) 9.89(2.50) 0.35 
Systolic blood pressure 
(mmHg) 
117.42(10.96) 120.67(15.32) 0.24 
Diastolic blood pressure 
(mmHg) 
69.50(8.21) 71.42(7.42) 0.31 
Fasting insulin (uIU/mL) 6.64(3.45) 7.35(4.40) 0.22 
2-h insulin (uIU/mL) 61.35(44.07) 57.49(41.66) 0.73 
HOMA score 1.75(1.01) 2.00(1.32) 0.12 
Serum cholesterol 
(mmol/L) 
4.75(0.77) 4.83(0.96) 0.44 
Serum triglyceride 
(mmol/L) 
1.27(1.00) 1.21(0.67) 0.77 
Serum HDL (mmol/L) 1.17(0.25) 1.20(0.26) 0.32 
Serum LDL (mmol/L) 3.00(0.77) 3.07(0.73) 0.62 
hs-CRP (mg/L) 4.22(5.33) 2.55(1.88) 0.27 
eGFR (ml/min/1.73 m2) 97.53(31.72) 95.98(25.85) 0.54 
Urine albumin (mg/d) 27.48(54.77) 9.19(10.58) 0.27 
Dietary intake of thiamin 
(mg/d) 
1.84(1.28) 1.69(0.93) 0.66 
 
 
The subjects were randomised to two groups (group A & group B) to receive either 
treatment 1 (placebo) for 6 weeks followed by a 14-week washout period and 
treatment 2 (supplement) for 6 weeks (Group A, n=5); or treatment 2 (thiamin 
supplement) for 6 weeks, a 14-week washout period and treatment 1 (placebo) for 6 
weeks (Group B, n=7) [Figure 23]. Accordingly, all 12 subjects received both 
treatment 1 (placebo arm) and treatment 2 (supplement arm) in a cross-over manner. 
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To assess the order effect, metabolic characteristics of subjects at visit week 0 of the 
first and second treatments in each group were compared, using a paired samples t-
test. The results showed that except for fasting insulin (group A) and total cholesterol 
(group A), subjects of each group had similar metabolic characteristics at the 
baseline of each treatment [Table 16].    
 
In addition, there was no significant difference between characteristics of subjects in 
placebo and supplement arms at the baseline [Table 17].  
 
No adverse effect was reported following consumption of 300 mg/d thiamin 
supplement or prepared placebo during the intervention period. All subjects had a 
compliance rate of at least 88% for the offered treatments, evaluated as indicated in 
Section 4.3.9.  
  
Changes in anthropometric measurements and physical activity score  
As presented in the Table 18, the mean values of subjects' weight, BMI, WC and 
physical activity score observed at week 0 were not significantly different from those 
at week 6 in both supplement and placebo arms.  
 
Changes in dietary thiamin intake and RBC thiamin level 
The dietary intake of thiamin assessed at week 6 did not change significantly from 
that observed at week 0 in placebo (1.89±1.20 vs. 1.84±1.28 mg/d, p=0.89) and 
supplement (1.19±0.32 vs. 1.69±0.93 mg/d, p=0.12) arms. Following 
supplementation with 300 mg/d thiamin, the subjects' RBC thiamin increased from 
0.93 (±0.17) nmol/g Hb at week 0 to 1.56 (±0.31) nmol/g Hb at week 6 (p<0.001), 
while there was no significant change in RBC thiamin of subjects consuming placebo 
(p=0.94) [Table 18].   
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Changes in plasma glucose 
In the placebo arm, the mean (±SD) of fasting plasma glucose observed at week 6 
was found to be significantly higher than that at week 0 (6.11±0.70 vs. 5.87±0.63 
mmol/L, p=0.003) and week 3 (6.11±0.70 vs. 5.87±0.77 mmol/L, p=0.003). 
However, there was no significant difference between fasting plasma glucose 
measured at week 0 and week 6 (6.02±0.68 vs. 6.01±0.79 mmol/L, p=0.83) or 
between week 3 and week 6 (6.04±0.70 vs. 6.01±0.79 mmol/L, p=0.78) in 
supplement arm [Figure 27]. There was also a significant difference between 
supplement and placebo arms for the changes in the fasting plasma glucose during 
the 6-week intervention period (-0.02± 0.25 vs. 0.23 ±0.15 mmol/L, p=0.009).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27. Fasting plasma glucose at week 0, week 3 and week 6 in placebo and 
supplement arms. In subjects receiving placebo, fasting plasma glucose at week 6 
was significantly higher than at week 0 (p=0.003) and at week 3 (p=0.003). Data are 
presented as mean ± SEM.   
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In the present study, glucose tolerance was assessed at week 0 and week 6. Our 
results showed that in placebo arm, 2-h plasma glucose at week 6 was higher than at 
week 0 (9.62±2.25 vs. 9.45±2.01 mmol/L, p=0.65), although it was not significant 
statistically. However, in the supplement arm, 2-h plasma glucose measured at the 
baseline decreased significantly after 6 weeks (9.89±2.50 vs. 8.78±2.20 mmol/L, 
p=0.004) [Figure 28]. Two arms were also significantly different when they were 
compared for the changes in 2-h plasma glucose (placebo arm: 0.17±0.85 mmol/L; 
supplement arm: -1.11±0.92 mmol/L, p=0.004). 
 
 
             
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28. Concentrations of 2-h plasma glucose measured at week 0 and week 6 
in placebo and supplement arms. A significant difference between 2-h plasma 
glucose at week 6 and those at week 0 was observed in the supplement arm 
(p=0.004), but not in subjects receiving placebo (p=0.65). Data are presented as 
mean ± SEM.   
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Figure 29 (a& b). Changes in 2-h plasma glucose of groups A and B, during the 
period that they received supplement or placebo (Periods 1& 2), with a cross- 
cover design (see Sections 4.1&4.3). P1.W0, Period 1.Week 0; P1.W6, Period 
1.Week 6; P2.W0, Period 2.Week 0; P2.W6, Period 2.Week 6. Data are presented as 
mean ± SEM.    
 
 
 
 
 
a 
b 
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Changes in plasma insulin and HOMA score  
In the placebo arm, fasting plasma insulin measured at week 6 was significantly 
higher than when measured at week 0 (7.67± 4.39 vs. 6.64± 3.45 μIU/mL, p=0.04), 
but there was no significant difference between fasting plasma insulin at week 3 and 
week 6 (7.17±3.50 vs. 7.67± 4.39 μIU/mL, p=0.30). In the subjects receiving 
supplement, there was no significant difference between fasting insulin measured at 
week 6 and week 3 or week 0 (7.46 ±4.67,  7.53±4.22 and 7.36± 4.40 μIU/mL, 
respectively, p> 0.05) [Figure 30]. These results were not changed considerably after 
adjusting for order effect.   
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30. Fasting plasma insulin measured at week 0, week 3 and week 6 in 
placebo and supplement arms. In subjects receiving placebo, fasting plasma 
insulin measured at week 6 was significantly higher than week 0 (p=0.04), but there 
was no significant change in fasting insulin levels in supplement arm (p> 0.05). Data 
are presented as mean ± SEM.   
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As to be expected, the significant changes in fasting plasma insulin and glucose in 
placebo arm was accompanied by a significant increase in HOMA score (week 0: 
1.75±1.01 vs. week 6: 2.10±1.32, p= 0.02). The change was not significant when 
HOMA score at week 6 was compared with week 3 (1.89±1.07, p= 0.17). In the 
supplement arm, there was no significant difference between the HOMA score 
determined at week 0 and week 6 (2.00±1.32 vs. 2.05±1.51, p=0.75) or between 
week 3 and week 6 (2.04±1.27 vs. 2.05±1.51, p=0.60) [Figure 31].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 31. HOMA score determined at week 0, week 3 and week 6 in placebo 
and supplement arms. In subjects receiving placebo, a significant increase in 
HOMA score was observed after six weeks from baseline (p= 0.02). However, 
HOMA score did not differ significantly in supplement arm. Data are presented as 
mean ± SEM.   
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The mean 2-h insulin measured at week 0 and week 6 were not significantly different 
in either placebo (61.35±44.07 vs. 68.34±52.58 μIU/mL, p=0.37) or supplement 
(57.49±41.66 vs. 64.88±49.92 μIU/mL, p=0.35) arms [Figure 32]. There was also no 
significant difference between supplement and placebo arms, when they were 
compared for the changes in 2-h insulin during the 6-week intervention period (7.39 
±32.85 vs. 6.99 ±18.57 μIU/mL, p=0.97).  
 
 
 
 
 
 Figure 32. Plasma insulin measured 2 hours after ingestion of glucose load, at 
weeks 0 and 6 in supplement and placebo arms. The mean of 2-h plasma insulin 
measured at week 0 and week 6 were not significantly different in placebo (p= 0.37) 
or supplement (p=0.35) arms. Data are presented as mean ± SEM.    
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Changes in SBP and DBP 
The mean systolic blood pressure measured at week 6 did not vary significantly 
compared to what measured at week 0 in the placebo arm (116.50±11.70 vs. 
117.42±10.95 mm Hg, p= 0.68). In the supplement arm, there was a tendency toward 
a lower SBP at week 6 relative to week 0, although it was not statistically significant 
(116.50±11.04 vs. 120.67±15.32 mm Hg, p=0.06) [Figure 33]. Diastolic blood 
pressure of subjects consuming thiamin supplement decreased significantly in week 
6 (67.92± 5.84 mm Hg) when compared with those at week 0 (71.42 ±7.41 mm Hg, 
p=0.005) and week 3 (70.90.±5.84 mm Hg, p=0.02) [Figure 34]. There was no 
significant change in the diastolic blood pressure of subjects in the placebo arm 
during the 6-week intervention period (69.50±8.22 (week 0) vs. 70.75±6.68 (week 6) 
mm Hg, p= 0.30). Also, there was no significant correlation between the changes in 
the blood pressure (systolic& diastolic) and hs-CRP.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 33. Systolic blood pressure measured in supplement and placebo arms. 
In supplement arm, there was a tendency toward a lower SBP at week 6 relative to 
those at week 0, although it was not statistically significant (p=0.06). Data are 
presented as mean ± SEM.  
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Figure 34. Diastolic blood pressure measured in supplement and placebo arms. 
Diastolic blood pressure of subjects consuming thiamin supplement decreased 
significantly in week 6 compared to week 0 (p= 0.005) and week 3 (p= 0.02). There 
was no significant change in the diastolic blood pressure of subjects in the placebo 
arm during the 6-week intervention period ( p= 0.30) Data are presented as mean ± 
SEM.     
 
 
 
Changes in lipid profile, hs-CRP and renal function tests 
As presented in the Table 19, no statistically significant change was detected in the 
supplement or placebo arms when they were assessed for fasting total cholesterol, 
triglyceride, HDL, LDL, hs-CRP, urine albumin and eGFR. There was also no 
significant difference in the change between two arms for these variables. 
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Changes in resting and postprandial energy expenditure, and diet-induced 
thermogenesis rate (DIT)  
 
In the supplement arm, resting energy expenditure assessed at week 6 was 
significantly lower than that at week 0 (59.78±11.63 vs. 61.78±11.47 kcal/24 h, 
p=0.02). This change remained significant after adjusting for the subjects' weight and 
gender as potential confounders (p=0.03). There was no significant difference 
between resting energy expenditure of subjects receiving placebo at week 6 and 
week 0 (60.42±10.73 vs. 60.22±10.82 kcal/24 h, p=0.81) [Figure 35]. No significant 
change was observed in the supplement or placebo arms for the postprandial energy 
expenditure and diet-induced thermogenesis [Table 20]. 
  
 
 
Figure 35. Resting energy expenditure determined in supplement and placebo 
arms. In the supplement arm, resting energy expenditure assessed at week 6 was 
significantly lower than that at week 0 (p=0.02). There was no significant change in 
resting energy expenditure of subjects receiving placebo. Data are presented as 
mean ± SEM.   
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4.6   Discussion 
The present intervention study was designed to investigate whether in hyperglycemic 
adults, chronic consumption of a thiamin supplement improves cardiovascular 
disease risk factors relative to control.  
 
Our results showed that in subjects receiving placebo, fasting plasma glucose 
increased significantly from baseline after six weeks.  This significant change was 
accompanied with concomitant increases in fasting plasma insulin and HOMA score, 
which is an indicator of insulin resistance. However, in the supplement arm there was 
no significant change in fasting plasma glucose, fasting insulin or HOMA score, 
indicating that supplementation with high dose thiamin may have prevented the 
natural progression of hyperglycemia toward diabetes mellitus in individuals with 
impaired glucose metabolism at early stages.  Recently, supplementation with 150 
mg thiamin (once daily) for 1 month was shown to decrease the fasting plasma 
glucose of 12 diabetic patients with HbA1C level < 8%, who were not treated with 
medications (Gonzalez-Ortiz et al. 2011); however, it did not change significantly in 
the placebo group (n=12). No data about the duration of diabetes since diagnosis in 
these patients were provided. These findings are inconsistent with the results of 
Rabbani et al. (2009) who showed no significant change in the fasting glucose of 40 
diabetic subjects receiving either placebo or thiamin (3×100 mg/d) treatment for 3 
months. In the study conducted by Rabbani and her colleagues subjects had 
persistent microalbuminuria, and had been diagnosed with diabetes for at least 5 
years. Also, except one subject who achieved glycemic control with diet only, all 
other patients were on treatment with antihyperglycemic medications.  These results 
suggest that thiamin therapy may be less effective on the fasting plasma glucose of 
patients with long-term diabetes mellitus.      
 
It is known that, in addition to thiamin, some other dietary factors (see Sections 2.3 
& 2.5.5) may influence the metabolism of glucose or thiamin. In the present study, 
we attempted to control for them by asking the subjects not to change their usual 
diets during the study. It was confirmed by the assessment of the subjects’ dietary 
habits (see Section 4.3.8) that did not reveal any significant changes.  
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This was particularly important for magnesium which, like thiamin, is a co-factor for 
transketolase in the pentose phosphate pathway (Fattal-Valevski 2011; Lonsdale, 
Shamberger, and Obrenovich 2011). It has also a role in the phosphorylation of 
thiamin to its active form (Voskoboyev and Ostrovsky 1982). As a result, co-existing 
magnesium deficiency may limit the response to thiamin therapy in the patients with 
thiamin deficiency (Traviesa 1974). There has been no evidence indicating 
hypomagnesemia in individuals with pre-diabetic hyperglycemia (Simmons, Joshi, 
and Shaw 2010), however both type 1 and type 2 diabetic patients are at risk of 
magnesium deficiency due to the increased excretion (Tosiello 1996). This may be a 
reason why in the study conducted by Rabbani et al. (2009), thiamin supplementation 
had no effect on the glucose levels of diabetic patients with nephropathy.      
 
We also found that in subjects with impaired glucose metabolism, supplementation 
with 300mg/day thiamin for six weeks could significantly decrease 2-h plasma 
glucose, relative to control. This finding supports a part of our second hypothesis that 
the chronic consumption of high doses of thiamin can decrease the risk of 
hyperglycemic complications by enhancing glucose tolerance.  
 
This finding is important from a clinical prospective. In a prospective cohort study 
involving 19,019 men followed for 38 years (Batty et al. 2008), a 1 mmol/L elevation 
in 2-h capillary whole blood glucose above the value 4.6 mmol/L was associated 
with a significant increase in the risk of stroke-related death (27%) and all-cause 
mortality (16%). In that study, the GTT was carried out using a glucose preparation 
containing 50 g carbohydrate.  
 
The potential association between thiamin and glucose tolerance in humans was 
studied by Bakker et al. (1998) who showed that thiamin intakes of 2196 men and 
women, 50-75 years old without diabetes were inversely correlated to 2-h plasma 
glucose concentrations, suggesting that supplementation with thiamin may have a 
role in improving glucose tolerance (see Section 2.5.10). However, there have been 
no published studies to test this relationship in individuals with impaired glucose 
tolerance or diabetes. Only in one publication, thiamin supplementation (50 mg/d for 
30 days) was shown to improve glucose tolerance in 25 patients with hepatic 
cirrhosis (Hassan, Qureshi, and Zuberi 1991).  
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As discussed before (see Section 2.5.6), patients with hyperglycemia have been 
reported to be prone to thiamin deficiency, because of an increased excretion of 
thiamin in the urine (Thornalley et al. 2007). Thiamin is known to play a critical 
regulatory role as a co-enzyme in metabolic pathways involved in glucose 
metabolism (see Section 2.5.7). Animal studies indicate that thiamin deficiency can 
reduce overall glucose utilisation (Hakim, Carpenter, and Pappius 1983; Hakim and 
Pappius 1981) and induce glucose intolerance (Oishi et al. 2002). Thus, additional 
thiamin may improve glycemic control in hyperglycemic patients.  
  
Under hyperglycemic conditions, high dose thiamin has been also suggested to 
increase glucose utilisation via increasing transketolase activity (Babaei-Jadidi et al. 
2003; Thornalley, Jahan, and Ng 2001), which leads to a shift in the excess levels of 
metabolic intermediates from the glycolytic pathway toward the reductive pentose 
shunt (see Section 2.5.9) (Hammes et al. 2003). This results in alleviating pressure on 
several pathways involved in hyperglycemia-induced complications, including the 
hexosamine pathway. In the liver of transgenic mice, overexpression of glutamine: 
fructose-6-phosphate amidotransferase (GFAT), the rate-limiting enzyme in the 
hexosamine pathway, was associated with impaired glucose tolerance (Veerababu et 
al. 2000). This suggests that in the presence of hyperglycemia, high dose thiamin 
may also influence some metabolic pathways which are specifically implicated in the 
pathogenesis of glucose intolerance.  
 
It is also possible that thiamin has an influence on insulin levels. Basal secretion of 
insulin and insulin secretion in response to glucose and tolbutamide were shown to 
decrease in isolated pancreatic islets of thiamin deficient rats (Rathanaswami, 
Pourany, and Sundaresan 1991; Rathanaswami and Sundaresan 1991). Also, thiamin 
therapy for six weeks was shown to resolve glucose intolerance in a mouse model of 
TRMA in which developed diabetes mellitus was associated with decreased insulin 
secretion (Oishi et al. 2002). These findings suggest that apart from the activation of 
thiamin-dependent enzymes and increased glucose utilisation, improvement of β-cell 
function and insulin secretion may contribute to the beneficial effect of thiamin on 
glycemic control (Thornalley 2005). This would help explain why thiamin 
supplement appears to be more effective in those who still have insulin secretory 
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capacity (Hassan, Qureshi, and Zuberi 1991; Oishi et al. 2002) compared with those 
pancreatic functions are destroyed (Babaei-Jadidi et al. 2004).       
 
It has been shown that 2-h plasma glucose is mainly determined by the postprandial 
insulin concentration at 30 minutes (Mitrakou et al. 1992), reflecting the response of 
beta-cells to the ingested glucose load. Unfortunately, this measurement was not 
undertaken in the present study. Therefore, although in our study no significant 
change was observed in 2-h plasma insulin in subjects treated with thiamin or 
placebo, it is not possible to judge that thiamin had no effect on insulin secretion. A 
further research focusing on the effect of high dose thiamin on insulin secretion by 
measuring postprandial plasma insulin every 30 minutes intermittently as well as C-
peptide concentration would be informative.    
 
While, the pathogenesis of hyperlipidemia associated with impaired glucose 
metabolism is not fully understood, a switch from lipid oxidation to lipogenesis in 
the liver has been considered as a possible mechanism (Taskinen 2003). The 
hexosamine pathway has been implicated in the glucose-mediated de novo 
lipogenesis in the liver and adipocytes by increasing mRNA levels of the lipogenic 
enzymes acetyl-CoA carboxylase,  glycerophosphate dehydrogenese and fatty acid 
synthase  (Rumberger et al. 2003; Veerababu et al. 2000). High dose thiamin has 
been suggested to inhibit these effects by diverting the excess glycolytic intermediate 
of fructose 6-phosphate away from the hexosamine pathway to the pentose phosphate 
shunt (Thornalley 2005). With regard to the importance of the hepatic hexosamine 
pathway in lipogenesis associated with hyperglycemia, it was proposed that 
supplementation with thiamin may alter this effect (Thornalley 2005). 
 
Babaei-Jadidi et al. (2004) showed that thiamin therapy prevents diabetes-induced 
increases in plasma triglyceride and cholesterol in diabetic rats. This was associated 
with a significant reduction in hepatic UDP-N-acetylglucosamine and fatty acid 
synthase activities. However, observations in humans are in contrast to results 
reported for rats.  
 
 The present study has shown that chronic consumption of high dose thiamin had no 
significant effect on serum triglyceride, cholesterol, HDL-cholesterol and LDL-
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cholesterol. This confirms the results of previous studies showing no significant 
change on lipid profile of diabetic patients receiving thiamin supplement (Gonzalez-
Ortiz et al. 2011).     
 
 In the study conducted by Babaei-Jadidi et al., the beneficial effects of thiamin were 
achieved with a high dose of 70 mg/kg/d, and there was no improvement in plasma 
cholesterol or triglyceride with a lower dose (7 mg/kg/d). Extrapolation of the 
effective dose of thiamin in rats (70 mg/kg/d) to human shows that about 5 g/day of 
thiamin might be required for an average person, which is not feasible. This may be 
why in the previous studies in diabetic patients (Gonzalez-Ortiz et al. 2011; Rabbani 
et al. 2009) and also our study no effect was observed on the lipid profile of 
hyperglycemic subjects who received 150 or 300 mg/d thiamin supplement. It could 
be also due to a species difference.  
 
There has been no published study so far to evaluate the effect of thiamin on the 
energy expenditure in humans. BMR is mainly dependent on the body size and 
composition. Accordingly, BMR reduces with age due to the loss of lean body mass 
(Tzankoff and Norris 1977). Furthermore, existing evidence indicates that body 
composition and subsequently energy expenditure can be influenced by the change in 
macro and micronutrient intake. For instance, some studies have shown that 
administration of thiamin increases muscle mass and energy expenditure in 
experimental animals (Hamano, Okada, and Tanaka 1999; Huang et al. 2010). The 
findings of  human studies investigating the effect of thiamin on the body weight 
have been controversial: in a clinical trial conducted by Wilkinson et al. (1997), 
thiamin supplementation (10 mg/d) for 3 months resulted in a considerable decrease 
in the weight of subjects with subclinical thiamin deficiency. By contrast, Smidt et 
al. (1991) found that the weight of subjects with marginal thiamin deficiency taking 
thiamin supplement (10mg/d) increased significantly after 6 weeks. In another study, 
dietary intake of thiamin was significantly correlated with the body mass index, 
based on a gender difference (Chen and Vieira 2007).   
 
In the present study, we have found a significant decrease in the RMR of subjects in 
the supplement arm which was not associated with measurable changes in the body 
weight or waist circumference Moreover, in spite of a significant decrease in 2-h 
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plasma glucose of subjects receiving thiamin, suggesting an improvement in the post 
prandial glucose utilisation, there was not a significant change in their post prandial 
energy expenditure and RQ. We are unable to offer an explanation for these findings, 
since this study did not include the measurement lean body mass. Also, we could 
only assess the fasting and postprandial energy expenditure 2 hours after glucose 
load. It would be interesting to have measurements at additional time points. The 
inconsistency between our results for the body weight and the findings of Wilkinson 
et al. and Smidt et al. may be partly because in those studies subjects were 
subclinical/marginal thiamin deficient, assessed by ETKA. While, subjects 
participating in our study had normal thiamin status, based on their erythrocyte 
thiamin levels. 
 
According to our results, high dose thiamin had also no significant effect on urinary 
albumin and eGFR. This was inconsistent with the results of some previous in vitro 
and in vivo studies, investigating the effect of thiamin on hyperglycemia-induced 
nephropathy (Babaei-Jadidi et al. 2003; La Selva et al. 1996; Rabbani et al. 2009).   
 
It is suggested that high cytosolic glucose concentration in renal endothelial cells and 
pericytes can result in the dysfunction of  protein kinase C, activation of hexosamine 
and polyol pathways; metabolic pseudohypoxia; increase in oxidative stress; and 
formation of advanced glycation end products (AGEs) (Brownlee 2001). 
Accumulating evidence has demonstrated the suppressive effect of thiamin on the 
multiple key pathogenic pathways involved in diabetic nephropathy in vitro (La 
Selva et al. 1996). Additionally, it has been shown that high doses of thiamin inhibit 
the development of incipient nephropathy (the initial stage of development of 
nephropathy) in the streptozotocin (STZ)-induced diabetic rats, and increase the 
thiamin-dependent enzyme transketolase activity in renal glomeruli (Babaei-Jadidi et 
al. 2003). Recently, the positive effect of high dose thiamin (300 mg/d) on 
microalbuminuria was confirmed in  human subjects with type 2 diabetes mellitus 
(Rabbani et al. 2009). In that study, volunteers were included if they had diabetes 
mellitus for a duration of at least five years, and persistent microalbuminuria (AER 
30-299 mg/24 h). However, the present study consisted of subjects with pre-diabetic 
ranges of hyperglycemia (IGT) and new cases of diabetes, with a mean albumin 
excretion rate at the normal range (<30 mg/24 h). This is a probable reason for the 
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observed discrepancy between our findings and the results of previous study in 
diabetic patients. A further trial in subjects with hyperglycemia at early stages and 
constant microalbuminuria may provide more information in this regard.  
 
We have found a significant decrease in diastolic blood pressure of subjects 
receiving thiamin supplement, but no significant change was observed in the placebo 
arm. It is of interest to note that in this study all subjects had diastolic blood pressure 
below the cut-off point for hypertension (90 mmHg).  It was in contrast to a previous 
study reporting no substantial change in diastolic blood pressure of normotensive 
diabetic patients treated with thiamin supplement (Gonzalez-Ortiz et al. 2011; 
Rabbani et al. 2009). In the present study, a tendency toward a decrease in systolic 
blood pressure was also observed in the supplement arm, although it was not 
statistically significant.  This is in line with a double - blind trial reporting thiamin 
(10 mg/d for 3 months) reduced the systolic blood pressure of elderly people with 
subclinical thiamin deficiency (Wilkinson et al. 1997). In that study, the subjects 
receiving thiamin supplement had a mean systolic blood pressure > 140 mm Hg at 
the baseline, while in our study subjects had a mean systolic blood pressure below 
the level considered as hypertension (140 mmHg). Thus, the results may be more 
significant in subjects with hypertension. In addition, based on thiamin status 
determined in RBC, there is no evidence that our subjects were thiamin deficient. In 
the study conducted in elderly people (Wilkinson et al. 1997), no data regarding the 
possible effect of thiamin on diastolic blood pressure were provided.   
 
Potential mechanisms by which thiamin may affect the blood pressure was studied 
by Tanaka et al. (2007) who showed that thiamin repletion attenuates the 
hypertension in CD36 - defective spontaneous hypertensive rats (SHR) which exhibit 
metabolic abnormalities similar to the human metabolic syndrome. In that 
experimental study, reduced blood pressure was accompanied with the correction of 
the uncoupling of glucose oxidation to its cellular entry. In epididymal adipose tissue 
of SHR, thiamin repletion down - regulated the expression of mRNAs implicated in 
the hexosamine biosynthetic pathway and renin - angiotensin system.  
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4.7   Conclusion 
This study has found that, in spite of significant increases in the fasting plasma 
glucose, fasting insulin and HOMA score in the control arm; these variables did not 
change in hyperglycemic subjects receiving high dose thiamin for six weeks. These 
results suggest that supplementation with high dose thiamin may prevent the natural 
progression of hyperglycemia toward diabetes mellitus as well as insulin resistance 
in individuals with pre-diabetic range of hyperglycemia. The next major finding was 
that high dose thiamin therapy can enhance glucose tolerance in patients with 
impaired glucose metabolism. The findings of this study indicate that thiamin 
therapy may be more effective in patients with hyperglycemia at early stages than 
individuals with developed diabetes mellitus. In addition, it was shown that 
supplemental thiamin can have positive effect on diastolic blood pressure. This has 
been accompanied with a tendency toward a decrease in the systolic blood pressure. 
Given that in the current study subjects had a mean systolic and diastolic blood 
pressure below the levels considered as hypertension, thiamin therapy may be more 
effective in patients with higher levels of blood pressure. Limited literature is 
available now and further studies are required to verify the positive effects of thiamin 
found in this study.  
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5. Overall conclusion 
It was shown that diabetic patients are at higher risk of thiamin deficiency; however 
there has been no published study to investigate thiamin status in individuals with 
pre-diabetic range of hyperglycemia.  
 
Our cross-sectional study has shown no significant difference in the levels of RBC 
thiamin in hyperglycemics relative to those in the normoglycemic subjects. The 
mean intakes of thiamin in both were greater than the Australian RDI for thiamin. 
Concentration of thiamin in erythrocytes is known as a useful index of thiamin 
status; however it may be less sensitive to detect thiamin deficiency in individuals 
with hyperglycemia, because of being affected by changes in the levels of thiamin 
transporter proteins. Due to technical limitations, we were unable to analyse thiamin 
urinary excretion and plasma status of our participants in this study. Further research 
could provide more definite evidence.  
  
In the first study, participants were also assessed for different cardiovascular risk 
factors, including arterial stiffness. Arterial stiffness can be easily evaluated by the 
Pulse Trace system which produces a digital volume pulse waveform. Our findings 
indicate that higher levels of DVP parameters (SI & RI) in the fasting state, together 
with a blunted response to ingested glucose load, may be a means of detecting 
vascular dysfunction in patients with impaired glucose metabolism.  
 
Previous studies examining the potential effects of thiamin under hyperglycemic 
condition have mainly been undertaken in animals. Limited literature investigated the 
effects of thiamin on metabolic outcomes in humans, particularly among individuals 
with hyperglycemia at early stages. In addition, the effect of supplemental thiamin on 
blood glucose of individuals with glucose intolerance has not been researched before.  
 
Our intervention study has shown that high dose thiamin therapy may control fasting 
blood glucose, and delay the progression of insulin resistance toward diabetes 
mellitus in patients with hyperglycemia at pre-diabetic ranges. The findings of this 
study also indicate that supplementation with thiamin can improve glucose tolerance, 
and reduce diastolic blood pressure in patients with impaired glucose metabolism.  
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The current clinical study indicates that individuals with hyperglycemia can benefit 
from thiamin supplementation. The findings of this research have the potential to 
inform food formulations and dietary recommendations for people who are at risk of 
developing diabetes mellitus, and may have a role in the prevention of 
hyperglycemic complications.  
 
One limitation of our study was that the number of subjects was relatively small. 
Further research with larger sample sizes is needed to confirm the above – mentioned 
findings. Our results serve as a base for further studies investigating the effects of 
supplemental thiamin on arterial stiffness and other hyperglycemic complications as 
well as the effectiveness of different doses of thiamin on cardiovascular risk factors. 
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Approximately 25% of Australian adults have blood 
glucose   higher than normal (hyperglycemia), while 
most of them are not aware of this. Studies indicate 
that hyperglycemia in both diabetic and pre-diabetic 
ranges is directly linked to a significant accelerated 
risk of cardiovascular diseases and other health 
problems being major causes of death and disability 
in Australia.  
 
Existing evidence shows that thiamin (vitamin B1) 
may have an effective role in prevention of vascular 
problems associated with hyperglycemia, such as 
cardiovascular problems and stroke as well as 
kidney, nerve and retina damages.  
 
However, according to recent findings, thiamin status may not be optimum in 
subjects with hyperglycemia, due to an increased excretion of the vitamin. It is 
envisaged that supplementation with thiamin may minimise the risk of 
complications in hyperglycemic people.    
 
Given the importance of pre- diabetic stage of hyperglycemia in preventing of 
diabetes and cardiovascular diseases, for the first time a research team from 
Curtin University is now conducting a key study to investigate the thiamin status in 
people with hyperglycemia in pre-diabetic range. We invite adult volunteers who: 
 
  Are aware of being Impaired Glucose Tolerance (according to a 
previous glucose tolerance test), 
 
 Have had a fasting blood glucose level higher than normal, however 
they have not done a glucose tolerance test already, or 
 
  Overweight and obese people who have a family history of diabetes or 
a history of gestational diabetes.  
 
Volunteers must not smoke, must not be diagnosed as diabetic or any serious 
diseases and must not be on chronic medications for systemic illness. 
 
The findings of this study may have a critical role in prevention of diabetes and 
cardiovascular complications, for those are at the risk of developing chronic 
disease. So, allocation up to 4 hours of your time for participating in this study will 
be very valuable in this service to science and humanity. Additionally, participants 
in this study will receive copies of all blood analyses results at the end of study, 
with a description of what these results indicate.  
 
For further details regarding this exciting study, please visit the web site of Curtin 
University at the following link: 
  
 http://www.publichealth.curtin.edu.au/projects/thiamin/thiaminstudy.cfm  
 
Or contact: : Phone no. (08) 9266 7452 
Email: fariba.alaeishahmiri@postgrad.curtin.edu.au 
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Approximately 25% of Australian adults have blood glucose 
higher than normal (hyperglycemia) and most of them are not 
aware of this.  
 
Recent evidence has shown that a pre-diabetic degree of 
postprandial hyperglycemia (impaired glucose tolerance) is 
directly linked to a significant accelerated risk of 
cardiovascular diseases. In addition, impaired glucose 
tolerance is known as a major risk factor for developing 
diabetes mellitus in the future.  
 
In people with impaired glucose tolerance (IGT), blood glucose level after consuming 
a standard glucose drink (glucose tolerance test) is higher than normal, but the fasting 
glucose level is normal or moderately raised. As a result, people who just have a 
fasting blood glucose test may remain undiagnosed. 
 
Existing evidence shows that thiamin (Vitamin B1) may have role in prevention of 
vascular problems associated with hyperglycemia.  However, according to recent 
findings, thiamin status may not be optimum in subjects with hyperglycemia, due to an 
increased excretion of the vitamin.  
 
  The aim of study: 
Given the importance of pre-diabetic stage of hyperglycemia, researchers from Curtin 
University of Technology are now conducting a key study to investigate the role of 
supplementation with thiamin in preventing diabetes and associated vascular 
problems in people with impaired glucose tolerance.  
 
  We invite adult volunteers who: 
 Are aware of being impaired glucose tolerance (according to a previous 
glucose tolerance test), or 
 
 Have had a fasting blood glucose level higher than normal, however they 
have not done a glucose tolerance test already, or 
 
  Overweight and obese people who have a family history of diabetes or a 
history of gestational diabetes.  
 
Volunteers must not smoke, must not be diagnosed as diabetic or any serious 
diseases and must not be on chronic medications for systemic illness. 
 
    
 What does the study involve? 
In this study, eligible volunteers will be tested for glucose tolerance. Also, thiamin 
status will be determined in individuals with impaired glucose tolerance relative to 
healthy people. For participating in the first phase of this study, there will be a total of 
two visits.  
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The initial visit will include a short screening session to determine volunteer suitability, 
which requires 1/2-hour time commitment. 
 
Once the screening criteria are met, there will be just one clinical visit that will 
commence in the morning and require up to 3-hour time commitment for body 
measurements, blood samples and answering a questionnaire. 
 
On the clinical visit, volunteers will be assessed for cardiovascular risk factors, glucose 
tolerance and blood and urine thiamin status, and they will be required to fast for 10-12 
hours before arriving in the morning. 
 
  Significance of the study:  
This clinical study will be fundamental to confirming the beneficial effects of thiamin on 
cardiovascular risk factors in individuals with a blood glucose level higher than normal. 
The findings of this study may have the potential to help develop new functional foods, 
food formulations and dietary recommendations for those who are at risk of developing 
these chronic diseases. Also, they may have an essential role in prevention of diabetes 
and vascular complications associated with hyperglycemia. So, volunteering in this 
study will be very valuable to science and humanity.   
 
  
  Benefits to the volunteers:  
Volunteers in the study will receive copies of all blood analyses and arterial compliance 
results with a description of what these results indicate. 
 
 
This study has been approved by the Curtin University Human Research Ethics 
Committee. 
 
 
If you would like to take part in this important study please fill the screening form 
available on-line at the web site of Curtin University at the link below: 
 
    http://publichealth.curtin.edu.au/research/projects/thiaminstudy.cfm   
         
               
Or contact Dr. Fariba Alaei on (08) 9266 7452  
        
   Email:  fariba.alaeishahmiri@postgrad.curtin.edu.au  
 
                    
                    
 
School of Public Health, Curtin University of Technology 
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Appendix 2  
Screening Checklist for Studies 1&2 
 
Name:……………………………………   ID:               Sex:     Male       Female 
 
Address: ………………………………………………                     
 
Phone No. (Circle best contact) 
H:…………………                W:……………                  Mobile:…………… 
 
EMAIL:………………………                  DOB:……………        Age:…… 
 
Weight:……..              Hight:……..               W/H circumference:…….                      
 
 
Medical History Yes No Details 
Are you a Smoker    
Females: Pregnancy, lactating, post-menopausal, 
gestational diabetes 
   
Have you had your glucose or insulin, cholesterol, 
TG, measured recently?  
Can you remember the results? 
   
Have you had, or have, a history of diabetes in your 
family? 
   
Medications    
Supplements    
Major operations    
Major illnesses/diseases: Do you have 
 Diabetes &High BP 
 Kidney disease (renal problems) 
 Liver disease &Hepatitis 
 HIV& Blood diseases 
 Heart disease& GI problems 
   
Did you have faints or blackouts?    
Do you have any allergies?     
Would you be able to have the following 
food/ingredients? 
 Thiamin supplement& Gluten 
 Herbs& spices  
 Ginger 
 Coconut milk 
 Dairy product ( Lactose ) 
   
What type of alcoholic drink do you usually drink?    
How many standard alcoholic drinks do you drink 
per day? How many days per week? 
   
Do you exercise regularly?    
Can we keep your contact details for future 
reference in clinical research? 
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Appendix 3  
WRITTEN INFORMED CONSENT FORM 
 
Project Title: Thiamin status in individuals with hyperglycemia 
 
I,      hereby consent to be a volunteer for 
the study “Thiamin status in individuals with hyperglycemia”. I understand 
that the screening and intervention process will involve: weight, height, 
waist/hip measurements, blood pressure, vascular stiffness measurement, 
filling food frequency questionnaire and screening questionnaire, and blood 
samples for assessments.  I consent to having blood samples drawn by a 
trained phlebotomist in fasting condition and after 2 hours of drinking a 
beverage containing glucose on the assessment day, which will be assessed 
for various biochemical assessments. I consent to collect my urine for 24 
hours prior to assessment day and bring it on the assessment day. The 
potential risks of all the procedures have been explained to me. I understand 
that my participation in this project is voluntary and I can withdraw from the 
project at any time. 
 
Signature:_____________________________ 
Name:________________________________ 
Witness:______________________________ 
Date:___/___/___ 
 
 
 
Any questions or misunderstandings may be answered or clarified by contacting  
Dr. Fariba Alaei on telephone 9266 7452 or email:  
fariba.alaeishahmiri@postgrad.curtin.edu.au , or  
Dr. Jill Sherriff on telephone 9266 7948 or email: J.Sherriff@curtin.edu.au   
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Appendix 4 
Participation Information sheet 
Project title: Thiamin status in individuals with hyperglycemia 
 
You have been accepted as a volunteer in this study . The following 
document must be read carefully and fully understood prior to signing the 
written consent form. Do not sign the consent form if there is any section in 
the following Participation Information Sheet that is not understood. Please 
feel free to ask any questions at any time. 
 
Background Information: 
Approximately 25% of Australian adults have a blood glucose higher than 
normal (hyperglycemia) and this rate is dramatically higher among 
overweight people. The findings of recent studies have shown that 
hyperglycemia is directly linked to accelerated risks of cardiovascular 
diseases and other health problems being major causes of death and 
disability in Australia. Accordingly, as a part of prevention strategies for 
chronic diseases, studies over the last decades have investigated the impact 
of macro and micronutrients on hyperglycemia. 
There are some suggestions that the thiamin status may not be optimum in 
subjects with hyperglicemia. This present study aims to evaluate thiamin 
status in people with a blood glucose level higher than normal relative to 
healthy people.  
 
What does the study involve?  
There will be a total of 2 visits at the School of Public Health, Curtin 
University. The initial visit will include a short screening session to determine 
volunteer suitability (see below), which requires 1/2-hour time commitment. 
Once the screening criteria are met, there will be just 1 clinical day. The 
clinical day will commence in the morning and require up to 3-hour time 
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commitment. Before the intervention day, subjects will be required to fast an 
overnight fast for about 12-14 hours. 
 
Screening visit:  
The screening visit will comprise a 15 to 30 minute session at the School of 
Public Health, Curtin University, where the study’s procedure and protocol 
will be fully explained and the written consent of each volunteer will be 
obtained.  
  
Main study: 
On the day before the clinical day you will be required to follow a diet 
provided by the investigators and collect your urine for a 24-hour period. On 
the clinical day, you will be assessed for cardiovascular risk factors as well as 
your blood and urine thiamin status. This visit will be for up to a 3-hour time 
period commencing in the morning and you will be required to fast for 10 -12 
hours before coming in on the morning of clinical day.   
Upon arrival to the School of Public Health, Curtin University, the following 
procedures will take place: 1) body weight, height, waist circumference, blood 
pressure and vascular stiffness will be measured 2) questionnaire pertaining 
to your dietary thiamin intake will be completed; 3) blood samples will be 
taken by a trained phlebotomist. After these measurements have been taken, 
you will be required to consume a beverage containing glucose. 2 hours after 
consuming the beverage, another blood sample will be taken for measuring 
your glucose level (oral glucose tolerance test) also vascular stiffness will be 
measured intermittently  every 30 minutes during the period of  2 hours after 
drinking  the beverage . 
 
Possible adverse effects:  
The blood samples may cause minor discomfort and possible bruising for 
some subjects. This bruising however is minor and will dissipate after a few 
days.  
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Benefits to the volunteers:  
 
This clinical study will be fundamental to evaluate thiamin status in 
individuals with blood glucose higher than normal. The findings of this study 
may have a critical role in prevention of cardiovascular complications, for 
those are at the risk of developing chronic disease. So, your participation in 
this study will be very valuable in this service to science and humanity.   
For your services as a volunteer in the study, you will receive copies of all 
blood analyses results with a description of what these results indicate. 
 
Please note that your participation in this study is completely voluntary and 
you are free to withdrawal at any time. All results and individual information 
are subject to strict confidentiality and are only accessible by members of the 
research group. 
 
Any questions or misunderstandings may be answered or clarified by 
contacting:  
 
Dr. Fariba Alaei   on telephone no: 9266 7452                                                                  
 Email: fariba.alaeishahmiri@postgrad.curtin.edu.au        or 
Associate Prof. Jill Sherriff on telephone no: 9266 7948   
Email: J.Sherriff@curtin.edu.au 
 
This study has been approved by the Curtin University Human Research 
Ethics Committee (Approval Number HR 118/2008).  If needed, verification of 
approval can be obtained either by writing to the Curtin University Human 
Research Ethics Committee, c/- Office of Research and Development, Curtin 
University of Technology, GPO Box U1987, Perth, 6845 or by telephoning 
9266 2784 or by emailing hrec@curtin.edu.au. 
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Appendix 5 
Participant Test Instruction Sheet 
Glucose Tolerance Test 
 
 You should be on a normal carbohydrate diet of at least 150-200 g of 
carbohydrate daily, during three days prior to the test. Fruits, breads, 
cereals, grains, rice, crackers, and starchy vegetables such as potatoes, 
beans, and corn could be considered as good sources of carbohydrate. 
 On the evening before the clinical day you will be required to consume a 
standard meal provided by the investigators.  
 Following consuming standard evening meal, you are required to fast 
overnight (10-12 hours) and have nothing to eat, including chewing gum, 
lollies, tea and coffee. You are permitted to drink water.  
 Upon arrival to the out-patient clinic, you should rest for 30 minutes before 
commencement of the test.  
 At the commencement of the test a blood sample will be taken and the 
fasting glucose checked.  
 After taking fasting blood sample, a glucose load in the form of a single 
bottle of glucose beverage will be given and you should drink the entire 
bottle within five minutes. 
 You are to stay in out-patient clinic for the duration of the test. So, please 
bring reading materials along with you if you like. 
 No smoking or physical activity is permitted during the test. It also 
includes walking around during the test. 
 One more blood sample will be taken at 2 hour after ingestion of glucose 
drink. 
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24 Hour Urine Collection 
 
 EAT AND DRINK NORMALLY prior and during to the collection, as the 
results will be affected. 
 It is recommended that you commence with your first morning urine on 
the day before clinical day.  
 For the first passing of urine, completely empty the bladder by urinating 
into the toilet – DO NOT SAVE IT INTO CONTAINER – but note the time 
and date on the container label. 
 After passing the first urine of the day, commence collection and collect 
all urine for the next 24 hours. DO NOT DISCARD ANY URINE DURING 
THIS COLLECTION TIME.  
 Exactly 24 hours after the start time, empty bladder and COLLECT 
URINE INTO THE CONTAINER. 
 Collection is now completed, you are to note this completion time on the 
label of the container – which should be the same time as the 
commencement time. 
 Store the container in a cool, dark and dry place. 
 Bring the completed 24 hour urine collection to the out-patient clinic, 
School of Public Health, Curtin University on the scheduled clinical day. 
 
Important 
 Given that an Acid preservative has been added to the container, please 
consider the following precautions: 
 Keep out of reach of children 
 Do not discard the preservative prior to starting collection. 
 Do not void directly into the container. Void into another clean container 
first and then transfer it completely into the 24-h urine collection container. 
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Appendix 6 
 
Protocol of the oral glucose tolerance test provided by WHO (Alberti and 
Zimmet 1998) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
187 
 
Appendix 7 
 
WHO Clinical criteria for metabolic syndrome (Alberti and Zimmet 1998) 
 
Insulin resistance, identified by 1 of the following: 
 Type 2 diabetes 
 Impaired fasting glucose 
 Impaired glucose tolerance  
   or for those with normal fasting glucose levels (_110  mg/dL),  
   glucose uptake below the lowest quartile for background population  
   under investigation under hyperinsulinemic, euglycemic conditions 
 
Plus any 2 of the following: 
 Antihypertensive medication and/or high blood pressure (_140 mm Hg   
systolic or _90 mm Hg diastolic) 
 Plasma triglycerides _150 mg/dL (_1.7 mmol/L) 
 HDL cholesterol _35 mg/dL (_0.9 mmol/L) in men or _39 mg/dL 
 (1.0 mmol/L) in women 
 BMI _30 kg/m2 and/or waist:hip ratio _0.9 in men, _0.85 in women 
 Urinary albumin excretion rate _20 _g/min   
   or albumin:creatinine ratio_30 mg/g 
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Appendix 9 
WRITTEN INFORMED CONSENT FORM 
Project Title: The chronic effects of thiamin on cardiovascular risk factors in 
individual with hyperglycemia 
                      
I,      hereby consent to be a volunteer for the 
study “the chronic effects of thiamin on cardiovascular risk factors in individuals with 
hyperglycemia”. I will attend an initial screening session where measurements of 
weight, height, waist/hip, and blood pressure will be taken to determine my suitability 
as a volunteer. I understand that once admitted into the project, I will attend the 
outpatient clinic of School of Public Health, Curtin University on three assessment 
days. Clinical measurements will be taken at weeks 0, 3 and 6. I understand that in 
two of these assessment days (week 0 and week 6) following fasting 
measurements, I will consume a liquid preload, containing glucose.  I consent to 
having blood samples drawn by a trained phlebotomist in fasting condition and after 
2 hours of drinking a beverage containing glucose on the assessment day, which 
will be assessed for various biochemical assessments. I consent to having my blood 
pressure and arterial stiffness measured in fasting condition to assess 
cardiovascular risk factors and indirect calorimetry, a non-invasive and safe method 
for measuring fat oxidation. I agree to filling in the screening questionnaire, food 
diary and physical activity log. I consent to collect my urine for 24 hours prior to 
assessment day and bring it on the assessment day. The potential risks of all the 
procedures have been explained to me.  I understand that my participation in this 
project is voluntary and the signing of this declaration does not prevent me from 
withdrawing from the study at any point in time, without prejudice. 
 
Signature: 
Name: 
Witness: 
Date:  / / 
 
Any questions or misunderstandings may be answered or clarified by contacting  
Dr. Fariba Alaei on telephone 9266 7452 or email: 
fariba.alaeishahmiri@postgrad.curtin.edu.au     , or  
Assoc. Prof. Jill Sherriff on telephone 92667948   or email:  J.Sherriff@curtin.edu.au 
Please see the comment mentioned for appendix 10. 
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Appendix 10 
Participation Information Sheet 
Project title: The chronic effects of thiamin on cardiovascular risk 
factors 
 
You have been accepted as a volunteer in this study because you have 
blood glucose levels above the normal range. The following document must 
be read carefully and fully understood prior to signing the written consent 
form. Do not sign the consent form if there is any section in the following 
Participation Information Sheet that is not understood. Please feel free to ask 
any questions at any time. 
 
Background Information: 
Approximately 25% of Australian adults have a blood glucose higher than 
normal (hyperglycemia) and this rate is dramatically higher among 
overweight people. The findings of recent studies have shown that 
hyperglycemia is directly linked to accelerated risks of cardiovascular 
diseases and other health problems which are major causes of death and 
disability in Australia. Accordingly, as a part of prevention strategies for 
chronic diseases, studies over the last decades have investigated the impact 
of macro and micronutrients on hyperglycemia. 
 
There are some studies showing thiamin supplement has many positive 
effects on cardiovascular risk factors under hyperglycemic condition. 
However, almost all of these previous studies have been done using animals. 
This present study aims to confirm the beneficial effects of thiamin on 
cardiovascular risk factors in humans, particularly in individuals with a blood 
glucose level higher than normal, but in the pre-diabetic range. 
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What does the study involve? 
Required commitment to the study:  
The amount of time that a subject will be involved in the study will be 
approximately 7 weeks from the initial to the final analysis. There will be a 
total of 4 visits to Curtin University. Before each of these visits, subjects will 
be required to fast overnight fast for about 12-14 hours. The initial visit will 
determine volunteer suitability and will include a screening session at the 
School of Public Health, Curtin University, which takes about 1/2 hour. Once 
the screening criteria are met there will be 3 clinical days, at weeks 0, 3 and 
6, which will take place at the School of Public Health, Curtin University. The 
clinical days will commence in the morning and at weeks 0 and 6 require up 
to 3-hour time commitment. The clinical day at week 3 takes about 1 hour. 
 
Screening visit:  
The screening visit will comprise a 15 to 30 minute session at the Curtin 
University where measurements of weight, height, waist/hip, and blood 
pressure will be taken. The study’s procedure and protocol will be fully 
explained and the written consent of each volunteer will be obtained. Also, if 
you are allergic to any supplements containing thiamin, please let the 
researcher know during screening visit. 
  
Food diaries and Physical activity logs:  
Physical activity logs and food diaries will be required to be completed 3 days 
before each day. Techniques for completing the food records and the activity 
logs will be explained to you in detail and any questions will be answered 
before the commencement of the study. 
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Main study: 
After screening, the volunteers will be randomly allocated into two groups to 
consume either 100 mg of thiamin or placebo supplements three times a day 
(300 mg/d) for 6 weeks. Clinical measurements will be taken at weeks 0, 3 
and 6.  The night before each assessment period, you will be required to fast 
overnight following a standard evening meal for 10-12 hours before attending 
the School of Public Health, Curtin University.  
 
On the day before the clinical day you will be required to eat an evening meal 
provided by the investigators and collect your urine for a 24-hour period. 
Over the course of the intervention, you should maintain your usual diet and 
level of physical activity, and to refrain from alcohol and strenuous exercise 
24 h before visits.  
 
On the clinical days at weeks 0 and 6, you will be required to visit the School 
of Public Health of Curtin University. These visits will be for up to a 3-hour 
time period commencing in the morning and you will be required to fast for 10 
-12 hours before coming in on the morning of each clinical day.   
 
Upon arrival to the outpatient clinic of School of Public Health, the following 
procedures will take place: 1) body weight, height, waist circumference, blood 
pressure, fat oxidation and vascular stiffness will be measured; 2) blood 
samples will be taken by a trained phlebotomist. 3) After these 
measurements have been taken, you will be required to consume a liquid 
preload, containing 75 g of glucose. 4) The second blood sample will be 
taken 2 hours after the test load.  
 
On the clinical day at week 3, you will be required to fast overnight following 
a standard evening meal for 10-12 hours before attending the School of 
Public Health, Curtin University for approximately 1/2 hour. Measurements 
will be taken, including fasting blood samples, blood pressure, fat oxidation 
and vascular stiffness. 
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Possible adverse effects:  
The blood samples may cause minor discomfort and possible bruising for 
some subjects. This bruising however is minor and will dissipate after a few 
days.  
 
The symptoms of toxicity or allergic sensitivity to thiamin, following its oral 
consumption in humans is very rare and they are usually relieved following 
cessation of treatment or reduction of dose. However, in order to minimise 
any risk, please let investigators know immediately, if you have any 
symptoms of skin redness, itching, eczema, headache, nausea, irritability, 
insomnia, rapid pulse and weakness. 
 
 
Benefits to the volunteers:  
 
This clinical study will be fundamental to confirm the beneficial effects of 
thiamin on cardiovascular risk factors in individuals with a blood glucose level 
higher than normal. The findings of this study may have the potential to help 
develop new functional foods, food formulations and dietary 
recommendations for those are at the risk of developing chronic disease. 
Also, they may have an essential role in prevention of hyperglycemia 
complications. So, your volunteering in this study will be very valuable in this 
service to science and humanity.   
 
As a volunteer in the study, you will receive copies of all blood analyses and 
arterial compliance results with a description of what these results indicate. 
Please note that your participation in this study is completely voluntary and 
you are free to withdraw at any time. All results and individual information are 
subject to strict confidentiality and are only accessible by members of the 
research group. 
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Any questions or misunderstandings may be answered or clarified by 
contacting: 
 
Dr. Fariba Alaei   on telephone no: 9266 7452                                                                  
 Email: fariba.alaeishahmiri@postgrad.curtin.edu.au       or: 
Assoc. Prof. Jill Sherriff on telephone no: 9266 7948   
Email: J.Sherriff@curtin.edu.au  
 
 
This study has been approved by the Curtin University Human Research 
Ethics Committee (Approval Number HR 161/2008).  The Committee is 
comprised of members of the public, academics, lawyers, doctors and 
pastoral carers. Its main role is to protect participations. If needed, 
verification of approval can be obtained either by writing to the Curtin 
University Human Research Ethics Committee, c/- Office of Research and 
Development, Curtin University of Technology, GPO Box U1987, Perth, 6845 
or by telephoning 9266 2784 or by emailing hrec@curtin.edu.au. 
 
 
 
 
 
 
Comment: this study was initially planned to be carried out with a parallel 
design. Therefore, the original participants' information sheet and consent 
form were prepared for a six - week intervention study. However, due to the 
problems in recruiting the required number of eligible subjects, the study 
design was changed to a cross - over design. Accordingly, following 
completion of the first part, subjects were invited to  pass a 14 -week wash 
out period and come back to receive alternative capsules for another six 
weeks.  
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Appendix 12      
 
PHYSICAL ACTIVITY QUESTIONNAIRE 
We are interested in finding out about the kinds of physical activities that 
people do as part of their everyday lives. The questions will ask you about 
the time you spent being physically active in the last 7 days. Please answer 
each question even if you do not consider yourself to be an active person. 
Please think about the activities you do at work, as part of your house and 
yard work, to get from place to place, and in your spare time for recreation, 
exercise or sport. 
 
Think about all the vigorous activities that you did in the last 7 days. 
Vigorous physical activities refer to activities that take hard physical effort 
and make you breathe much harder than normal. Think only about those 
physical activities that you did for at least 10 minutes at a time. 
 
1.  During the last 7 days, on how many days did you do vigorous 
           physical activities like heavy lifting, digging, aerobics, or fast bicycling? 
     
    _____ days per week 
  
     No vigorous physical activities → Skip to question 3 
 
2. How much time did you usually spend doing vigorous physical 
            activities  on one of those days? 
 _____ hours per day 
 _____ minutes per day 
  
    Don’t know/Not sure 
 
Think about all the moderate activities that you did in the last 7 days. 
Moderate activities refer to activities that take moderate physical effort and 
make you breathe somewhat harder than normal. Think only about those 
physical activities that you did for at least 10 minutes at a time. 
 
3.  During the last 7 days, on how many days did you do moderate  
           physical activities like carrying light loads, bicycling at a regular pace, 
           or doubles tennis?  
           Do not include walking. 
  
 _____ days per week 
 
   No moderate physical activities →  Skip to question 5 
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4.  How much time did you usually spend doing moderate physical 
           activities on one of those days? 
  
 _____  hours per day 
 _____  minutes per day 
  
   Don’t know/Not sure 
 
Think about the time you spent walking in the last 7 days. This includes at 
work and at home, walking to travel from place to place, and any other 
walking that you might do solely for recreation, sport, exercise, or leisure. 
 
5.  During the last 7 days, on how many days did you walk for at least 10 
 minutes at a time? 
  
 _____ days per week 
 
   No walking → Skip to question 7 
 
6.  How much time did you usually spend walking on one of those days? 
  
 _____ hours per day 
 _____ minutes per day 
  
   Don’t know/Not sure 
 
The last question is about the time you spent sitting on weekdays during the 
last 7 days. Include time spent at work, at home, while doing course work 
and during leisure time. This may include time spent sitting at a desk, visiting 
friends, reading, or sitting or lying down to watch television. 
 
7.  During the last 7 days, how much time did you spend sitting on a 
week  day? 
  
 _____ hours per day 
 _____ minutes per day 
 
   Don’t know/Not sure 
 
This is the end of the questionnaire, thank you for participating. 
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